NZ749754B2 - Methods and compositions for treatment of demyelinating diseases - Google Patents

Abstract

Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions. Oral compositions of methylglyoxal bis(guanylhydrazone) (MGBG) combined with fingolimod and a pharmaceutically acceptable carrier are claimed. ive conditions. Oral compositions of methylglyoxal bis(guanylhydrazone) (MGBG) combined with fingolimod and a pharmaceutically acceptable carrier are claimed.

Description

METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES This application claims the benefit of priority of United States provisional applications no. 61/750,336, filed January 8, 2013, and no. 61/823,276, filed May 14, 2013, and is a divisional application out of New Zealand Patent Application No. 709157, the disclosures of which are incorporated by reference as if written herein in their entireties.

Disclosed herein are new oral ceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis tors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

MGBG (methylglyoxal bis(guanylhydrazone); mitoguazone) is a competitive ine inhibitor of S-adenosyl methionine oxylase (SAMDC, AMD-I), which catalyzes the sis of spermidine, a polyamine. The amino-acid-derived polyamines have long been associated with cell growth and cancer, and specific oncogenes and tumor-suppressor genes regulate polyamine metabolism. Inhibition of polyamine synthesis has proven to be generally ineffective as an anticancer strategy in clinical trials, but it is a potent cancer chemoprevention gy in preclinical studies. Despite its novel mechanism of action and promising preclinical data, initial clinical trials of MGBG were ceased in the middle of 1960s due to severe toxicity especially to self-renewing normal tissues such as the bone marrow and intestinal tract cularly severe mucositis), which were both dose and schedule ent.

Regardless, research has continued with MGBG. A number of studies have examined potential uses in ation with other chemotherapeutic agents and innovative dosing regimens, ed to minimize side effects and dose where possible. Others have focused on elucidating MGBG's modes of action in the body. Yet others have investigated MGBG's ty in diseases other than cancer.

Perhaps due to negative clinical gs in these early studies, to date, MGBG had been confined to intravenous use. As a practical matter, this presents a number of problems for treatment of many diseases, particularly of chronic or recurrent conditions. Administration via IV injection or infusion must be done by a medical professional in a al setting. This not only presents an inconvenience and increased cost to the subject, but it also exposes him or her to al-based infections and illnesses, this latter both from ncture and the hospital or clinic visit itself. In immunocompromised individuals, duals undergoing treatment with immune system suppressors, and the elderly, this is a relevant concern. Thus, a subject with a long-term chronic condition such as an autoimmune or hyperproliferative disorder, or a doctor treating such a subject, might find the cost, inconvenience, and risks of such a treatment more important than any ial therapeutic benefits the drug might offer. Additionally, I.V. infusion drugs suffer from high Cmax and Tmax ities as opposed to oral drugs, which are more slowly absorbed.

An oral formulation of MGBG, in contrast, would present several benefits. First, an oral formulation, for example a simple pill or tablet, may be taken outside of a al setting, increasing the potential for subject ease of use and compliance. This s a subject to avoid infection risks concomitant with IV administration and hospital visits.

Where early treatment can prevent the development of disease complications, this is of particular benefit. Chronic low-dose administration of MGBG is practically impossible in an IV ation. Additionally, oral delivery typically avoids the high concentration peak and rapid clearance associated with an IV bolus dose. Yet another advantage of an oral drug would be the ability to formulate MGBG as a combination composition with one or more other eutic agents.

SUMMARY OF THE INVENTION [006A] The present invention provides an oral pharmaceutical composition comprising MGBG and fingolimodtogether with a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS shows the mean clinical scores of ts in the first 28-day murine model of experimental autoimmune encephalomyelitis (EAE) (a chronic progressive model of MS) induced by inoculation with myelin oligodendrocyte glycoprotein (MOG) peptides, n test (followed by page 2a) subjects were dosed with vehicle, 30 mpk MGBG (twice-daily), or 3 mpk fingolimod (oncedaily ), and compared with mmunized subjects. shows the mean percentage change in body weight (relative to study start) of ts in the first 28-day MOG EAE model, wherein test subjects were dosed with e, 30 mpk MGBG (twice-daily), or 3 mpk fingolimod (once-daily), and compared with mockimmunized subjects. shows the reduction in spinal cord inflammation as measured by the number of inflammatory foci in spinal cord athological samples, from the 28-day MOG EAE model, wherein test subjects were dosed with vehicle, 30 mpk MGBG (twice-daily), or 3 mpk fingolimod (once-daily), and compared with mock-immunized subjects. shows reduction in spinal cord demyelination in histopathological samples from the 28-day MOG EAE model, wherein test subjects were dosed with vehicle, 30 mpk [FOLLOWED BY PAGE 3] 2014/010714 MGBG (twice-daily), or 3 mpk fingolimod (once-daily), and compared with mock- immunized subjects. shows reduction in cellular sis in spinal cord histopathological samples from the 28-day MOG EAE model, wherein test subjects were dosed with vehicle, mpk MGBG (twice-daily), or 3 mpk fingolimod (once-daily), and ed with mock- immunized ts. shows the mean clinical scores of subjects in the second 28-day murine MOG EAE model, wherein test subjects were dosed with vehicle, 30 mpk MGBG (twice- daily), or 1 mpk fingolimod (once-daily), and compared with mock-immunized subjects; MGBG suppressed EAE comparably to 1 mpk fingolimod. shows the mean percentage change in body weight (relative to study start) of subjects in the second 28-day MOG EAE model, wherein test ts were dosed with vehicle, 30 mpk MGBG -daily), or 1 mpk fingolimod (once-daily), and compared with mock-immunized subjects. shows that MGBG, but not fingolimod, reduces CNS A) CD11c+ dendritic cells associated with antigen presentation and B) IL12+ dendritic cells associated with promotion of the Th1 response. shows that MGBG, but not fingolimod, reduces A) Th1 and B) M1 macrophages. shows that fingolimod preferentially A) suppresses Ih17 and B) increases M2 macrophages; thus, MGBG and fingolimod have distinct, but eutically complementary activities in MS. shows that although plasma levels of MGBG are almost undetectable by 28 hours after a single dose in the rat, MGBG levels in the spleen and liver remain detectably higher even 48 hours ose. This is consistent with a selective uptake mechanism for MGBG. shows the daily mean clinical scores of subjects in the third 28-day murine MOG EAE model, where fingolimod was dosed at 0.1 mpk (once-daily); MGBG dosed at 30 mpk (twice-daily) suppressed EAE comparably to 0.1 mpk fingolimod, and the ation of MGBG and fingolimod entirely suppressed development of EAE throughout the course of the study (no animals developed disease with the ation therapy). , showing the cumulative mean clinical scores of subjects in the third EAE study, further illustrates the significance of the above results. MGBG at 30 mpk (twice-daily) and fingolimod at 0.1 mpk (once-daily) were equivalently efficacious in preventing EAE development, and the combination of the two ly suppressed development of EAE. shows the change in body weight ive to study start) of subjects in the third 28-day EAE model, corroborating the results in . shows the reduction in spinal cord in?ammation as measured by the number of in?ammatory foci in spinal cord histopathological samples, from the third EAE model. Again, MGBG at 30 mpk (twice-daily) and fingolimod at 0.1 mpk (once-daily) were equivalently efficacious in reducing the number of in?ammatory foci, and the combination of the two apparently suppressed their development completely. shows the reduction in cellular apoptosis in spinal cord athological s from the third EAE model. Again, MGBG at 30 mpk (twice-daily) and fingolimod at 0.1 mpk (once-daily) were equivalently efficacious in reducing apoptosis, and the combination of the two ntly suppressed apoptosis completely. shows reduction in spinal cord demyelination in histopathological samples from the third EAE model. Again, MGBG at 30 mpk (twice-daily) and fingolimod at 0.1 mpk (once-daily) were equivalently efficacious in reducing demyelination, and the combination of the two apparently prevented ination completely.

Accordingly, provided herein is a method of treatment or prevention of a demyelinating disease, or a symptom thereof, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC tor is selectively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain ments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the demyelinating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory inating disease, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, central pontine olysis, Tabes dorsalis, yelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory neuropathy (Chacot-Marie-Tooth e), cerebrotendinious xanthanomatosis, and leukodystrophies including adrenoleukodystrophy, myeloneuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy (Krabbe disease), Canavan disease, vanishing white matter e, der disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In n ments, the demyelinating disease is multiple sclerosis. [03 1] In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-la, interferon b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, yl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In n embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day. [03 6] Also provided herein are ments in which each of the embodiments above in paragraphs [0024] — [0035] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also provided herein is a method of treatment of a symptom of an autoimmune disease affecting the nervous system comprising the administration of a eutically effective amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC inhibitor is selectively uptaken into cells. [03 9] In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 .

In certain embodiments, the symptom is chosen from CNS in?ammation, demyelination, and sis.

In certain embodiments, the autoimmune disease affecting the nervous system is chosen from multiple sclerosis, polymyalgia, myasthenia gravis, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, acute disseminated encephalomyelitis (ADME), ophic lateral sclerosis (ALS), autoimmune peripheral neuropathy, lupus erythematosus, psoriatic arthritis, toid arthritis, osteoarthritis, and rheumatic fever.

In certain embodiments, the mune disease affecting the nervous system disease is multiple sclerosis.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-la, interferon beta-lb, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain ments, fingolimod is dosed at 0.25 mg per day.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [0037] — [0049] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also provided herein is a method of treatment or prevention of a demyelinating disease comprising the contemporaneous administration of a SAMDC inhibitor and an agent chosen from interferon beta-la, interferon beta-lb, glatiramer acetate, ntrone, natalizumab, fingolimod, dimethyl fumarate, and teri?unomide.

In certain embodiments, the other agent is imod.

In certain embodiments, the SAMDC tor is ively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the stration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the demyelinating disease is chosen from multiple sclerosis, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse is, Balo concentric sclerosis, pernicious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) athy, tary motor and y neuropathy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and leukodystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy e disease), Canavan disease, vanishing white matter disease, der disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In certain ments, fingolimod is dosed at 0.5 mg per day.

In certain ments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [005 l] — [0061] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or tions.

Also provided herein is a pharmaceutical composition comprising a SAMDC inhibitor and another agent chosen from interferon beta-la, interferon beta-lb, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, and teri?unomide, together with a pharmaceutically able carrier.

In n embodiments, the SAMDC inhibitor is selectively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the other agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

In certain embodiments, the pharmaceutical formulation comprising the SAMDC tor and fingolimod is formulated for oral administration.

In certain embodiments, the pharmaceutical formulation yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject.

In certain embodiments, the pharmaceutical formulation is formulated for once- daily dosing.

In certain embodiments, the pharmaceutical formulation comprises 0.5 mg fingolimod per dosage unit.

In certain embodiments, the pharmaceutical ation comprises less than 0.5 mg fingolimod per dosage unit.

In certain embodiments, the pharmaceutical formulation comprises 0.25 mg fingolimod per dosage unit.

In certain embodiments, the pharmaceutical ation is formulated for twice- daily dosing.

In n embodiments, the pharmaceutical ation ses 0.25 mg fingolimod per dosage unit.

In certain embodiments, the pharmaceutical ation comprises less than 0.25 mg fingolimod per dosage unit.

In certain embodiments, the pharmaceutical formulation comprises about 0.125 mg fingolimod per dosage unit.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [0063] — [0080] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment es the two or more recited elements and/or limitations.

Also provided is a method of prevention of relapse or progression, or decreasing ty of symptoms in a relapse, of a demyelinating disease in a patient, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, provided is a method of prevention of progression, or decreasing severity of ms in a relapse, of a demyelinating disease in a patient, comprising the administration of a therapeutically effective amount of MGBG.

In certain embodiments, the inating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre Syndrome, chronic in?ammatory inating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory athy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and leukodystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, romatic leukodystrophy, globoid cell ystrophy (Krabbe disease), Canavan disease, vanishing white matter e, Alexander disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In n embodiments, the demyelinating disease is multiple sis.

In certain embodiments, the SAMDC inhibitor is ively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain ments, the SAMDC inhibitor is not a T-cell regulator.

In certain ments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, teratogenicity, decreased pulmonary function, macular edema, peripheral neuropathy, severe skin reactions, increased risk of infections (including latent bacterial and viral), impairment of innate ty, impairment of adaptive immunity, and flushing, as compared to another therapeutic agent approved for the treatment of a demyelinating disease.

In certain embodiments, the inating disease is multiple sclerosis.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, imod, dimethyl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In certain ments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In n embodiments, fingolimod is dosed at 0.25 mg per day.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from nia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from penia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least two side effects chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and genicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a d incidence of cytopenia, nephrotoxicity, and hepatotoxicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and penia.

In certain embodiments, administration additionally occurs concomitant with a reduced incidence of cardiotoxicity, and teratogenicity.

Also provided herein are embodiments in which each of the embodiments above in aphs [0082] — [0104] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also provided is a method treatment of ssive multiple sclerosis in a patient, comprising the administration of a therapeutically ive amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC inhibitor is selectively n into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the ssive multiple sclerosis is primary progressive.

In certain embodiments, the progressive multiple sclerosis is secondary progressive.

In certain embodiments, the progressive multiple sclerosis is progressive relapsing.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 .

In certain embodiments, the method additionally comprises the stration of an agent chosen from interferon beta-1a, interferon beta-1b, amer acetate, mitoxantrone, natalizumab, imod, laquinimod, dimethyl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In n embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain ments, fingolimod is dosed at 0.25 mg per day.

In certain embodiments, the treatment prevents relapse or ssion of MS.

In certain embodiments, the SAMDC inhibitor is not a T-cell regulator.

In certain embodiments, stration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, toxicity, cardiotoxicity, teratogenicity, decreased pulmonary function, r edema, peripheral neuropathy, severe skin reactions, increased risk of ions (including latent bacterial and , impairment of innate immunity, impairment of adaptive immunity, and flushing, as compared to another therapeutic agent approved for the treatment of a demyelinating disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, toxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least two side effects chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In n embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of cytopenia, nephrotoxicity, and hepatotoxicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration additionally occurs concomitant with a reduced incidence of toxicity, and teratogenicity.

Also provided herein are embodiments in which each of the ments above in aphs [0106] — [0129] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or tions.

Also provided is a method of blocking antigen presentation on cells in a patient having a demyelinating disease, wherein the antigens are d from, mimic, or resemble antigens in the myelin , comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the cells are of myeloid lineage.

In certain embodiments, the cells are pro-in?ammatory.

In certain embodiments, the cells are chosen from dendritic cells, macrophages, and B-cells.

In certain ments, the cells are dendritic cells.

In certain embodiments, the cells are M1 hages.

In certain embodiments, the demyelinating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre me, chronic in?ammatory demyelinating uropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, central pontine myelinolysis, Tabes is, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory neuropathy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and ystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy (Krabbe disease), Canavan disease, vanishing white matter disease, Alexander disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-1a, interferon beta-1b, glatiramer e, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In n embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

WO 10154 In certain embodiments, the SAMDC inhibitor is not a T-cell regulator.

In certain embodiments, the SAMDC tor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, teratogenicity, decreased pulmonary function, r edema, peripheral athy, severe skin reactions, increased risk of infections (including latent ial and viral), impairment of innate immunity, impairment of adaptive immunity, and flushing, as compared to another therapeutic agent approved for the ent of a demyelinating disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In certain embodiments, stration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least two side effects chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of cytopenia, nephrotoxicity, and hepatotoxicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration additionally occurs itant with a reduced incidence of cardiotoxicity, and teratogenicity.

Also provided herein are ments in which each of the ments above in paragraphs [0131] — [0156] is ed with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also provided is a method of inhibition of infiltration of an antigen-presenting cells into the central nervous system of a patient having a demyelinating disease, comprising the administration of a eutically effective amount of a SAMDC inhibitor.

In certain embodiments, the cells are pro-in?ammatory.

In certain embodiments, the cells are chosen from dendritic cells, macrophages, and B-cells.

In certain embodiments, the cells are dendritic cells.

In certain embodiments, the cells are M1 macrophages.

In certain embodiments, the SAMDC inhibitor is selectively uptaken into cells.

The method as recited in any one of claims 76-80, wherein the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain ments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl te, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, imod is dosed at 0.25 mg per day.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, teratogenicity, decreased pulmonary function, macular edema, peripheral neuropathy, severe skin ons, sed risk of infections (including latent bacterial and viral), impairment of innate immunity, impairment of adaptive immunity, and flushing, as ed to another therapeutic agent approved for the ent of a demyelinating disease.

In certain ments, the demyelinating disease is multiple sclerosis.

In n embodiments, stration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In n embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least two side effects chosen from nia, nephrotoxicity, toxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a d incidence of cytopenia, nephrotoxicity, and hepatotoxicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration additionally occurs concomitant with a reduced incidence of cardiotoxicity, and teratogenicity.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [0158] — [0180] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also ed is a method of tion or reduction in ty of the initiation phase of autoimmune response in a patient having a demyelinating disease, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the administration additionally prevents or reduces the amplification phase of autoimmune response in a patient having a demyelinating disease.

In n embodiments, the demyelinating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, ious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG n-associated glycoprotein) neuropathy, hereditary motor and sensory neuropathy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and leukodystrophies including leukodystrophy, myeloneuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy (Krabbe disease), Canavan disease, ing white matter e, Alexander disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating disease is le sclerosis.

In certain embodiments, the SAMDC inhibitor is not a T-cell regulator.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain ments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 .

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl fumarate, and teriflunomide.

In certain embodiments, the agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least one side effect chosen from cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, teratogenicity, decreased pulmonary function, macular edema, peripheral neuropathy, severe skin reactions, increased risk of infections (including latent bacterial and viral), impairment of innate immunity, impairment of adaptive immunity, and flushing, as compared to another therapeutic agent approved for the treatment of a demyelinating disease.

In certain embodiments, the inating disease is multiple sclerosis.

In certain embodiments, administration occurs concomitant with a reduced nce of at least one side effect chosen from cytopenia, toxicity, toxicity, cardiotoxicity, and teratogenicity.

In certain ments, the cytopenia is chosen from lymphopenia and neutropenia.

In certain embodiments, administration occurs concomitant with a reduced incidence of at least two side effects chosen from nia, nephrotoxicity, hepatotoxicity, cardiotoxicity, and teratogenicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and penia.

In certain embodiments, administration occurs concomitant with a reduced incidence of cytopenia, nephrotoxicity, and hepatotoxicity.

In certain embodiments, the cytopenia is chosen from lymphopenia and penia.

In certain ments, administration onally occurs concomitant with a reduced incidence of cardiotoxicity, and teratogenicity.

Also provided herein are embodiments in which each of the ments above in paragraphs [0182] — [0203] is combined with one or more of the other ntradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also provided is a method of treatment or prevention of demyelination in a subject in need thereof, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC inhibitor is selectively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain ments, the demyelinating e is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory neuropathy t-Marie-Tooth disease), cerebrotendinious nomatosis, and ystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, romatic leukodystrophy, globoid cell leukodystrophy (Krabbe e), n disease, vanishing white matter disease, Alexander e, Refsum e, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In n embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl fumarate, and teri?unomide.

In certain embodiments, the agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [0205] — [0216] is ed with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or limitations.

Also ed is a method of ion in severity of cellular apoptosis in the nerve tissue of a subject in need thereof, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC inhibitor is selectively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the demyelinating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre me, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sis, pernicious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, tary motor and sensory neuropathy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and ystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic ystrophy, globoid cell leukodystrophy e e), Canavan disease, vanishing white matter disease, Alexander disease, Refsum disease, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating disease is multiple sclerosis.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-la, interferon beta-lb, amer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl te, and teri?unomide.

In certain embodiments, the agent is fingolimod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In n ments, fingolimod is dosed at 0.25 mg per day.

Also ed herein are embodiments in which each of the embodiments above in paragraphs [0218] — [0229] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more d elements and/or limitations.

Also provided is a method of prevention of or reduction in the development of in?ammatory foci in the nerve tissue of a subject in need thereof, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

In certain embodiments, the SAMDC inhibitor is selectively uptaken into cells.

In certain embodiments, the SAMDC inhibitor is MGBG.

In certain embodiments, the administration of MGBG is oral.

In certain embodiments, MGBG is dosed at 20 mg/day to 400 mg/day.

In certain embodiments, the demyelinating disease is chosen from multiple sclerosis, optic neuritis, an idiopathic in?ammatory demyelinating disease, Guillain-Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, ious anemia, central pontine olysis, Tabes dorsalis, neuromyelitis optica (NMO), progressive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory athy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and leukodystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy (Krabbe e), Canavan disease, vanishing white matter disease, Alexander disease, Refsum e, and Pelizaeus-Merzbacher disease.

In certain embodiments, the demyelinating e is multiple sclerosis.

In certain embodiments, the method additionally comprises the administration of an agent chosen from interferon beta-la, interferon beta-lb, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, laquinimod, dimethyl te, and teriflunomide.

In certain embodiments, the agent is imod.

In certain embodiments, fingolimod is dosed at 0.5 mg per day.

In certain embodiments, fingolimod is dosed at less than 0.5 mg per day.

In certain embodiments, fingolimod is dosed at 0.25 mg per day.

Also provided herein are embodiments in which each of the embodiments above in paragraphs [023 l] — [0242] is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited elements and/or tions.

The present disclosure contemplates not only the methods disclosed above, but also: 0 the corresponding use of the compounds above in the treatment of disease, and in the specific diseases discussed; and 0 the corresponding use of the compounds above in the manufacture of medicaments for the treatment of the diseases discussed.

In the interest of avoidance of repetition, such embodiments are not explicitly re- written herein. However, these ments should be understood to be ed as if so written. For example, the present disclosure provides for: 0 Use of a therapeutically effective amount of a SAMDC tor in the treatment or prevention of a demyelinating disease; 0 Use of a therapeutically effective amount of a SAMDC inhibitor in the treatment of a m of an mune disease affecting the s system; 0 Use of a therapeutically effective amount of a SAMDC inhibitor and an agent chosen from interferon beta-la, interferon beta-lb, amer acetate, mitoxantrone, natalizumab, fingolimod, dimethyl fumarate, and unomide in the treatment or prevention of a demyelinating disease; Use of a therapeutically effective amount of a SAMDC inhibitor in the prevention of relapse or progression, or decreasing severity of symptoms in a e, of a demyelinating e; Use of a therapeutically effective amount of a SAMDC tor in the ent of progressive multiple sclerosis in a t; Use of a eutically effective amount of a SAMDC inhibitor in blocking antigen presentation on cells in a patient having a demyelinating disease, wherein the ns are derived from, mimic, or resemble antigens in the myelin sheath; Use of a therapeutically effective amount of a SAMDC inhibitor in the inhibition of infiltration of an antigen-presenting cells into the central nervous system of a t having a demyelinating disease; a method of prevention or reduction in severity of the initiation phase of autoimmune se in a patient having a demyelinating disease, comprising the administration of a therapeutically effective amount of a SAMDC inhibitor.

Use of a therapeutically effective amount of a SAMDC inhibitor in the treatment or tion of demyelination in a subject in need thereof; Use of a therapeutically effective amount of a SAMDC inhibitor in the reduction in severity of cellular apoptosis in the nerve tissue of a subject in need thereof; and/or Use of a therapeutically effective amount of a SAMDC inhibitor in the prevention of or reduction in the development of in?ammatory foci in the nerve tissue of a subject in need thereof; and all dependent embodiments listed above in paragraphs [0024] — [0242] above and in the claims below. The present disclosure also provides for: Use of a SAMDC inhibitor in the manufacture of a medicament for the treatment or prevention of a demyelinating disease; Use of a SAMDC inhibitor in the manufacture of a medicament for the ent of a symptom of an autoimmune disease affecting the nervous system; Use of a SAMDC inhibitor and an agent chosen from interferon beta-la, interferon beta-lb, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, yl fumarate, and teriflunomide in the manufacture of a medicament for the treatment or prevention of a demyelinating disease; 0 Use of a SAMDC inhibitor in the cture of a medicament for the prevention of relapse or progression, or decreasing severity of symptoms in a relapse, of a demyelinating disease; 0 Use of a SAMDC inhibitor in the manufacture of a medicament for the treatment of progressive le sclerosis in a patient; 0 Use of a SAMDC inhibitor in the manufacture of a ment for blocking antigen presentation on cells in a patient having a demyelinating disease, wherein the antigens are derived from, mimic, or resemble antigens in the myelin sheath; 0 Use of a SAMDC inhibitor in the manufacture of a medicament for the inhibition of infiltration of an antigen-presenting cells into the central nervous system of a t having a demyelinating disease; 0 a method of prevention or reduction in the manufacture of a ment for ty of the initiation phase of mune response in a patient having a inating disease, sing the administration of a SAMDC inhibitor. 0 Use of a SAMDC inhibitor in the manufacture of a medicament for the treatment or prevention of demyelination in a subject in need thereof; 0 Use of a SAMDC inhibitor in the cture of a medicament for the reduction in severity of cellular apoptosis in the nerve tissue of a subject in need thereof; and/or 0 Use of a SAMDC inhibitor in the cture of a ment for the prevention of or reduction in the development of in?ammatory foci in the nerve tissue of a subject in need thereof; and all dependent embodiments listed above in paragraphs [00]24 — [0242] above and in the claims below.

Also disclosed herein are oral pharmaceutical formulations of MGBG and other polyamine analogs, polyamine biosynthesis inhibitors, and polyamine inhibitors of SAMDC, Also disclosed are methods for the treatment of diseases comprising the administration of MGBG and other polyamine analogs, polyamine biosynthesis inhibitors, and polyamine inhibitors of SAMDC.

Also provided herein are methods for the treatment of pain comprising the administration of MGBG and other polyamine analogs, polyamine biosynthesis inhibitors, and polyamine inhibitors of SAMDC.

WO 10154 Also ed herein is a pharmaceutical composition for oral delivery, comprising a polyamine analog or polyamine biosynthesis inhibitor together with at least one pharmaceutically acceptable oral excipient.

Also provided herein is an oral pharmaceutical composition, comprising polyamine analog or ine biosynthesis tor together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma polyamine analog or polyamine thesis tor level when orally administered to a subject.

Also provided herein is an oral pharmaceutical composition, comprising polyamine analog or polyamine biosynthesis inhibitor together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma polyamine analog or polyamine biosynthesis inhibitor level for the treatment of pain when orally administered to a subject.

In certain embodiments, the polyamine analog or polyamine biosynthesis inhibitor is a compound disclosed herein.

In certain embodiments, the polyamine analog or polyamine thesis inhibitor is one known in the art.

In certain embodiments, the pharmaceutical ition yields a therapeutically ive ic plasma level of a polyamine analog or polyamine biosynthesis inhibitor for aperiod of at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 36, or 48 hours. In further embodiments, the pharmaceutical composition yields a therapeutically ive ic plasma level of a ine analog or polyamine biosynthesis inhibitor for at least a 6-hour period. In further embodiments, the pharmaceutical composition yields a therapeutically effective systemic plasma level of a polyamine analog or polyamine biosynthesis inhibitor for at least a 12-hour period. In further embodiments, the pharmaceutical composition yields a therapeutically effective systemic plasma level of a polyamine analog or polyamine thesis inhibitor for at least an 18- hour period. In further embodiments, the pharmaceutical composition yields a therapeutically effective systemic plasma level of a polyamine analog or polyamine biosynthesis inhibitor for at least a 24-hour period.

In certain embodiments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 25, 50, 55, 60, 65, 75, 80, 85, 90, or 95 percent of the peak plasma concentration for at least 4 hours. In certain embodiments, the ceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 75% of the peak plasma concentration for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 hours. In certain ments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 75% of the peak plasma concentration for at least 4 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis tor of at least 75% of the peak plasma concentration for at least 6 hours. In certain embodiments, the ceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 75% of the peak plasma concentration for at least 8 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 50% of the peak plasma concentration for at least 8 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 50% of the peak plasma concentration for at least 12 hours. In certain ments, the ceutical ition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 50% of the peak plasma concentration for at least 18 hours. In n embodiments, the pharmaceutical composition yields a plasma level of a polyamine analog or polyamine biosynthesis inhibitor of at least 25% of the peak plasma concentration for at least 18 hours. In further ments, the peak plasma concentration is a therapeutically effective concentration. In yet further embodiments, the percentage of peak plasma concentration is therapeutically effective over the given time period.

In certain embodiments, the pharmaceutical composition comprising the polyamine analog or polyamine biosynthesis tor has an oral bioavailability of at least , 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, or 60 percent.

In further embodiments, the pharmaceutical composition has an oral bioavailability of at least %, 20%, 25%, 30%, 35%, 40%, or 45%. In further embodiments, the ceutical composition has an oral bioavailability of at least 30%, at least 35 %, at least 40% or at least 45%. In certain embodiments, the pharmaceutical composition has an oral ilability of at least 20%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 30%. In certain ments, the pharmaceutical composition has an oral bioavailability of at least 35%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 40%. In certain ments, the pharmaceutical composition has an oral bioavailability of at least 45%. In certain embodiments, the pharmaceutical composition has an oral bioavailability which yields a therapeutically effective plasma level of a polyamine analog or polyamine biosynthesis inhibitor for at least a 24 hour period in the subject with once-daily . In certain embodiments, the pharmaceutical composition has an oral bioavailability which yields a therapeutically effective plasma level of a polyamine analog or polyamine biosynthesis inhibitor for at least a 24 hour period in the subject with twice-daily dosing. In n embodiments, the pharmaceutical composition has an oral bioavailability which yields a eutically effective plasma level of a polyamine analog or polyamine biosynthesis inhibitor for at least a 24 hour period in the subject with thrice-daily dosing.

In certain embodiments, the pharmaceutical composition comprising the polyamine analog or polyamine biosynthesis tor has a half life of at least 4, 6, 8, 10, l2, l4, l6, l8, 19, 20, 21, 22, 23, 24, 26, 28, 30, or 36 hours. In certain embodiments, the pharmaceutical composition has a half life of at least 12 hours. In r embodiments, the pharmaceutical ition has a half life of at least 18 hours. In further embodiments, the pharmaceutical composition has a half life of at least 20 hours. In further embodiments, the pharmaceutical composition has a half life of at least 24 hours. In certain embodiments, the pharmaceutical composition has a half life of at least 48, 72, 96, or 120 hours.

Additionally provided herein is a pharmaceutical composition for oral delivery, comprising MGBG together with at least one pharmaceutically acceptable oral excipient.

Also provided herein is an oral pharmaceutical composition, comprising MGBG together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject.

Also provided herein is an oral pharmaceutical composition, comprising MGBG together with at least one oral pharmaceutically able excipient, which yields a therapeutically effective systemic plasma MGBG level for the ent of pain when orally administered to a subject.

In n embodiments, the pharmaceutical composition yields a therapeutically effective systemic plasma MGBG level for a period of at least 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, l4, l5, l6, l7, l8, 19, 20, 21, 22, 23, 24, 30, 36, or 48 hours. In further embodiments, the pharmaceutical composition yields a eutically effective systemic plasma MGBG level for at least a 6-hour period. In further embodiments, the pharmaceutical composition yields a eutically effective systemic plasma MGBG level for at least a 12-hour period. In further embodiments, the pharmaceutical composition yields a therapeutically ive systemic plasma MGBG level for at least an 18-hour period. In further embodiments, the pharmaceutical ition yields a therapeutically effective systemic plasma MGBG level for at least a 24-hour .

In certain embodiments, the pharmaceutical composition yields a plasma level of MGBG of at least 25, 50, 55, 60, 65, 75, 80, 85, 90, or 95 percent of the peak plasma concentration for at least 4 hours. In certain embodiments, the ceutical composition yields a plasma level of MGBG of at least 75% of the peak plasma tration for at least 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of MGBG of at least 75% of the peak plasma concentration for at least 4 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of MGBG of at least 75% of the peak plasma tration for at least 6 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of MGBG of at least 75% of the peak plasma concentration for at least 8 hours. In certain embodiments, the pharmaceutical ition yields a plasma level of MGBG of at least 50% of the peak plasma concentration for at least 8 hours. In certain embodiments, the pharmaceutical composition yields a plasma level of MGBG of at least 50% of the peak plasma concentration for at least 12 hours. In certain embodiments, the pharmaceutical ition yields a plasma level of MGBG of at least 50% of the peak plasma concentration for at least 18 hours.

In certain ments, the pharmaceutical composition yields a plasma level of MGBG of at least 25% of the peak plasma concentration for at least 18 hours. In further embodiments, the peak plasma concentration is a therapeutically effective concentration. In yet further embodiments, the percentage of peak plasma concentration is therapeutically effective over the given time period.

In certain embodiments, the pharmaceutical composition comprising MGBG has an oral bioavailability of at least 10, 20, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, or 60 percent. In further ments, the pharmaceutical composition has an oral bioavailability of at least 10%, 20%, 25%, 30%, 35%, 40%, or 45%. In further embodiments, the pharmaceutical composition has an oral bioavailability of at least 30%, at least 35%, at least 40% or at least 45%. In certain embodiments, the ceutical composition has an oral bioavailability of at least 20%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 30%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 35%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 40%. In certain embodiments, the pharmaceutical composition has an oral bioavailability of at least 45%. In certain embodiments, the pharmaceutical composition has an oral bioavailability which yields a therapeutically effective plasma level of MGBG for at least a 24 hour period in the subject with once-daily . In certain embodiments, the pharmaceutical composition has an oral ilability which yields a eutically effective plasma level of MGBG for at least a 24 hour period in the subject with twice-daily dosing. In certain embodiments, the pharmaceutical composition has an oral bioavailability which yields a therapeutically effective plasma level of MGBG for at least a 24 hour period in the subject with thrice-daily dosing.

In certain embodiments, the pharmaceutical composition comprising MGBG has a half life of at least 4, 6, 8, 10, l2, l4, 16, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, or 36 hours.

In certain ments, the pharmaceutical composition has a half life of at least 12 hours.

In further embodiments, the pharmaceutical composition has a half life of at least 18 hours.

In further embodiments, the pharmaceutical composition has a half life of at least 20 hours.

In further embodiments, the pharmaceutical composition has a half life of at least 24 hours.

In certain embodiments, the pharmaceutical composition has a half life of at least 48, 72, 96, or 120 hours.

Also provided herein is a pharmaceutical ition comprising MGBG together with at least one oral pharmaceutically able excipient, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject, which does not have substantially dose-limiting side effects. In n embodiments, said side effects are gastrointestinal. In further embodiments, said gastrointestinal side effects are chosen from nausea, vomiting, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, gastrointestinal ations, gastrointestinal ulcers, gastrointestinal obstructions, and gastrointestinal bleeds. In further ments, said gastrointestinal side effects are chosen from inhibition of gastrointestinal mucosal proliferation, inhibition of migration of developing epithelial lumen cells, and tion of differentiation of stem or itor cells into epithelial lumen cells. In certain embodiments, said side effects are chosen from thrombocytopenia, leukopenia, phlebitis, laryngitis, cellulitis, dermatitis, and hypoglycemia.

Also provided herein is a low-dose oral pharmaceutical composition for chronic delivery, comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side effects. In certain embodiments, the low-dose oral pharmaceutical composition for chronic ry, comprising a therapeutically effective amount of MGBG and at least one pharmaceutically acceptable excipient, which does not have substantial gastrointestinal side 2014/010714 effects, yields a therapeutically effective plasma level of MGBG for at least a 24 hour period in the subject with once-daily dosing.

In certain ments, the pharmaceutical composition is formulated as a tablet or capsule. For e, in certain embodiments, the pharmaceutical composition comprises: 0. 1-50% of a polyamine analog or a ine biosynthesis inhibitor; 0.l-99.9% of a filler; 0-10% of a disintegrant; 0-5% of a lubricant; and, 0-5% of a t.

In certain ments, the pharmaceutical composition comprises: 01-50% of MGBG; .9% of a filler; 0-10% of a disintegrant; 0-5% of a lubricant; and, 0-5% of a glidant.

In further embodiments, said filler is chosen from a sugar, a starch, a cellulose, and a poloxamer; said disintegrant is chosen from ne and crospovidone; said lubricant is magnesium stearate; and said glidant is silicon dioxide.

In further embodiments, said filler is chosen from lactose and microcrystalline cellulose; said disintegrant is chosen from povidone and crospovidone; said lubricant is magnesium stearate; and said glidant is silicon dioxide.

In certain embodiments, the pharmaceutical composition comprises: -300 mg of a polyamine analog or a polyamine biosynthesis inhibitor, making up 2- 50% of the tablet content or capsule fill content; 0-10% of a disintegrant; 0-5% of a lubricant; 0-5% of a glidant; and -98% of a filler.

In n embodiments, the pharmaceutical composition comprises: -300 mg of MGBG, making up 2-50% of the tablet content or capsule fill content; 0-10% of a disintegrant; 0-5% of a lubricant; 0-5% of a glidant; and -98% of a filler.

In further embodiments, the pharmaceutical composition comprises 01-10% of a binder; 0-5% of a tant; 0-10% of an intergranular disintegrant; and 0-10% of an extragranular disintegrant.

In further embodiments, the pharmaceutical composition may additionally comprise 0-10% of a binder; 0-5% of a surfactant; 0-10% of an intergranular disintegrant; and 0-10% of an extragranular disintegrant.

In further embodiments, said binder is chosen from vidone, ypropyl-cellulose, hydroxypropylmethylcellulose, and povidone; said surfactant is chosen from polyoxyethylene (20) sorbitan monooleate, a poloxamer, and sodium lauryl sulfate; said intergranular disintegrant is chosen from croscarmellose sodium, sodium starch glyconate, and crospovidone; and said extragranular disintegrant is chosen from croscarmellose sodium, sodium starch glyconate, and crospovidone.

Also provided herein is a method of treating or ng the onset or pment of a condition in a t in need thereof comprising the administration of an oral pharmaceutical ition comprising MGBG and at least one pharmaceutically acceptable excipient. In certain embodiments, the oral pharmaceutical ition is red in a therapeutically effective amount. In certain embodiments, said oral pharmaceutical composition has an oral bioavailability of at least 30%. In certain embodiments, said oral pharmaceutical composition does not have substantially dose-limiting side effects. In certain embodiments, the plasma level of MGBG is at least 75% of the peak plasma concentration for 4 or more hours. In further embodiments, said oral pharmaceutical composition yields a therapeutically effective systemic plasma MGBG level for at least a 12-hour period when orally administered to a subject.

In certain embodiments, said condition is chosen from a erative er, an in?ammatory disease, and an autoimmune disease, a neuropathy, and a neurodegenerative disease. In certain embodiments, said condition is chosen from rheumatoid tis, osteoarthritis, le sclerosis, amyotrophic lateral sclerosis, HIV neuropathy, and HIV associated dementia.

In n embodiments, said proliferative er is chosen from a cancer, psoriasis, psoriatic arthritis and atopic dermatitis. In certain ments, the neuropathy is chosen from peripheral neuropathy, diabetic neuropathy, entrapment neuropathy (carpel tunnel syndrome), postherpetic neuralgia (PHN), chemotherapy-induced neuropathy, and HIV neuropathy.

In certain embodiments, the condition is chosen from a proliferative disorder, rheumatoid tis, osteoarthritis, multiple sclerosis, and amyotrophic lateral sclerosis,. In certain embodiments, the erative disorder could, for example, be chosen from a cancer, psoriasis, psoriatic arthritis, and atopic dermatitis.

Also provided is an oral pharmaceutical composition, comprising a polyamine analog or polyamine biosynthesis inhibitor together with at least one oral pharmaceutically acceptable excipient, which yields a eutically effective systemic plasma level of the polyamine analog or polyamine thesis inhibitor for the treatment of pain when orally administered to a subject. Also provided is an oral ceutical composition, comprising MGBG together with at least one oral pharmaceutically acceptable excipient, which yields a therapeutically effective systemic plasma level of MGBG for the treatment of pain when orally administered to a subject.

Also provided herein is a method of treatment of pain in a subject in need thereof comprising the administration of a polyamine analog or a polyamine biosynthesis inhibitor, or a salt or protected derivative thereof. Also provided herein is a method of treatment of pain in a subject in need thereof comprising the administration of MGB G. In certain embodiments, the MGBG is administered in a therapeutically effective amount. Further provided is a method of treatment of pain in a subject in need thereof comprising the stration of a therapeutically effective amount of a pharmaceutical composition comprising MGBG and at least one pharmaceutically acceptable excipient.

In n embodiments, the pain is chosen from inflammatory pain, pain due to nerve injury, chronic pain, intractable cancer pain, complex regional pain syndrome, neuropathic pain, surgical or post-surgical pain, dental pain, pain resulting from dermal injury, lower back pain, headaches, migraine, tactile allodynia, and hyperalgesia. In certain embodiments, the pain is chronic. In other embodiments, the pain is acute. In n embodiments, the pain is in?ammatory pain.

In certain embodiments, the administration of MGBG or its ceutical composition is oral. In other embodiments, the administration is intravenous.

In certain embodiments, the administration is a combination of oral and intravenous. In certain embodiments, the first administration is oral and the second IV; in others the first is IV and the second oral; in either case, additional oral or IV dosing may follow. In certain ments, the pain is surgical or post-surgical pain. For example, in certain embodiments, the pre-surgical administration is oral and the peri-surgical administration is IV; in others the pre-surgical administration is IV, the pre-surgical stration is also IV, and the post-surgical administration is oral. In either case, additional oral or IV dosing may follow. In certain embodiments, the pre-, peri-, and post- surgical administration is IV.

Also provided herein is a method of treatment of a condition in a subject in need thereof comprising the administration of an oral pharmaceutical composition comprising MGBG and at least one pharmaceutically acceptable excipient; and another therapeutic agent.

In certain embodiments, the MGBG is delivered in a therapeutically effective amount. In other embodiments, the MGBG is delivered in a subtherapeutic amount. In n embodiments, the other therapeutic agent is delivered in a therapeutically effective amount. In other embodiments, the other eutic agent is delivered in a subtherapeutic amount. In certain embodiments, the MGBG and the other eutic agent are red together in amounts which would individually be subtherapeutic but which together are therapeutically ive. In other ments, the MGBG and the other therapeutic agent are delivered together in amounts which are individually therapeutically effective.

Additionally ed herein is a method of treating a condition. The method comprises administering to a subject in need of such treatment an effective amount of MGBG, a salt of MGBG, a protected derivative of MGBG, or a ine analog or polyamine biosynthesis inhibitor or a salt, a protected tive, or a stereoisomer thereof, wherein the condition is chosen from Crohn's disease, Parkinson's disease, in?ammatory bowel disorder, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), hepatitis, HBV, HCV, nephritis, cerebritis, glomerulonephritis, rheumatoid arthritis, type 2 diabetes, cardiac fibrosis and angiotensin type II associated hypertension, orosis, a mast cell produced IgE mediated hypersensitivity immune reaction, peripheral sensory neuropathy associated with HIV infection or diabetes mellitus, asthma, autism, dermatomyositis, frailty, obesity, primary biliary cirrhosis, primary sclerosing cholangitis, post-radiation syndrome, psoriatic arthritis, sarcoidosis, scleroderma with or without pulmonary fibrosis, a kidney related autoimmune condition, diabetic nephropathy, a diabetic vascular complication, and a lymphoproliferation related autoimmune condition. onally provided herein is a method of decreasing differentiation of macrophages from monocytes, comprising contacting a monocyte with an ive amount of an agent that inhibits S-adenosyl methionine oxylase or inhibits polyamine biosynthesis in the monocyte. In n embodiments the agent is MGBG, or a salt or protected tive thereof.

In one embodiment, the agent is capable of inhibiting SAMDC or any pathway ning AMD I, e. g., any entity upstream or downstream of a pathway ning SAMDC, especially any pathway containing SAMDC and associated with adenosine production. In another embodiment the agent is capable of inhibiting polyamine biosynthesis or any pathway involved in polyamine biosynthesis. In general, a pathway containing SAMDC or adenosine is understood to refer to a pathway in which either SAMDC or ine is involved, including, for e, as a substrate, st, product or by-product.

The agent can be any kind of known or later discovered agent that can inhibit the activity of the enzyme S-adenosyl nine decarboxylase, can t polyamine biosynthesis in, for example, a cell. In one embodiment, the agent is a chemical agent, including, but not limited to, organic molecules and salts, protected derivatives and stereoisomers thereof, inorganic molecules or various ionic or elemental entities.

Compounds for use in the methods and compositions disclosed herein e polyamine analogs and polyamine biosynthesis inhibitors, as well as salts, prodrugs, solvates, anhydrous forms, protected derivatives, structural isomers, stereoisomers, amino acid conjugates, and porphyrin conjugates f. Any polyamine analog is suitable for use in the methods of the present invention.

Exemplary polyamine analogs used in the methods of the invention include compounds of the structural as l, 2, 3, 4, 5, 6, and 7 and the corresponding stereoisomers, salts, and protected tives f.

Formula 1 has the structure wherein R1, R2, R4, R6 and R7 are independently chosen from hydrogen, alkyl and aryl; and R3 and R5, are alkyl groups.

Formula 2 has the structure /N\ /N\ /N\ /N\ R1 R3 R5 R7 R9 wherein R1, R2, R4, R6, R8, and R9 are independently chosen from hydrogen, alkyl and aryl; R3, R5 and R7 are alkyl groups.

Formula 3 has the structure N N N N N R1/ \/\/\/\/\R3 R5 R7 R9 R11 wherein R1, R2, R4, R6, R10 and R11 are independently chosen from hydrogen, alkyl and aryl; R3, R5, R7 and R9 are alkyl groups. a 4 has the structure N N N N R1 R2 R3 R4 R5 wherein R1 and R5 are independently chosen from methyl, ethyl, n-propyl, and isopropyl; R2, R3, and R4 are independently chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl-C3-C6 cycloalkyl- C1-C6 alkyl, C3-C10 aryl, and C1-C6 alkyl-C3-C10 aryl- C1-C6 alkyl; and R6, R7, R8 and R9 are independently chosen from hydrogen, methyl, and ethyl; Formula 5 has the structure R7 R8 R9 R10 R11 /N\ /N\ /N\ /N\ /N\ R1 R2 R3 R4 R5 R6 wherein R1 and R6 are independently chosen from methyl, ethyl, n-propyl, and isopropyl; R2, R3, R4 and R5 are independently chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl- C3-C6 cycloalkyl- C1-C6 alkyl, C3-C10 aryl, and C3-C10 aryl- C1-C6 alkyl; and R7, R8, R9, R10 and R11 are independently chosen from hydrogen, methyl, and ethyl.

In another ment, the polyamine s are compounds of the structures 2 and 3, wherein R3, R5, R7 and R9 are independently (CH2)x groups; X is an integer from 2 to 6; and R4, R6 and R8 are hydrogen atoms.

In yet another embodiment, the polyamine s are compounds of the structures 2 and 3, wherein R3, R5, R7 and R9 are independently (CH2)x groups; X is an r from 2 to 6; R4, R6 and R8 are hydrogen atoms; R1 and R10 are alkyl groups; and R2 and R11 are hydrogen atoms.

In yet another embodiment, the polyamine analogs are compounds of the structures 2 and 3, wherein R3, R5, R7 and R9 are independently (CH2)x groups; X is an integer from 2 to 6; R4, R6 and R8 are hydrogen atoms; R1 and R10 are alkyl groups; R2 and R11 are hydrogen atoms; and the polyamine analogs have a molecular weight less than 500.

Further embodiments of compounds of the ure 4 e those wherein R6, R7, R8 and R9 are hydrogen.

In other embodiments, R1 and R5 are ethyl.

In yet further embodiments, R6, R7, R8 and R9 are hydrogen; and R1 and R5 are ethyl.

In yet further embodiments, R2 and R4 are independently chosen from C1-C6 alkyl; and R3 is chosen from C1-C6 alkyl, C2-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkyl- C3-C6 cycloalkyl- C1-C6 alkyl, C3-C10 aryl, and C1-C6 alkyl- C3-C10 aryl- C1-C6 alkyl.

Additional polyamine analogs useful in the present invention include compounds of the a 6, and the corresponding stereoisomers, salts, and protected derivatives thereof: R8 R9 R10 R11 /N\ /N\ /R R1 R2 R3 4‘R5/N\ /N\R6 R7 wherein R4 is chosen from C2-C6 n-alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, and C3-C6 aryl; R3 and R5 are independently chosen from a single bond, C1-C6 alkyl, and C1-C6 alkenyl; R2 and R6 are independently chosen from C1-C6 alkyl, C1-C6 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, and C3-C6 aryl; R1 and R7 are independently chosen from hydrogen, C1-C6 alkyl, and C2-C6 alkenyl; R8, R9 and R11 are hydrogen.

, R10, In certain ments of the compounds of formula 6, R1 and R7 are independently chosen from C1-C6 alkyl and C2-C6 alkenyl.

Additional polyamine analogs useful in the present invention e compounds of the formula 7, and the corresponding stereoisomers, salts, and protected derivatives thereof: R8 R9 R10 R11 I I | | N N R N N /\/\/ 4‘R5/\/\ R1 R2 R3 R6 R7 wherein R4 is chosen from C1-C6 l and C1-C6 branched alkyl; R3 and R5 are independently chosen from a single bond or C1-C6 alkyl; R2 and R6 are independently chosen from C1-C6 alkyl, C1-C6 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, or C3-C6 aryl; R1 and R7 are ndently chosen from H, C1-C6 alkyl, or C2-C6 alkenyl; and R8, R9, R10, and R11 are hydrogen.

In certain ments of the compounds of a 7 R2 and R7 are independently chosen from C1-C6 alkyl or C2-C6 alkenyl; 2014/010714 R4 is chosen from C1-C6 ted n-alkyl and C1-C6 saturated branched alkyl; and R3 and R5 are independently chosen from a single bond and C1-C6 ted n-alkyl.

According to another ment of the present invention, the agent is a chemical moiety that inhibits the activity of S-adenosyl methionine decarboxylase, inhibits polyamine biosynthesis, and/or increases the activity of adenosine.

Examples of such moieties include, but are not limited to, those listed in Table 1.

Irrespective of the form of the moiety listed in Table 1, it is understood that it includes, as applicable, a salt, protected derivative, and stereoisomer thereof.

Table 1.

Pub Chem nd Official Name (Not IUPAC) Decarboxylated s-adenosylmethylthiopropylamine 535 1 154 Mitoguazone or Methygyl 1 oxalb'1s(guanylh dy razone) 9561662 "MGBG" EGBG Ethylglyoxal bis(guanylhydrazone) 2354 Berenil Diminazene or Diminazene aceturate 4735 4- [5-(4-carbamimidoylphenoxy)pentoxy] benzenecarboximidamide Pentamidine 5'—(Dimethylsulphino)-5'—deoxyadenosine S-adneosylmethylthiobutyrate S-adenosyl-S-methyl-L-cysteine S-(5'—Deoxy-5'—adenosyl) methylthioethylhydroxylamine EMGBG Ethylmethylglyoxal anylhydrazone) DEGBG Diethylglyoxal bis(guanylhydrazone) 9574151 6-((2-carbamimidoylhydrazono)methyl) CGP-33’829 5479208 picolinimidamide CGP-36’958 CGP-39’937 2,2'-bipyridine-6,6'-bis(carboximidamide) CGP-48664 or 4-amidinoindanone 2'-amidinohydrazone 548681 1 CGP48664Aor SAM 364A AbeAdO 5'-[[(Z)amin0—2-buteny1] methylamin0]-5'- 6436013 0rMDL-7381 1 deoxyadenosine '-deoxy-5'—[N-methy1-N-[2- MAOEA 308 1018 (aminooxy)ethy1]amin0]aden0sine '-deoxy-5'—[N-methyl-N-(3- MHZPA 122092 hydrazinopropy1)amin0]adenosine xy-5'—[(2-hydrazinoethy1)- MHZEA methylamin0]aden0sine S-(5’-deoxy- 5'-aden0sy1)amm0nio AdoMaC 3083364 (methylsulfonio)-2cyclopentene S-(5’-deoxy- 5'—aden0sy1)amin0xy AdoMao (methylsulfonio)Cyclopentene APA 1-Aminooxyamin0pr0pane 65020 AOE-PU N- [2-amin00xyethy1]—1,4-diamin0butane 00x N-[3-amin0y Pr0Py1]-amin0Pr0Pane AP—APA 1 ,1 1-bis(ethy1)n0rspermine BES 1,8-bis( ethy1)spermidine BES 1,12-bis(ethy1)spermine DESPM N1 ,N12-diethy1spermine BE3-3 1,1 1-bis(ethylamin0)-4,8-diazaundecan BE4-4 1 ,14-bis(ethy1amin0)-5,10-diazatetradecane DEHOP 0r Diethylhomospermine, N1 ,N14- DEHSPM diethylhomospermine DENOP diethyl-norspermine BE44 1 ,19-bis(ethy1amin0)-5,10,15-triaza-n0nadecane N-ethyl-N'—(2-(3'-ethy1amin0—pr0py1amin0 SL1 1037 methyl)-Cis-Cyclopr0py1methy1)-pr0pane 1,3- e tetrahydrochloride 1—N'-(2-(3'—eth lamino-y pr0pylamino SL11038 methyl)-trans—cyclobuty1methy1)-pr0pane 1,3- diamine tetrahydrochloride N-ethyl-N'—(2-(3'-ethylamino-propylamino SL1 1044 methyl)-transcyclopropylmethyl)-propane 1,3- diamine tetrahydrochloride SL1 1047 or N,N'-bis(3-ethylaminopropyl)-cis-butene-1,4- SL47 diaminetetrahydrochloride N,N'-(cyclopropane-1,2- SL11093 or diylbis(methylene))bis(N4-ethylbutane-1,4- SL93 diamine) In yet another embodiment, the agent is a compound chosen from MGBG, MDL73811, CGP48664, Berenil, Pentamidine, SL47, and SL93, or a combination of two or more f. In yet another embodiment, the agent is MGBG, SL47 or SL93. In still another embodiment, two or more agents are used. The two or more agents can be used either sequentially or simultaneously.

MGBG is 1,1’[methylethanediylidene]dinitrilodiguanidine and is also known as methylglyoxal bis(guanylhydrazone), methyl-GAG, Me-G, and mitoguazone. As used herein, MGBG includes the free base and salts thereof. It is commonly, but not necessarily, used as a dihydrochloride. MGBG may be t as any one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, e of one or more thereof: ,N \ /N NH \ N \ 2 /N NH2 H2N N Y\N HY H2N N \ N Y H NH NH2 , , NH )sz NH2 “2” \N H HZNANH H HZNAN N\ NH2 N\ \ \ ,N IN \ /N \ NH ““2 / \ \ N \n/ 2 WAN \n/ N NH NH NH2 , , , H2N \ N NH NH2 NH2 HZNAN’Nj/§N H2NJ\\N’N\ \N H2NJ\\N’N\ \N H Hl\ll\n/NH2 NYNHZ HN\n/NH2 NH NH2 NH , , , NH NH2 NH2 HZNJJWyH HzNJRI}J H2NJ§N In certain embodiments, MGBG may be t one of the following isomers, or a tautomer and/or a syn/anti isomer thereof, mixture of one or more thereof: H HZNANH HszN’NwN’NYNHz H H NH NWANMTNHZNH , , NH HZNJLNH In certain embodiments, compounds have a structure chosen from Formulas 8a- 82 '33 B4 '35 RrNME‘m”MM, M H H n n n H R1/ My MW Mx My M2 \Re (8b) R1 R7 R7 R6 N N ?n—NL) (8C) R1 — R6 are chosen from hydrogen, alkyl and aralkyl having from 1 to 12 carbon atoms, provided that, in formula (8a), R1, and R6 are not hydrogen; R7 chosen from hydrogen, alkyl, aryl and aralkyl having from 1 to 12 carbon atoms; m, n, are each independently an integer from 3 to 6, inclusive; and V, w, X, y, and z are each independently an integer from 3 to 10, inclusive.

Additional disclosure may be found in WO98/ 10766, the disclosure of which is incorporated by nce as if written herein in its entirety, for example on pp. 3-4.

In n embodiments, compounds have a structure of Formula 9a: E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH-E wherein A is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl; B is independently selected from the group consisting of: a single bond, C1-C6 alkyl, and C2-C6 alkenyl; and E is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 l, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl; with the o that either at least one A moiety is selected from the group consisting of C2-C6 alkenyl, C2-C6 l, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl, or at least one B moiety is selected from the group consisting of C2-C6 alkenyl; and all salts, hydrates, solvates, and stereoisomers thereof.

In another embodiment, the conformationally restricted polyamine analog is ed from among the group of compounds of the formula 9b: E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH(-B-A-B-NH)X-E wherein: A is independently selected from the group consisting of C1-C6 alkyl, C2-C6 l, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl; B is independently selected from the group consisting of: a single bond, C1-C6 alkyl, and C2-C6 alkenyl; and E is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl; X is an integer from 2 to 16; with the o that either at least one A moiety is selected from the group consisting of C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl, or at least one B moiety is selected from the group consisting of C2-C6 alkenyl; and all salts, hydrates, solvates, and isomers thereof.

In another embodiment, X is 4,6, 8, or 10.

In another embodiment, X is 4. In another embodiment, X is 6.

In another ment, X is 8.

In another embodiment, X is 10.

In r embodiment, the conformationally restricted polyamine analog is ed from among the group of compounds of the formula 9c: E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH(-B-A-B-NH)X-E wherein: A is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 aryl, and C3-C6 cycloalkenyl; B is independently selected from the group consisting of: a single bond, C1-C6 alkyl, and C2-C6 alkenyl; and E is independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkanol, C3-C6 cycloalkanol, and C3-C6 hydr0Xyaryl, with the proviso that at least one E moiety be selected from the group consisting of C1-C6 alkanol, C3-C6 cycloalkanol, and C3-C6 hydr0Xyaryl; and X is an integer from 0 to 16; and all salts, hydrates, solvates, and stereoisomers thereof.

In another embodiment, the conformationally cted ine analog is selected from among the group of compounds of the formula 9d: E-NH-D-NH-B-A-B-NH-D-NH-E wherein A is selected from the group consisting of C2-C6 alkene and C3-C6 cycloalkyl, cycloalkenyl, and aryl; B is independently selected from the group consisting of a single bond and C1-C6 alkyl and alkenyl; D is independently selected from the group consisting of C1-C6 alkyl and alkenyl, and C3-C6 lkyl, cycloalkenyl, and aryl; E is independently ed from the group consisting of en, C1-C6 alkyl and alkenyl; and all salts, hydrates, solvates, and stereoisomers thereof.

In another embodiment, the conformationally restricted polyamine analog is selected from macrocyclic polyamines of the formula 9e: )k A 1 M N/ NY I Y ' A A 2 R N/ 3‘N k Y Y wherein A1, each A2 (if present), and A3 are independently selected from C1-C8 alkyl; each Y is independently selected from hydrogen or C1-C4 alkyl; M is ed from C1-C4 alkyl; k is 0, 1,2, or 3; and R is ed from C1-C32 alkyl; and all salts, hydrates, solvates, and stereoisomers thereof.

In additional ments, the Y group is hydrogen or -CH3.

In another embodiment, A1, each A2 (if present), and A3 are independently selected from C2-C4 alkyl.

In yet another embodiment, M is -CH2-.

In another embodiment, the conformationally restricted polyamine analog is selected from macrocyclic polyamine analogs of the formula 9f: wherein A1, each A2 (if present), and A3 are independently selected from C1-C8 alkyl; A4 is selected from C1-C8 alkyl or null; X is selected from - hydrogen, -Z, -CN, -NH2, -C(=O)- C1-Cg-alkyl, or -NHZ, with the proviso that when A4 is null, X is hydrogen, -C(=O)- C1-Cg-alkyl, or -Z; Z is selected from the group ting of an amino protecting group, an amino capping group, an amino acid, and a peptide; each Y is independently selected from hydrogen or C1-C4 alkyl; M is selected from C1-C4 alkyl; k is 0, 1,2, or 3; and R is selected from C1-C32 alkyl; and all salts, hydrates, solvates, and stereoisomers f.

In certain embodiments, A4 is null.

In other embodiments, X is -Z, and -Z is hydrogen.

In other embodiments, X is -Z, and -Z is holinocarbonyl.

In other embodiments, X is -Z and -Z is acetyl.

In other embodiments, X is -Z and -Z is t-Boc or Fmoc.

In other embodiments, Y is -CH3.

In other embodiments, M is -CH2-.

In still r embodiments, k is 1.

In further embodiments, A, and A3 are -CH2CH2CH2-.

In still further embodiments, - CHZCHZCHZCH2-.

In still further embodiments, R is C13H27.

In yet further embodiments, one or more of the specific limitations on A4, X, Z, Y, M, k, A1, A3, and R are combined.

In further embodiments of macrocyclic polyamine analog compounds, A4 IS C1-C8 alkyl, X is —NHZ; and Z is selected from one of the 20 genetically encoded amino acids (alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, methionine, asparagine, proline, ine, arginine, serine, threonine, , tryptophan, tyrosine), a peptide of the a acetyl-SKLQL-, a peptide of the formula acetyl- SKLQ-I3-alanine-, or a peptide of the formula acetyl-SKLQ-.

In these cases, where Z is an amino acid or e, the therapeutic agent to be used is a polyamine-amino acid conjugate or ine-peptide conjugate.

In one embodiment, the only conformational restriction of the polyamine analog is due to a carbon-carbon double bond (an ethenyl group, C=C) in the molecule.

In another embodiment, the only conformational restriction of the polyamine analog is due to a cycloalkyl group, such as a cyclopropyl group, in the molecule. 2014/010714 Compounds include, but are not limited to: HzN/\/\/NH2 HZN/\/\N/\/\/NH2 HZNMNWNWNHZ H H \/N\/\/\N/\/\/N\/\/\N/\ ‘5HCI H H H H H HO\/\N/\/\/N\/\/\N/\/\/N\/\/\N/\ .5HCI H H H H H HO\/\N/\/\/N\/\/\N/\/\/N\/\/\N/\ H H H \/\/N\/\/\N/\/\ 92HC| ANWNV07HC| AN/WQNV010HC| AHW1\/ H H H H /N\/—\/N\/\/N\/_ ‘4HCI H H \/N\/\/N\/\/\N/\/\N/\ ‘4HCI H H H H H H H H HOWNW‘NNNMNV H H H H HOWMWNRNWMIXN_ H H AHWNWNWHQ 04HC|_ H H /\N/\/\/N\/—\/N\/\/\N/\ 04HC|_ H H WO 10154 wNv=\/N\/\/\N/\/\/N\/=\/N\/ ’4HCI H H WO 10154 2014/010714 H H \/N\/\/N N\/\/N\/ H H AMWN N\/\/\N/\ 04HC| H H D H H \/N\/\/N\5 3/N\/\/N\/ WO 10154 HN ‘4HCI V HN HN v HN H A N\/\/\N/\ ‘4HCI .4HC| A HN HN \/ HN HN MH HNJ HN HN HNV NH NH H2N NH2 H NH HN HN NH NH WO 10154 /\/\ ,GIn—Leu Additional disclosure may be found in WO2007/040535, the disclosure of which is incorporated by reference as if written herein in its entirety.

Additional analogs and derivatives include those encompassed by the following formula 10a: R-X-polyamine wherein R is selected from H or from the group of a ht or branched Cl-50 saturated or unsaturated aliphatic, yalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted aliphatic; an aliphatic-substituted single or multiring ic; a single or multiring heterocyclic; a single or multiring heterocyclic 25 aliphatic; a Cl-10 alkyl; an aryl yl; or cyano; X may be -CO-, -SOZ, or -CH2- and "polyamine" may be any naturally occurring, such as putrescine, spermine or spermidine, or synthetically produced polyamine. ably, R is at least about C5, at least about C10, at least about C11, at least about C12, at least about C13, at least about C14, at least about C15, at least about C16, at least about C17, at least about C18, at least about C19, at least about C20, or at least about C22.

The e between X and the polyamine may be direct, wherein there are no atoms between X and the nitrogen of the amine group of the polyamine, or indirect, where there may be one or more atoms between X and the nitrogen of the amine group of the ine. The e. between X and the polyamine may occur via any amino group within the polyamine, although a primary amino group is used in preferred embodiments of the invention.

In preferred embodiments of the invention where the linkage between X and the polyamine is indirect, the intervening one or more atoms are preferably those of an amino acid or a derivative thereof. In particularly preferred embodiments of this type, the intervening one or more atoms are those of lysine, aspartic acid, glutamic acid, omithine, or aminobutyric acid. Preferred compounds of this type may be represented as in Formula 10b: R-X-L-polyamine wherein R is a ht or branched C10-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted or unsubstituted aliphatic; an aliphatic-substituted or unsubstituted single or multiring aromatic; a single or multiring heterocyclic; a single or multiring heterocyclic aliphatic; an aryl sulfonyl; X is -CO-, -SOz-, or -CH2-; and L is a covalent bond or a lly occurring amino acid, ornithine, 2,4- diaminobutyric acid, or derivatives thereof. [03 50] The analogs and derivatives of the invention, may be optionally further substituted at one or more other positions of the polyamine. These include, but are not limited to, internal nitrogen and/or internal carbon atoms. In one aspect of the ion, preferred substituents are structures that increase ine transport tion, binding ty or otherwise enhance the irreversibility of binding of the nd to a polyamine binding molecule, such as the polyamine transporter, an enzyme or DNA. Such additional substituents include the aziridine group and various other tic, ic, mixed aliphatic-aromatic, or heterocyclic multi-ring structures. Reactive moieties which, like aziridine, bind ntly to a ine transporter or another polyamine binding molecule, are also within the scope of this invention. Examples of reactive groups that react with nucleophiles to form covalent bonds include chloro-, bromo- and iodo-acetamides, sulfonyl?uorides, esters, nitrogen mustards, etc. Such reactive moieties are used for affinity labeling in a diagnostic or research context, and may contribute to pharmacological activity in inhibiting ine transport or polyamine synthesis. The reactive group can be a reactive photoaffinity group such as an azido or benzophenone group. Chemical agents for photoaffinity labeling are well-known in the art (Flemming, S.A., Tetrahedron 1995,51, 12479-12520).

A preferred aspect of the invention relates to a ine analog or derivative that is a highly specific polyamine transport inhibitor with pharmaceutical utility as an anticancer chemotherapeutic. One class of a polyamine analog or derivative of the invention that binds to a polyamine-binding site of a molecule and/or inhibits polyamine ort, is bed by the following formula 10c: (O)n HN’X‘R1 Rex.ng?fNHMaNMNMON” (0)n wherein a, b, and c independently range from 1 to 10; WO 10154 d and e independently range from 0 to 30; each X is independently either a carbon (C) or sulfur (S) atom, and R1 and R2 are as bed below, or each of R1X(O)n- and of R2X(O)n- are independently replaced by H; and * denotes a chiral carbon position; and with the provisos that ifX is C, then n is l; ifX is S, then n is 2; and if X is C, then the X(O) group may be CH2 such that n is o.

In the above formula, R1 and R2 are ndently ed from H or from the group of a straight or ed Cl-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a Cl-8 alicyclic; a single or multiring aryl substituted aliphatic; an aliphatic-substituted single or multiring aromatic; a single or multiring aromatic or saturated heterocyclic; a single or ing cyclic aliphatic; a Cl-10 alkyl; an aryl sulfonyl; or cyano.

Examples of heterocyclic rings as used herein include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, 3-pyrroline, pyrrolidine, pyridine, pyrimidine, purine, quinoline, isoquinoline, and carbazole. [03 54] All of the above described aliphatic, carboxyalkyl, carbalkoxyalkyl, alkoxy, 30 alicyclic, aryl, aromatic, and heterocyclic moieties may, of course, also be optionally substituted with 1-3 substituents independently selected from halo (?uoro, chloro, bromo or iodo), lower alkyl (l-6C) and lower alkoxy (l-6C).

As used herein, carboxyalkyl refers to the tuent -R'-COOH wherein R' is ne; and carbalkoxyalkyl refers to -R'-COOR wherein R' and R are alkylene and alkyl respectively. In preferred embodiments, alkyl refers to a ted straight- or branched-chain hydrocarbyl radical of 1-6 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tbutyl , n-pentyl, 2-methylpentyl, n-hexyl, and so forth. Alkylene is the same as alkyl except that the group is divalent. Aryl or alkyl sulfonyl moieties have the formula SOZR and alkoxy moieties have the formula -O-R, wherein R is alkyl, as defined above, or is aryl n aryl is phenyl, optionally substituted with 1-3 substituents independently selected from halo (?uoro, chloro, bromo or iodo), lower alkyl (l-6C) and lower alkoxy (l-6C).

A preferred group of nds encompassed by the above is where d is 4 and e is 0. [03 57] An additional class of a polyamine analog or derivative of the invention that binds to a polyamine-binding site of a le and/or inhibits polyamine transport, is bed by the following formula 10d: HN R1 H ( d H H H RZYN e* ”MaNMbNMcNHZ R4 0 wherein a, b, and C independently range from 1 to 10; d and e independently range from 0 to 30; R1 and R2 are defined as above for formula 8c and R3 and R4 are independently selected from organic substituents including -CH3 and as defined above for R1 and R2 in formula 8c above. This grouping of analogs is produced by ive amination of the free amino precursor with a ketone.

In one red embodiment of the invention, R1 and R2 are identical and as described for formula 8c. Positions R3 and R4 may also be cal, and all of R1 through R4 may also be identical. Additionally, each of positions R1, R2, R3, and R4 in a 8d may also be independently H.

In an onal aspect of the invention the proximal and/or the distal amino group relative to the polyamine (such as spermine) can be di-alkylated to form tertiary amines.

These materials can be synthesized by reductive amination with a large excess of the yl component. Additionally, these materials may be produced by a conjugate addition of the amine precursor to an (LB-unsaturated carbonyl or (LB-unsaturated nitrile.

Each of R1, R2, R3, and R4 can be independently varied and are as defined as above for formula III. Each of R1, R2, R3, and R4 may also be independently H. The values of a, b, c, d and e are as described above for formula 8d. This aspect of the invention is depicted in the following formula 10e: R1 \ ,R3 Rz/ e* Ma Mb MC 2 In a further aspect of the ion, compounds which lack the proximal or distal amino group on the acyl portion of the molecule are also provided. These are represented by formula 10f: 2014/010714 22 H H H NH e* ‘(Vfa ‘(VTb ‘(")’c 2 wherein Z1 is NR1R3 and Z2 is selected from - R1, -CHR1R2 or -CR1R2R3 (wherein R1, R2, and R3 are as defined above for formula 8c); or Z2 is NR2R4 and Z1 is selected from -R1, -CHR1R2 or - CR1R2R3 in R1, R2, and R3 are as defined above for formula 8d). Values for a, b, and C independently range from 1 to 10; d and e independently range from 0 to 30. nds encompassed by formula V may be prepared by first coupling amino acid derivatives (modified to contain the non-amine containing Z group) to a polyamine followed by appropriate derivatization of the amine containing Z group. Chemistries for such reactions are known in the art and disclosed herein.

In preferred embodiments of the invention, positions R1, R2, R3, and R4, of all the formulas set forth above are independently selected from the following, where each of g, h, i, j, and k are independently selected from 0 to 15: WowE wherein E refers to "entgegen" and Z refers to men".

Compounds include, but are not limited to: WO 10154 WO 10154 QT NH2 W m/\/\NH @gw NH2 WH H N\/\/N\/\/\N/\/\NH2 :NH NH2 NH H H H O ”WNWNNMMNHZ Additional disclosure may be found in /053519, the disclosure of which is incorporated by nce as if written herein in its entirety.

Additional analogs and derivatives include synthetic tives of original polyamines, wherein a carbon atom of said original polyamine comprises an amide group, said synthetic derivative inhibiting the cellular uptake of a natural polyamine by specifically g a cellular transporter for said natural polyamine.

In certain embodiments, the carbon to which said amido group is located is between two internal nitrogen atoms of said al polyamine.

In certain embodiments, the synthetic tive comprises a dimer of said original polyamine, the monomers of said dimer being linked together by a spacer side chain anchored to the amido group of each monomer. [03 68] In certain embodiments, the original polyamine is selected from the group ting of putrescine, spermidine and spermine.

In certain embodiments, the original polyamine is spermine.

In certain embodiments, said synthetic derivative has the following general formula 1 la: 2014/010714 T2 H I R1\TH/\(CH2)W\/(CH2)x /N (CH2)z R1 | \NA(CH2)y\/ I\”/ 0(0) R2 R3 l in which R1 and R11 independently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms, R2, R12, or R3 and R13 independently represent a hydrogen atom or a methyl group, wand z independently represent an r of 2 or 3, X ents an integer from 0 to n, n represents an integer from 3 to 6, the sum of X and y equals n, and S represents a hydrogen atom or a molecule which cannot be captured by said natural polyamine transporter.

In certain embodiments, said monomer has the following general formula llb: H I R1\NH/\(CH2)W\/| /N (CH2)X |N/\(CH2)yV 2)2/ l 0(0) R3 l in which R1 and R11 ndently represent a hydrogen atom or an alkyl group having 1 to 2 carbon atoms, R2, R12, or R3 and R13 independently represent a hydrogen atom or a methyl group, w and z independently represent an integer of 2 or 3, X represents an integer from 0 to n, n represents an integer from 3 to 6, the sum of X and y equals n, and wherein the spacer side chain comprises a linear hydrocarbon-containing backbone of 3 to 8 atoms.

In certain ments, said backbone comprises sulfur, 0Xygen or nitrogen.

In certain embodiments, w=2, z=2 X=o and y=3.

In certain embodiments, w=2, z=2, X=o and y=3.

In certain embodiments, w=2, z=2, X=o and y=4.

Compounds include, but are not limited to: 2014/010714 2N N/Vj/ \/\(H H2N N\/\)\ «A W N NH2 2NJ\?m/\:Nj/H\/YNH2 H2N2NW/VNVH\J\N/\)\NH WNNE/HVWNW MW)WANH MmNVWN/NHZ MMNWT: WWZHWW H N2 WN\/\j\NMNH HZNMMMINWNHZ M 0 H2NMM/\/I\/\/NH2 ?n 0 K/NH o /NH\/\I”MNH HZNMMA/IWNH2 M 0 HZNMH N\/\/NH2 ?n 0 o NH2 H2N/\/\N 2 {\N o 803 s 0 ;\ NH2 0 N/\/N > HZNMN N\/\/NH2 Fu 0 3; N3 O OH H2N/\/\H/\/I \/\/NH2 HN O HN O HN2 \/\/ij”MNH HZNMH/? \/\/NH2 HN O HZNMNA/I \/\/N NH2 HN O 2014/010714 HzNJmN/VVNVYNHZH ((EHz) H2N2:L; Additional disclosure may be found in WO98/ 17632, the disclosure of which is incorporated by reference as if written herein in its entirety.

Additional analogs and tives e those encompassed by the following formula 12a: RHNMH |\ H /\/ \R1 wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, -CH3,-CH2CH3, 2-aminoethyl, 3-aminopropyl, obutyl, 5- aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminooctyl, N-methylaminoethyl, N- methylaminopropyl, N-methylaminobutyl, N-methylaminopentanyl, yl aminohexyl, N-methylaminoheptyl, N-methylaminooctyl, N-ethylaminoethyl, N- ethyl minopropyl, N-ethylaminobutyl, N-ethylaminopentyl, N-ethylaminohexyl, N-ethylaminoheptyl or N-ethylaminooctyl and R, is a moiety ed from the group consisting of a hydrogen or a straight or branched CI-20 saturated or unsaturated aliphatic; aliphatic amine but not propylamine when R =H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring cyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted ic; and halogenated forms thereof.

In certain ments, the s and derivatives that can be used ing to this disclosure can be further modified as described in formula 12b: RHNWN \ R3 R4 H | H /\/ 7R1 wherein n can be 0 to 8, R and R1 are described as above, R2 can be independently selected from en, -CH3,-CH2CH3, and R3 and R4 may be the same or different and are independently selected from hydrogen, or ?uorine.

In certain embodiments, compounds that can be used according to this disclosure are described in formula 12c: R3 R4 RHNWN R3 R4 m H/UM N R n R2 0 wherein, m and n can be 0 to 7 independently, but m cannot equal n when R1 equals R2 and R3 equals R4, 0 can be 2 to 4, R can be independently selected from H, -CH3,-CH2CH3, R1 and R2 can be independently selected from hydrogen, -CH3,-CH2CH3, and R3 and R4 may be the same or different and are independently selected from hydrogen or ?uorine.

In certain ments, nds have formula 12d: wherein, R is hydrogen, --CH3,-CH2CH3, m and n can be 0 to 7 independently and o can be 2 to 4, R2 can be independently selected from hydrogen, -CH3,-CH2CH3, and R3 and R4 may be the same or different and are independently selected from hydrogen or ?uorine.

In certain embodiments, compounds of the present invention are represented by formula l2e: R3 R4 H H | \/\N R R2 / H wherein, R is hydrogen, -CH3,-CH2CH3, m can be 0 to 7, n can be 0 to 8 and 0 can be 2 to 4, R2 can be independently selected from hydrogen, -CH3,-CH2CH3, and R3 and R4 may be the same or different and are independently selected from hydrogen or ?uorine.

Compounds e, but are not limited to: HZNMN HZNMN H H H NH2 N\/\/\/\ /\/\/\/NH2N H N N 2 \/\/ \/\/\N NH2 H2N\/\/\/N\/\/\N/\©\/NH NH2 H2N/\/\/N\/\/\N H2N/\/\M/\©\/HVON \ N ”WEI H H \N/\E>\/N\/OH WooN\/\/NH2 '4sz” H | f N \ \ N H2N / H2N N H2N/\/\H H H H N NH2 /\/\ H2N N S N\/\/\/\NH2 Additional disclosure may be found in WOOS/105729, the disclosure of which is incorporated by reference as if n herein in its entirety.

Additional analogs and derivatives include compounds of the formulas l3a—d: HAHN R1/\M/\/\/ NNNARZ R2/\N/\/\/ NNAR1 H H H\/A.u‘\ H R1/\N/\/\/N ”m vR2 R H H 2\/ NN/lll'A/N H NMAR1 wherein R1 and R2 are independently selected from the group consisting of 0 alkyl, -C3- C10 cycloalkyl, -C1-C10 alkylene-cycloalkyl, -C6-C10 aryl, and -C1-C10 alkylene-aryl, wherein when both R1 and R2 are alkyl, at least one of R1 and R2 is —C2-C10 alkyl and wherein both R1 and R2 are not ulyl; and all salts, hydrates, solvates, and stereoisomers thereof; and all mixtures of stereo isomers thereof, including racemic mixtures. In one embodiment, the substituents on the ropyl ring are trans to each other. In another embodiment, the substituents on the cyclopropyl ring are cis to each other.

In one embodiment, when both R1 and R2 are alkyl, at least one of R1 and R2 is straight-chain alkyl. In r embodiment, when both R1 and R2 are alkyl, both R1 and R2 are straight-chain alkyl. In one embodiment, one of R1 and R2 is 0 alkyl and the other is -C2-C10 alkyl. In one embodiment, one of R1 and R2 is -C1-C10, alkyl and the other is —C4-C10 alkyl. In one ment, both R1 and R2 are -C4-C10 alkyl. In one embodiment, one of R1 and R2 is -C6-C10 alkyl. In one embodiment, both R1 and R2 are 0 alkyl. In one embodiment, one of R1 and R2 is -C1-C10 alkyl and the other is selected from the group consisting of -C2-C4 straight-chain alkyl and —C4-C10 alkyl. In r embodiment, R1 and R2 are independently selected from the group consisting of -CH3, -(CH2)3CH3, and - (CH2)sCH3, provided that both R1 and R2 are not -CH3.

In one embodiment, one of R1 and R2 is -C1-C10 alkyl and the other is -C3-C10 cycloalkyl, 0 alkylene-cycloalkyl, -C6-C10 aryl, or -C1-C10 alkylene-aryl. In one embodiment, one of R1 and R2 is —C1-C10 alkyl and the other is - C3-C10 cycloalkyl or -C1-C10 alkylene-cycloalkyl. In one embodiment, one of R1 and R2 is -C1-C10 alkyl and the other is - C3-C10 cycloalkyl. In one ment, one of R1 and R2 is —C1-C10 alkyl and the other is -C6- C10 aryl or -C1-C10 alkylene-aryl. In one embodiment, one of R1 and R2 is -C1-C10 alkyl and the other is -C6-C10 aryl. In another embodiment, both R1 and R2 are -C6-C10 aryl. In another embodiment, both R1 and R2 are -C3-C10 cycloalkyl. In one embodiment, the aryl group is benzene. In one embodiment, the cycloalkyl group is adamantyl. In one embodiment, the adamantyl group is l-adamantyl. In another embodiment, the adamantyl group is 2- adamantyl. In another embodiment, R1 and R2 are independently selected from the group consisting of—CH3, phenyl, and adamantyl, provided that both R1 and R2 are not -CH3.

Compounds include, but are not limited to: > WHASI m IZ “(GHQQCHs ZI ZI H30(H20)g/\u/V\/ i) : 5ZI H30(H20)g/\u/V\/ < \/NNN/II“A,H H NMAmHzHCHs AMA/V MA(CH2)4CH3 0)4/\N/\/\/N”A”NNMA Hammett/mm”HVA-\“\ /\/\/HH V \/NNN/III'A/H H NNAmHzMCHs /\/\/N\/A\/NH H CF NT) Additional disclosure may be found in W02008/112251, the disclosure of which is orated by reference as if written herein in its entirety.

Additional analogs and tives e compounds of the formula 14a: R1-X-R2 wherein R1 is H, or is a head group ed from the group consisting of a straight or branched CHO aliphatic, alicyclic, single or multi-ring aromatic, single or multiring aryl tuted aliphatic, aliphatic-substituted single or multiring aromatic, a single or multiring heterocyclic, a single or multiring heterocyclic-substituted aliphatic and an aliphatic-substituted aromatic; R2 is a polyamine; and X is CO, NHCO, NHCS, or $02 [03 92] In r embodiment of the above composition, R2 has the formula )nNH(CH2)pNH(CH2)qNHR3 wherein n, p and q vary independently and n=p=q=l to 12; and R3 is H; CHO alkyl; CHO alkenyl; CHO alkynyl; alicyclic; aryl; aryl-substituted alkyl, alkenyl or alkynyl; alkyl-, alkenyl-, or alkynyl-substituted aryl; guanidino; heterocyclic; heterocyclic-substituted alkyl, alkenyl or alkynyl; and alkyl-, l-, or alkynyl-substituted heterocyclic. [03 93] The above composition may further comprise, linked between X and R2, a linker L and an additional group Y, such that said composition has the formula 14b: R1-X-L-Y-R2 wherein L is a CHO alkyl; CHO alkenyl; CHO alkynyl, alicyclic, or heterocyclic; X is CO, 802, NHCO or NHCS; and Y is CONH, SO2NH, NHCO, NHCONH, NHCSNH, NHSO2, 802, O, or S.

In the foregoing compositions R1 can have the formula: wherein R4, R5, R6, R7, and R8 are, independently, H, OH, halogen, N02, NH2,NH(CH)nCH3, N((CH)nCH3)2, CN, (CH)nCH3, O(CH)nCH3, nCH3, NCO(CH2)nCH3, O(CF2)nCF3, or CO-O(CH)nCH3 where n=0 to 10.

Alternatively, R1 has the formula: / /v6/\’ R5 R4 wherein R4 and R5 are, independently, H, OH, halogen, NOZ, (CH)nCH3, N((CH)nCH3)2, CN, (CH)nCH3, O(CH)nCH3, S(CH2)nCH3, NCO(CH2)nCH3, nCF3, or CO-O(CH)nCH3 where n=0 to 10. [03 96] In yet r embodiment, R1 has the formula: R7m?0Q |\\/lR ,\/ ,\’J 4 RSVRg R6 VRS wherein r and s vary ndently and r=s= 0 to 6; R4, R5, R6, R7, R8, and R9 are, ndently, H, OH, halogen, NOZ, NH2,NH(CH)nCH3, N((CH)nCH3)2, CN, (CH)nCH3, CH3, S(CH2)nCH3, NCO(CH2)nCH3, nCF3, or CO-O(CH)nCH3 where n=0 to 10; Q is CONH, SOZNH, NHCO, NHCONH, NHCSNH, NHSOZ, 802, O, or S.

Furthermore, R1 may have the a: ”(Q/()5 RSVRQ R5 wherein r and s vary independently and are 0 to 6; R4, R5, R6, and R7 are, independently, H, OH, NOZ, NH2,NH(CH)nCH3, N((CH)nCH3)2, CN, (CH)nCH3, O(CH)nCH3, S(CH2)nCH3, NCO(CH2)nCH3, O(CF2)nCF3, or CO-O(CH)nCH3 where n=0 to 10; and Q is CONH, SOzNH, NHCO, NHCONH, NHCSNH, NHSOZ, 802, O, or S.

In the foregoing compositions, R1 may be selected from the group consisting of naphthalene, phenanthrene, anthracene, pyrene, dibenzofuran, acridine, 2,1,3- benzothiodiazole, quinoline, isoquinoline, benzofuran, indole, carbazole, ?uorene, 1,3- benzodiazine, phenazine, phenoxazine, phenothiazine, adamantane, camphor, piperidine, alkylpiperazine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, thiophene, furan, pyrrole, alkyl-l,2-diazole, alkylimidazole, alkyl-lH-l,2,3- l, alkyl-lH-l,2,3,4-tetrazole, thiazole, oxazole, 1,3,4-thiadiazole, pyridinyl, pyrimidine, 1,2-diazine, 1,4-diazine and 1,3,5-triazine, 4-dimethylaminoazobenzene, yl methylisooxazole, 3-(2-chlorophenyl)methylisooxazole, hloropheny)methyl chloroquinoline, 6-chloroimidazo[2,1-B]thiazole, (x-methylcinnamic acid, and 2-[1,2-dihydro- 2H-1,4-benzodioxepinyl]thiazole.

R1 may also be a D- or L-amino acid.

Also provided is the above composition where R1 has a formula selected from the group consisting of (A)R12-R13-Y1-Ri4 (B) R12-Y1-R13-Z1-R14 | \Z’l—R15 (D) /R12 wherein R12 and R13, independently, are H, naphthalene, phenanthrene, anthracene, pyrene, dibenzofuran, acridine, 2,1,3-benzothiodiazole, quinoline, isoquinoline, uran, indole, carbazole, e, 1,3-benzodiazine, phenazine, phenoxazine, phenothiazine, adamantane, camphor, pipiridine, alkylpiperazine, morpholine, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, eptyl, cyclooctyl, thiophene, furan, e, alkyl-I,2-diazole, alkylimidazole, alkyl-lH-1,2,3 -triazol, alkyl-lH-l,2,3,4-tetrazole, thiazole, oxazole, 1,3,4- thiadiazole, pyridinyl, dine, 1,2-diazine, 1,4—diazine and 1,3,5-triazine, 4- ylaminoazobenzene, 3-phenylmethylisooxazole, 3-(2-chloropheny1) methylisooxazole, 2-(4-chloropheny)methy1chloroquinoline, 6-chloroimidazo[2, l- B]thiazole, (x-methylcinnamic acid, or 2-[1,2-dihydro-2H-1,4-benzodioxepinyl]thiazole; and further, wherein a ring of R12, R13 or both in formulas (A), (B) and (D), is optionally substituted with one or more of OH, halogen, N02, NH2,NH(CH)nCH3, N((CH)nCH3)2, CN, (CH)nCH3, O(CH)nCH3, S(CH2)nCH3, NCO(CH2)nCH3, O(CFz)nCF3, or CO-O(CH)nCH3 where n=0 to 10 R14and R15 and, in formula (C), R13, ndently, are (CH2)n, (CH2)nCH=CH, (CH2)n(CH=CH)mCO, or (CH2)nCO where n=0 to 5 and m=1 to 3; Y1, and 21, independently, are CONH, SOZNH, NHCO, NHCONH, , NHSOZ, SOz-NHSOZ, 802, O, S, or COO; when R1 is of a (A) or (B), Yl represents a bond between a C or N atom of R12, and a C or N atom of R13, and 21 represents a bond between a C or N atom of R13, and a C or N atom of R14; or when R1 is of formula (C) or Y1 represents a bond between the C and a C or N atom of R13 and 21 represents a bond between the C and a C or N atom of R14; or when R1 is of formula (D) Y1 represents a bond between a C or N atom of R12 and a C or N atom of R14 and 21 represents a bond between a C or N atom of R13 and a C or N atom of R15.

In the above itions, R2 preferably has the formula NHCH(21)(CH2)nNH(CH2)pNH(CH2)qCH(Zl)NHR3 wherein n, p and q vary independently and n=p=q=l to 12; and R3 is H; C1_10 alkyl; C1_10 alkenyl; C1_10 l; alicyclic; aryl; aryl-substituted alkyl, l or alkynyl; alkyl-, alkenyl-, or l-substituted aryl; guanidine or heterocyclic; Z, is CH3, CH2CH3OI' cyclopropyl.

In another embodiment, R2 has the formula: N N \ R10/ ‘6‘); R1 1 wherein X=l to 4; y=l to 3, R10 and R11 are, independently, H, (CH2)nNHR12 or (CH2)kNH(CH2)l NHR12, where n=k=l=l to 10, and R12 is H or C(N=H)NH2.

In the above compositions, R2 is preferably selected from the group consisting of Nl-acetylspcrmine, Nl-acetylspermidine, N8-acetylspermidine, N'-guanidinospermine, cadaverine, aminopropylcadaverine, homo spermidine, caldine (horspermidine), 7- hydroxyspermidine, thermine (norspermine), thermospermine, canavalmine, aminopropylhomospermidine, N,N'—bis(3-amin0pr0py1)cadaverine, aminopentylnorspermidine, N4-aminopropylnorspermidine, N4-amin0pr0pylspermidine, caldopentamine, homocaldopentamine, N4-bis(amin0pr0py1)norspermidine, pentamine, N4-bis(aminopropy1)spermidine, examine, homothermohexamine, homocaldohexamine, N-(3-amin0pr0py1)-1,3-pr0panediamine, N,N'—bis(3- aminopropyl)ethylendiamine, N,N'—bis(3-amin0pr0py1)-1,4-piperazine, N,N'—bis(3- aminopropy1)-1 ,3-piperazine, N,N'—bis(3-amin0pr0py1)-1,3-pr0panediamine, N,N'—bis(2- aminoethyl)-1,3-pr0panediamine, tris(3 -amin0pr0py1)amine, and minoethy1)amine.

Compounds include, but are not limited to: WO 10154 WO 10154 WO 10154 WO 10154 HN/ HN M 8/ NH ,0 \\O NH O o O/ NS HN HN NI 0 \NH NH NH n HN NH NH2 HN HN O / M NH NH a O WO 10154 \ / O’l'o \/\/\S /,\\ ' O H /N N D I o \n/N / \ H H o”§ N CI 0 o \V/ H H Cl S\NwN N\/\/\N/\/\NH2 H H 0w H H \N 0 S\N | H/\/\/\n/N NNHMNHZ 0 O O \\I/ H H \N 8\N . O NHZ k0 CAN H H H/\n/N\/\/N\/\/\N/\/\NH2H CI 0\\S// H H S \/\/N\/\/\N/\/\N/\ H \ EM H H N \ O 0 qu H H \N N«ANH2 | ‘N/V\/\n/ H H H H HZNW \/\/ NMMNHZ O\‘S// H H \NMNWNNNMNHH 2 H H /\//8\\’N\/\/N\/\/\N/\/\NH2H WO 10154 NH H2 WO 10154 )0? CH2 H H O ”WNWNNm/WNHZ WO 10154 H H HZNWNWNNMMNHZ H 2 WO 10154 0w& HN HN O,CRu NH NH 0w& HN HN NH NH2 ow,s\ HN HN NH NH N HN n NH NH O H HN HN h S H2N ,.

H H HN W (1:00 (iii (If? N— N— N— / / / (120% W, % Woo,O Additional disclosure may be found in WO99/03823, the disclosure of which is incorporated by reference as if written herein in its entirety.

Yet further compounds include, but are not limited to: NH /| NH H NH N NH \ ,N NH2 \N 2 \ H2N N \H/ HzNJLN / NH NH H <f)N O N H2N/\=/\Ncm N H2N/VI'ICHF2NH2 ,NH2 . HzN/T\O OH HO O Additional disclosure may be found in: Ackermann, JM; Pegg, AE; McCloskey, DE; Progress in Cell Cycle Research, 2003, Vol. 5, 8; Ekelund, S; Nygren, P; Larsson, R; mical Pharmacology, 2001, 61, 1183—1193; Huang, Y; e, A; Casero Jr, RA; Davidson, NE; Anti-Cancer Drugs, 2005, 16, 229—241; and , JL; Annu. Rev.

Pharmacol Toxicol. 1995, 35, 55-91; the disclosure of which is incorporated by reference as if written herein in their entireties.

Polyamine analogs depicted above may be prepared both as salts and as free bases. In certain embodiments, the salt is the hydrochloride salt. In certain embodiments, the number of coordinated ion pairs (for example H+Cl') will be tional to the number of amino groups in the polyamine. Such nation typically occurs at said amino groups, forming, for example, NH3+Cl' groups. However, not every amino group may be coordinated. For example, if the amino group is adjacent to an on-withdrawing group such as carbonyl or sulfonyl, it may not retain sufficient electron density to coordinate an ion.

In further embodiments, the number of coordinated ions will be proportional to the number of primary and/or ary amino groups in the ine.

Additional compounds which may be used in the methods and compositions described herein include: lly occurring polyamines found in prokaryotes and eukaryotic cells, polyamine analogs, polyamine biosynthesis inhibitors, and polyamine transport inhibitors.

Naturally occurring polyamines found in prokaryotes and eukaryotic cells include, but are not limited to: putrescine, spermidine, spermine, diaminopropane, cadaverine, norspermidine, aminopropylcadaverine, homospermine, rmine, thermospermine, aminopentylnorspermidine, bis(aminopropyl)cadaverine, aminopropylhomospermine, 30 canavalmine, homospermine, entamine, aminopropylcanavaline, bis(aminopropyl)homospermidine, bis(aminobutyl)norspermidine, aminobutylcanavalmine, ropylhomospermine, homopentamine, N5-aminobutylhomospermine, caldohexamine, thermohexamine, homothermohexamine, agmatine and N6-methylagmatine. See, e. g., Morgan D. M. L., 1999, Molecular Biotechnology 11: 229.

Polyamine analogs include, but are not limited to, 4 [1,19-bis (ethylamino)-5,10,15-triazanonadecane]; -3 [Nl,Nl1-diethylnorspermine; DENSPM; 1,11-bis (ethylamino)-4,8-diazaundecane; thermine; Warner-Parke-Davis]; BE3[N1,N7- bis(ethyl) norspermidine]; BE4[N1,N8-bis(ethyl) spermidine]; BE44 [N1,N9-bis(ethyl) homospermidine]; BE-343 [N1,N12-bis(ethyl) spermine; diethylspermine-Nl-N12; DESPM]; BE-373 [N,N'-bis (3-ethylamino) propyl)-1,7-heptane diamine, l-Dow]; BE4-4 [N1,N14-bis(ethyl) homospermine; lhomospermine-Nl-Nl-l]; BE43 [1,17- bis(ethylamino)-4,9,14triazaheptadecane]; BE34 [l,17-bis(ethylamino)-5,9,13- triazaheptadecane]; and 1,12-Mez-SPM [1,12-dimethylspermine]. (W002007/040535).

Polyamine synthesis inhibitors e but are not limited to: inhibitors of ornithine decarboxylase such as DFMO, aceylenic putrescine, ooxyaminopropane, antizyme, 2-butylputrescine, cadaverine, L-canaline, 5'-deoxy-5'—[N-methyl-N- [3(aminooxy)ethy1]amino]adenosine, 5'-deoxy-5'—[N-methyl-N-[3- (hydrazinopropy1)amino]adenosine, diaminopropane, 1,3-diaminopropanol, 2- di?uoromethyl putrescine, di?uorophenylethy1(4-aminopropylamidinohydrazone), 2,3- dimethylputrescine, N-dimethylputrescine, 2-ethy1putrescine, (+ or -)- alpha?uoromethylomithine, 2-?uoro putrescine, lputrescine, 2- hydrazinoomithine, ibuprofen, D-methyl acetylenic putrescine, methylglyoxal bis(3aminopropylamininohydrazone), 2-methylornithine, 2-methy1putrescine, 2- mono?uoromethyl-trans-dehydorornithine, 2-mono?uoromethy1 dehydroputrescine, monoquoromethylomithine, 2-monoquoromethy1putrescine, in, D-omithine, 2- pentylputrescine, p-phenylenediamine, opeptide MG 25000, phosphothreonine, phosphotyrosine, 2-propy1putrescine, putrescine, allo-S-adenosyl-L-methionine, S- ethylthioadenosine, methylthioadenosine, and 5' -methy1-thioadenosine as discussed in r H. (1993) ok of Enzyme Inhibitors, 2nd Ed. Weinheim:Basel(Switzerland); tors of S-adenosylmethionine decarboxylase, such as SAM486A (4-aminoindanon-1(2‘ amidino)hydrazone dihydrochloride monohydrate), S-adenosyl-1,8-diamino-3thiooctane, S- (5'—adenosyl)methylthioaminooxyethan, S-adenosy1methylthio-i-propy1amine, 5'-{ [(2)- 4-aminobuteny1]methylamino}-5'—deoxyadenosine, 5'—amino-5'deoxyadenosine, 5'- [(aminoiminomethy1)amino]-5']deoxyadenosine dihydrogensulphate, 1-aminooxy aminopropane, [2-(aminooxy)ethy1](5'—deoxyadenosine-5'y1)(methy1)sulphonium, 5'-[(3- aminopropyl]-amino)-5'—deoxyadenosine, 5'-[(3aminopropyl]-methy1amino)-5'— deoxyadenosine, 9-[6(RS)-amino-5,6,7-trideoxy-beta-D-ribo-octofuranosyl]-9H-purin amine, dride, n-butylglyoxal bis(guanylhydrazone), 9-[6(RS)-c-carboxamido-5,6,7- trideoxy-beta-D-ribo-octofuranosyl]-9H-purinamine, cyanide, cyanoborohydride, S-(5' deoxy-5'adenosyl)methionylethylhydroxylamine, S-(5' deoxy- 'adenosyl)methionylthiohydroxylamine, 5' -deoxy-5'—[N-methy1—N- [2(aminooxy)ethy1]amino]adenosine, )-diamino-5,6,7,8,9-pentadeoxy-beta-D-ribonanofuranosyl ]-9H-purinamine, diethylglyoxal bis(guanylhydrazone), ophynylethyl (4-aminopropylamidinohydrazone), dimethy1(5' -adenosy1jsulfonium, dimethylglyoxal bis(guanylhydrazone), ethylglyoxal bis(guanylhydrazone), hydroxylamine, 4- hydroxypenenal, MDL 73811, 5'[[3-methy1amino)propyl]amino]-5'-deoxyadenosine(1,1'- (methylethanediylidine)dinitro)bis(3-aminoguanididne), methylglyoxal bis(3- aminopropylamidinohydrazone), methylglyoxal bis(cyclohexylamidinohydrazone), pentanedialdehyde bis(guanylhydrazone), phenylhydrazine, propanedialdehyde bis(guanylhydrazone), semicarbazide, sodium dride, sodium cyanoborohydride, and spermine as discussed in Zollner H. (1993) Handbook of Enzyme Inhibitors, 2nd Ed. onal disclosure may be found in W02002/053519, the disclosure of which is incorporated by reference as if written herein in its entirety. onal ne analogs include N-(2-mercaptoethyl)spermine carboxamide (MESC), the disulfide from thereof, namely 2,2 1-dithiobis(N-ethyl-spermine- -carboxamide) (DESC), and N-[2,2,1-dithio(ethyl 1,1-aminoethyl)]sperminecarboxamide (DEASC). (WO98/17623) Polyamine ors that are small molecule inhibitors or modulators of key enzymes in the ine biosynthetic pathway include, but are not limited to: ODC inhibitors such as di?uoromethylomithine , alpha-mono?uoromethylomithine (MFMO), and methyl acetylenicputrescine (MAP); AdometDC inhibitors such as S-(5- deoxy-5adenoxyl)methyIthioethylhydroxylamine (AMA), 5-deoxy [(2aminooxyethyl)methyllamino]adenosine (MAOEA), and methylglyoxal bis(guanylhydrazone) (MGBG); spermidine synthase inhibitors such as S-adenosyll,8- diaminothiooctane TO), cyclohexylamine, and butylamine; spermine synthase inhibitors such as S-adenosyl-l,12-diaminothioazadodecane (AdoDATAD) and N-(n- butyl)-1 ,3-diaminopropane (BDAP).

In certain embodiments, the polyamine effector is a polyamine or arginine analog that carries a functional group that confers a cellular or DNA protective effect to the molecule, or that modulates the polyamine biosynthetic or catabolic pathway. Compounds of this nature include, but are not limited to amifostine, roxy-arginine (NORA), N1, N11-bis(ethyl) rmine (BE3-3), N12-bis(ethyl)spermine (BE4-3), N,N-bis[3- (ethylamino)-propyl]-1 ,7heptanediamine (BE7-3), BE3-3, BE4-3, BE7-3,N1- ethyl-N1 1-propargyl azaundecane, and the analogs SL-11141 and SL-11050 (structures set forth in one or more of U.S. Patent 5,889,061, Valasinas et aI., 2001,supra, WO 00/66587 and WO 02/38105). onal disclosure may be found in W003/013245, the disclosure of which is incorporated by nce as if written herein in its entirety.

As used herein, the terms below have the meanings indicated.

The term ine,” as used herein, alone or in combination, means signaling molecules secreted by cells of the immune system which have a local immunoregulatory . Cytokines may include, without limitation, IL-l, ILl-Ra, IL-2, IL-6, 1L8, IFNy, IP- , IL-17, MCP-l, MMP-9, MIP-lB, TNF-(x, TGFB, CRP, OPN, and RANTES.

When ranges of values are sed, and the notation “from n1 to n2” or “between n1 and n2” is used, where n1 and n2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range n them. This range may be integral or uous between and including the end values. By way of example, the range “from 2 to 6 carbons” is ed to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 uM (micromolar),” which is intended to include 1 uM, 3 HM, and everything in between to any number of significant figures (e.g., 1.255 uM, 2.1 uM, 2.9999 uM, etc.).

The term “about,” as used herein, is intended to y the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard ion to a mean value given in a chart or table of data, is recited, the term ” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant s.

The term “substantially” as used herein is intended to mean predominantly or having the overriding characteristic of, such that any opposing or detracting characteristics reach a level of ificance. By way of example, a composition “substantially” free of water might not be absolutely free of all traces of water, but would be sufficiently anhydrous that any remaining water would not in?uence the composition in any significant way. By way of r example, “substantially dose-limiting side effects” might be side effects which limited a dose to a level which was below that required for therapeutic efficacy.

The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,77 CCsyndrome,” and “condition” (as in medical condition), in that all re?ect an abnormal ion of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced on or quality of life.

A “proliferative disorder” may be any disorder characterized by dysregulated cellular proliferation. Examples include cancers, psoriasis, and atopic dermatitis.

As used herein, algesia” means a heightened sensitivity to pain, and can be considered a type of pain or a measure of pain-related behavior.

As used herein, “progressive” multiple sclerosis refers to forms of the e which progress towards an ever-worsening disease state over a period of time. Progressive MS includes, for example, primary progressive MS, secondary progressive MS, and progressive relapsing MS. These subtypes may or may not feature episodic ?are-ups of the disease, but are each associated with increased symptoms, such as increased demyelination or pain and reduced capacity for movement, over time.

As used herein, reference to "treatment" of a patient is intended to include prophylaxis. Treatment may also be tive in nature, i.e., it may include prevention of e. Prevention of a disease may involve complete tion from disease, for example as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect d to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.

The term "combination therapy" means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner.

In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

The term “patient” is generally synonymous with the term “subject” and means an animal differing from a disease, disorder, or condition treatable in ance with the methods disclosed herein, including all mammals and . es of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. ably, the patient is a human.

An “effective amount” or a “therapeutically effective amount” is a quantity of a compound (e.g., MGBG, a polyamine , a polyamine biosynthesis inhibitor or any agent) that is sufficient to achieve a desired effect in a subject being treated. For ce, this can be the amount necessary to treat a disease, disorder, ion, or adverse state (such as pain or in?ammation) or to ise measurably alter or alleviate the symptoms, markers, or mechanisms of the disease, er, condition, or e state. As just one example, an effective amount for the treatment of pain is an amount sufficient to prevent, delay the onset of, or reduce pain or one or more pain-related symptoms in a subject, as measured by s known in the art. Similar s of ing response to treatment of a number of diseases are well-know in the art. The effective amount of a compound of the present invention may vary depending upon the route of administration and dosage form. In addition, specific dosages may be adjusted depending on conditions of disease, the age, body weight, WO 10154 general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of agents.

The term “low dose,” in nce to a low dose formulation of a drug or a method of treatment specifically employing a “low dose” of a drug, means a dose which for at least one indication is subtherapeutic, or is a fraction of the dose typically given for at least one indication. Take for example the case of a drug for the treatment of proliferative disorders — a low dose formulation for the treatment of, say, multiple sis, might be a fraction of the dose for the treatment of an aggressive cancer. In this way, the dose for one disease might be an amount which would be subtherapeutic for another e. Alternatively, for a drug which is therapeutic in different individuals or tions at ent doses, and is available in a range of doses, a low dose may be simply a dose toward the low end of recognized therapeutic efficacy. Chronic diseases represent an embodiment treatable by low dose formulations and methods. Additionally, a subtherapeutic amount of a drug might be used in combination with one or more other drugs (themselves in either therapeutic or subtherapeutic amounts) to yield a combination formulation or treatment which is potentiated, that is, more efficacious than the expected effects of the sum of the drugs given alone. A low dose for the treatment of one tion may be two-fold, three-fold, four-fold, five-fold, six-fold, seven- fold, eight-fold, old, ten-fold, fifteen-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, may be one hundred-fold less than the therapeutic dose for a ent indication.

The phrase "therapeutically effective" is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.

The term “therapeutically acceptable” refers to those nds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are le for use in contact with the tissues of subjects without undue toxicity, irritation, and ic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

The term “drug” is used herein interchangeably with “compound” and “agent.” When a compound is referred to herein as “not a T-cell regulator,” what is meant is that any direct activity against T-cells is negligible and/or secondary to ty attributable to another leukocyte subtype. In certain embodiments, a cell which is “not a T-cell regulator” will be a cell of myeloid lineage. In certain ments, such a cell will be a dendritic cell, a monocyte, or a macrophage.

The phrase “reduced incidence of at least one side effect” as used herein means reduced to a degree that is significant. icance can be demonstrated by statistical methods (i.e., by non-overlapping standard deviations or appropriate ence intervals).

Significance of reduced nce of side effects may also be demonstrated by reference to qualitative measures such as, for example, the ability to achieve or maintain a eutic dose without dose-limiting toxicity (in all patients or in a patient subpopulation), the ability to prevent or delay e e or progression, or patient preference.

The phrase “approved for the treatment of a demyelinating disease,” as used herein, means approved by a drug regulatory agency (in the United States, Europe or any EPO country, Japan, Canada, or Australia) for the treatment of a demyelinating disease. In any ment disclosed herein, the demyelinating disease may be, specifically, multiple sclerosis.

The term “SAMDC inhibitor” means an tor of the enzyme S-adenosyl methionine decarboxylase. MGBG is believed to be one such SAMDC inhibitor, and other polyamines, polyamine analogs, and ine biosynthesis inhibitors may also be SAMDC inhibitors.

As used , a “polyamine” is any of a group of aliphatic, straight-chain amines d biosynthetically from amino acids; polyamines are reviewed in Marton et al. (1995) Ann. Rev. Pharm. Toxicol. 35:55-91. By “polyamine” is generally meant a naturally- occurring polyamine or a polyamine which is naturally produced in eukaryotic cells.

Examples of polyamines include putrescine, spermidine, ne and cadaverine.

As used herein, a “polyamine analog” is an c cation structurally similar but non-identical to naturally-occurring polyamines such as spermine and/or spermidine and their precursor, diamine putrescine. Polyamine analogs can be branched or un-branched, or incorporate cyclic moieties. Polyamines may comprise primary, secondary, tertiary, or quaternary amino groups. In one embodiment, all the nitrogen atoms of the polyamine analogs are independently secondary, tertiary, or quaternary amino , but are not so limited. Polyamine s may include imine, amidine and guanidine groups in place of amine . The term “polyamine analog” includes stereoisomers, salts and protected derivatives of ine analogs.

A “stereoisomer” is any optical isomer of a compound, including enantiomers and diastereomers. Unless otherwise indicated, structural formulae of compounds are intended to embrace all possible stereoisomers.

A “salt” or “pharmaceutically acceptable salt” is a compound formed by the replacement of one or more hydrogen atoms with elements or groups, which is composed of anions and cations, which usually ionizes in water; a salt is formed, for instance, by neutralization of an acid by a base. Examples of salts include, but are not limited to, halide, for example, chloride, e, or iodide, nitrate, sulfate, bisulfate, ate, acid ate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, rate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p- toluenesulfonate and pamoate (i.e., 1,1'—methylene-bis-(2-hydroxy- 3-naphthoate)) salts.

“Protected derivative” is used to refer to a compound protected with a protecting group. cting group” refers to a chemical group that exhibits the following teristics: 1) reacts selectively with the desired functionality in good yield (preferably at least 80%, more preferably at least 90%, more preferably at least 95%, still more preferably at least 99%) to give a protected substrate that is stable to the projected reactions for which protection is desired; 2) is selectively removable from the protected substrate to yield the desired functionality; and 3) is ble in good yield (preferably at least 80%, more preferably at least 90%, more preferably at least 95%, still more preferably at least 99%) by reagents compatible with the other functional group(s) present or generated in such projected reactions. Examples of suitable protecting groups can be found in Greene et al. (1991) Protective Groups in Organic Synthesis, 2nd Ed. (John Wiley & Sons, Inc., New York).

Exemplary ting groups for the amino functionality include, but are not limited to, mesitylenesulfonyl (MesSOz ) t- , benzyloxycarbonyl (CBz), t-butyloxycarbonyl (Boc), butyldimethylsilyl (TBDIMS), 9-f1uorenylmethyloxycarbonyl (Fmoc), or suitable photolabile protecting groups such as overatryloxy carbonyl (Nvoc).

The term “acyl,” as used herein, alone or in combination, refers to a yl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a —C(O)CH3 group. An carbonyl” or “alkanoyl” group refers to an alkyl group ed to the parent molecular moiety through a carbonyl group. Examples of such groups include carbonyl and ethylcarbonyl. es of acyl groups include formyl, alkanoyl and aroyl.

The term “alkenyl,” as used herein, alone or in combination, refers to a straightchain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as lene [(—CH=CH—),(—C::C—)]. es of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4- butadienyl and the like. Unless otherwise specified, the term yl” may include “alkenylene” .

The term y,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as defined below. Examples of suitable alkyl ether radicals e methoxy, , n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, utoxy, and the like.

The term “alkyl,” as used herein, alone or in combination, refers to a straightchain or branched-chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, said alkyl will se from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH2—). Unless otherwise specified, the term “alkyl” may include ene” groups.

The term “alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, ylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.

The term yl,” as used herein, alone or in combination, refers to a straight- chain or branched chain hydrocarbon radical haVing one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further ments, said alkynyl comprises from 2 to 4 carbon atoms.

The term “alkynylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —CEC—). Examples of alkynyl radicals include ethynyl, propynyl, hydroxypropynyl, butyn-l-yl, butynyl, pentyn- l -yl, 3-methylbutyn-l-yl, hexynyl, and the like. Unless otherwise specified, the term yl” may include “alkynylene” groups.

The terms “amido” and “carbamoyl,”as used herein, alone or in combination, refer to an amino group as described below attached to the parent lar moiety through a yl group, or Vice versa. The term “C-amido” as used herein, alone or in combination, refers to a -C(O)N(RR’) group with R and R’ as d herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R’)- group, with R and R’ as defined herein or as defined by the specifically enumerated “R” groups designated. The term "acylamino" as used , alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an "acylamino" group is acetylamino (CH3C(O)NH—).

The term “amino,” as used herein, alone or in combination, refers to —NRR7, wherein R and R7 are independently selected from the group consisting of hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R’ may combine to form heterocycloalkyl, either of which may be optionally substituted.

The term "aryl," as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term "aryl" embraces aromatic groups such as phenyl, naphthyl, cenyl, and phenanthryl.

The term “arylalkyl” or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group. The term “carboxyl” or “carboxy,” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a ylic acid salt. An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein. A “C-carboxy” group refers to a —C(O)OR groups where R is as d .

The term “cyano,” as used herein, alone or in combination, refers to —CN.

The term “cycloalkyl,” or, alternatively, “carbocycle” or “alicyclic,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, said cycloalkyl will comprise from 5 to 7 carbon atoms. es of such cycloalkyl groups include cyclopropyl, utyl, entyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, hydro-lH-indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are ed to include both fused ring s, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[l,l,l]pentane, camphor, adamantane, and o[3,2,l]octane.

The term “halo,” or “halogen,” as used herein, alone or in combination, refers to ?uorine, chlorine, bromine, or iodine.

The term "heteroalkyl," as used herein, alone or in combination, refers to a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations f, fully ted or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms ed from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atom may optionally be quatemized. The heteroatom(s) O, N and S may be placed at any interior on of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3.

The term "heteroaryl," as used herein, alone or in combination, refers to a 3- to l5-membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom selected from the group consisting of O, S, and N. In certain embodiments, said heteroaryl will comprise from 5 to 7 carbon atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, olyl, pyrazolyl, pyridyl, dinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, olyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, alinyl, quinazolinyl, indazolyl, riazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, hiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, ofuranyl, nyl, phenanthridinyl, xanthenyl and the like.

The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, ic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently selected from the group consisting of nitrogen, oxygen, and sulfur In certain embodiments, said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring s. In further embodiments, said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said hetercycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said hetercycloalkyl will comprise from 3 to 7 ring members in each 2014/010714 ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring s, and carbocyclic fused and benzo fused ring s; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group.

Examples of heterocycle groups e aziridinyl, azetidinyl, l,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[l,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihy-dropyridinyl, 1,3- dioxanyl, l,4-dioxanyl, l,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.

The term “lower,” as used herein, alone or in a combination, where not otherwise ically defined, means containing from 1 to and including 6 carbon atoms.

The term “sulfonyl,” as used , alone or in combination, refers to —S(O)2—.

Any definition herein may be used in combination with any other definition to describe a composite ural group. By convention, the trailing t of any such tion is that which attaches to the parent moiety. For e, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.

When a group is defined to be “null,” what is meant is that said group is .

The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower cycloalkyl, lower haloalkyl, lower kenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower arbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, C02CH3, COZH, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Two substituents may be joined together to form a fused five-, siX-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy. An optionally substituted group may be tituted (e. g., -CH2CH3), fully tuted (e. g., -CF2CF3), bstituted (e. g., -CH2CH2F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e. g., -CH2CF3). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as ; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted wit .” The term R or the term R’, ing by itself and without a number designation, unless otherwise defined, refers to a moiety selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted. Such R and R’ groups should be understood to be ally substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R’ and RH where n=(l, 2, 3, ...n), every tuent, and every term should be understood to be independent of every other in terms of selection from a group.

Should any le, substituent, or term (e. g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other ence. Those of skill in the art will further recognize that certain groups may be ed to a parent molecule or may occupy a position in a chain of elements from either end as written. Thus, by way of example only, an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.

Asymmetric centers exist in the compounds disclosed herein. These centers are ated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, including reomeric, enantiomeric, and epimeric forms, as well as d-isomers and l-isomers, and mixtures thereof. Individual stereoisomers of nds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers ed by separation or tallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. ng compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds sed herein may exist as geometric isomers. The present invention es all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof.

Additionally, compounds may exist as ers; all tautomeric isomers are provided by this invention. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.

In general, the solvated forms are considered lent to the unsolvated forms.

The term “bond” refers to a covalent e between two atoms, or two es when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, , or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.

The term "prodrug" refers to a compound that is made more active in vivo.

Certain compounds sed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism .‘ try, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally ed forms of the compound that readily undergo al changes under physiological conditions to provide the compound.

Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a nd when placed in a transdermal patch oir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have ed solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

The compounds disclosed herein can exist as therapeutically acceptable salts. The present invention includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both c and inorganic acids.

Such acid addition salts will normally be pharmaceutically able. However, salts of non-pharmaceutically acceptable salts may be of utility in the ation and purification of the compound in on. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to ceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. VCHA, Zurich, Switzerland, 2002).

The term “therapeutically acceptable salt,” as used herein, ents salts or rionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the riate nd in the form of the free base with a le acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate ate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, e, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quatemized with methyl, ethyl, propyl, and butyl des, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include nic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as , maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

Basic addition salts can be prepared during the final isolation and purification of the compounds by ng a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an c primary, secondary, or tertiary amine. The cations of eutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as ic quaternary 2014/010714 amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N—dimethylaniline, N—methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, benzylphenethylamine, 1-ephenamine, and N,N-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

While it may be possible for the compounds disclosed herein to be administered as the raw chemical, it is also possible to present them as a ceutical formulation.

Accordingly, provided herein are pharmaceutical ations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, gs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e. g., in Remington’s Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e. g., by means of tional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

The agent — a polyamine , polyamine biosynthesis inhibitor, polyamine ort inhibitor, or agent that inhibits SAMDC — may also be administered in combination with one or more entities. In one embodiment, the entity is a therapeutic entity, including, but not limited to, an anti-viral or anti-retroviral agent, a steroid or other anti-in?ammatory agent.

In another embodiment, the entity is a pharmaceutically acceptable carrier.

The l dose, frequency of administration, and on of treatment with the agent in a subject may vary from subject to subject, depending on the disease to be d or clinical endpoint to be reached (for example, tion of infiltration of macrophages to a tissue, or mitigation of pain) the subject's condition, the subject's age, weight, response to the treatment, and the nature of the therapeutic entity. Determination of the optimal dose and on of treatment is within the scope of one of skill in the art. The l dose and duration of ent may be best determined by monitoring the subj ect's response during the course of the treatment. In some ces, the administration of higher doses may permit less frequent administration, and lower doses may require more frequent stration in order to achieve a clinically significant improvement in the subj ect's condition. The agent(s) of the invention may be stered as a single dose or in multiple doses.

Generally, a therapeutically effective dose of the agent in accordance with the t methods will be one or more doses of from about 10 to about 1100 mg/mz. Lower dose regimens include doses of , 10-100, 10-50 and 20-200 mg/mz. Higher dose regimens e 200-400,250-500, 0, 500-800 00 and 800-1100 mg/mz. In one embodiment, the dose regimens range from 200-400 mg/mz. In another embodiment, the dose regimens range from 250-500 mg/mz. In yet another embodiment, the dose regimens range from 600-1 000 mg/mz. In some ments the agent is administered daily, once per week, once every other week, or once per month. In one embodiment, a dose regimen ranging from 200-400 mg/m2 is administered once a week. In another embodiment, a dose regimen ranging from 250-500 mg/m2 is administered once every other week.

The doses may be nt over the entire treatment period, or they may se or decrease during the course of the treatment. In one embodiment, the agent is administered once a week and starts with the administration of 200 mg/mz, and increases to 300 mg/m2 and 400 mg/m2 in the second and third weeks, respectively. In another embodiment, the agent is administered once every other week and is kept constant for the entire duration of treatment with the stration of 250 mg/mz. The doses of the agent may be administered for at least one week, at least two weeks, at least three weeks, at least four weeks, at least 6 weeks, or even at least 8 weeks. Adjusting the dose of the agent within these ranges for a particular subject is well within the skill of the ordinary clinician.

The agent may be stered via any conventional route normally used to administer a medicament including, but not limited to, oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal (including nasal), transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) routes. Intravenous delivery may take place via a bolus injection or via infusion; infusion may be done over a period ranging from less than a minute to several hours to continuously. In certain ments, a course of treatment will involve administration by a combination of routes.

For example, the agent may be administered via a combination of intravenous and oral routes for the treatment of pain or another disorder. In one embodiment, a “loading” dose may be administered IV in order to bring the concentration of drug to the desired therapeutic level, followed by one or more maintenance doses via the oral route to keep it there. In a further embodiment, a combination of oral and IV delivery may be used to mitigate pain in a surgery patient. The agent may be delivered pre-, peri-, and post- surgically by a combination of IV and oral routes. In one embodiment, the patient may be administered or may self-administer the drug orally prior to surgery, be stered the drug via IV infusion during surgery and just after, and may thereafter be administered or may self- administer the drug orally after surgery. In another embodiment, the patient may be administered the drug IV prior to surgery, be administered the drug via IV infusion during surgery and just after, and may thereafter be administered or may dminister the drug orally after y.

The agent may be administered as a pharmaceutical ition in a variety of forms including, but not limited to, liquid, , suspensions, tablets, pills, capsules, sprays and ls. The pharmaceutical compositions may include various pharmaceutically acceptable additives ing, but not limited to, carriers, excipients, binders, stabilizers, antimicrobial agents, antioxidants, diluents and/or supports. Examples of suitable excipients and carriers are described, for example, in “Remington's Pharmaceutical Sciences,” Mack Pub. Co., New Jersey (1991). In some ments, the agent may be administered via an IV infusion in an aqueous sugar on. The agent may also be associated with another substance that facilitates agent delivery. For example, the agent may be associated into liposomes. The liposomes, in turn, may be conjugated with targeting substance(s), such as IgGFc receptors.

Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as es, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid on. The active ingredient may also be presented as a bolus, electuary or paste. ceutical preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of n and a plasticizer, such as glycerol or sorbitol. Tablets may be made by ssion or molding, optionally with one or more accessory ients. Compressed tablets may be prepared by compressing in a le machine the active ingredient in a free-?owing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to e slow or controlled release of the active ient therein. All ations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as e, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active nds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable gs. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

The compounds may be formulated for parenteral administration by injection, e. g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e. g., in ampoules or in multi-dose containers, with an added preservative.

The compositions may take such forms as suspensions, ons or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose ners, for example sealed es and vials, and may be stored in powder form or in a freeze- dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, ately prior to use. oraneous injection solutions and suspensions may be prepared from sterile s, granules and tablets of the kind previously described.

Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may n antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include ding agents and thickening . Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection sions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl ose, sorbitol, or dextran. Optionally, the suspension may also contain le stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

WO 10154 In addition to the formulations described previously, the compounds may also be formulated as a depot ation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.

Thus, for e, the compounds may be ated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels ated in conventional manner. Such compositions may comprise the active ingredient in a ?avored basis such as e and acacia or tragacanth.

The compounds may also be formulated in rectal compositions such as itories or retention enemas, e. g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

Certain compounds disclosed herein may be administered topically, that is by non- systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.

In contrast, systemic administration refers to oral, intravenous, eritoneal and intramuscular administration. ations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of in?ammation such as gels, liniments, s, creams, nts or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain ments, the active ingredient may se from 2% w/w to % w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.

For administration by inhalation, compounds may be conveniently delivered from an insuf?ator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a le propellant such as dichlorodi?uoromethane, trichloro?uoromethane, dichlorotetra?uoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by tion or insuf?ation, the compounds ing to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

Exemplary unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.

Fillers to be used in the compositions herein include all those now known and in use, as well as those ped in the future. Examples of fillers, or diluents, include, without limitation, e, mannitol, xylitol, dextrose, sucrose, sorbitol, compressible sugar, microcrystalline cellulose (MCC), ed cellulose, cornstarch, pregelatinized starch, dextrates, dextran, dextrin, dextrose, maltodextrin, calcium carbonate, dibasic m phosphate, tribasic calcium phosphate, calcium sulfate, magnesium carbonate, magnesium oxide, poloxamers such as polyethylene oxide, and hydroxypropyl methyl cellulose. Fillers may have complexed solvent molecules, such as in the case where the lactose used is lactose monohydrate. Fillers may also be proprietary, such in the case of the filler PROSOLV® (available from JRS ). PROSOLV® is a proprietary, optionally high-density, silicified microcrystalline cellulose composed of 98% microcrystalline cellulose and 2% dal silicon e. Silicification of the microcrystalline cellulose is achieved by a patented s, ing in an intimate association n the colloidal silicon e and microcrystalline cellulose. ProSolv comes in different grades based on particle size, and is a white or almost white, fine or ar powder, practically insoluble in water, acetone, ethanol, toluene and dilute acids and in a 50g/l solution of sodium hydroxide.

Disintegrants to be used in the compositions herein e all those now known and in use, as well as those developed in the future. Examples of disintegrants include, without limitation, sodium starch ate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, povidone, crospovidone (polyvinylpolypyrrolidone), methyl cellulose, microcrystalline cellulose, powdered cellulose, low-substituted hydroxy propyl cellulose, starch, pregelatinized starch, and sodium alginate.

Lubricants to be used in the compositions herein include all those now known and in use, as well as those developed in the . Examples of lubricants include, without limitation, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, enated vegetable oil, light mineral oil, magnesium te, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, c acid, talc, and zinc stearate.

Glidants to be used in the compositions herein e all those now known and in use, as well as those developed in the future. Examples of ts e, without limitation, silicon dioxide (SiOz), talc cornstarch, and poloxamers. Poloxamers (or LUTROL®, available from the BASF Corporation) are A-B-A block copolymers in which the A segment is a hydrophilic polyethylene glycol homopolymer and the B segment is hydrophobic polypropylene glycol homopolymer.

Tablet binders to be used in the compositions herein include all those now known and in use, as well as those developed in the future. Examples of tablet s include, without limitation, acacia, alginic acid, carbomer, carboxymethyl cellulose sodium, dextrin, ethylcellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, copolyvidone, methyl cellulose, liquid e, maltodextrin, polymethacrylates, povidone, pregelatinized starch, sodium alginate, , sucrose, tragacanth, and zein.

Examples of surfactants include, without limitation, fatty acid and alkyl sulfonates; commercial surfactants such as benzethanium chloride (HYAMINE® 1622, available from Lonza, Inc., Fairlawn, N.J.); TE SODIUM® (available from Mallinckrodt Spec. Chem., St. Louis, MO); polyoxyethylene sorbitan fatty acid esters (TWEEN®, available from ICI Americas Inc., Wilmington, DE; LIPOSORB® P-20, available from Lipochem Inc., son NJ; CAPMUL® POE-0, available from Abitec Corp., Janesville, WI), polyoxyethylene (20) an monooleate (TWEEN 80®, available from ICI as Inc., Wilmington, DE); and natural tants such as sodium taurocholic acid, l-palmitoyloleoyl-sn-glycerophosphocholine, lecithin, and other phospholipids and mono- and diglycerides. Such materials can ageously be employed to increase the rate of dissolution by tating g, thereby increasing the maximum ved concentration, and also to inhibit crystallization or precipitation of drug by interacting with the dissolved drug by mechanisms such as complexation, formation of inclusion complexes, formation of micelles or adsorbing to the surface of solid drug Drug complexing agents and solubilizers to be used in the compositions herein include all those now known and in use, as well as those developed in the . Examples of drug complexing agents or lizers include, without limitation, the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins.

The addition of pH modifiers such as acids, bases, or buffers may also be beneficial, retarding or enhancing the rate of dissolution of the composition, or, alternatively, helping to improve the chemical stability of the composition. Suitable pH modifiers to be used in the compositions herein include all those now known and in use, as well as those developed in the future.

It should be tood that in addition to the ingredients particularly mentioned above, the formulations provided herein may include other agents conventional in the art having regard to the type of formulation in question. Proper ation is dependent upon the route of administration chosen. Any of the well-known ques, carriers, and ents may be used as suitable and as understood in the art; e.g., Remington, supra. The pharmaceutical compositions may be manufactured in a manner that is itself known, e. g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, ping or compression processes.

Compounds may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day.

Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is ive at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.

The precise amount of compound administered to a subject will be the responsibility of the attendant physician. The specific dose level for any particular subject will depend upon a variety of factors including the ty of the specific compound employed, the age, body weight, l health, sex, diets, time of administration, route of administration, rate of ion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity. Dosing frequency may also be selected or adjusted based on factors including those above as well as the formulation of the compound delivered. Dosing may occur, for example: once daily, twice daily, three or four times daily, every other day, weekly, bi-weekly, or monthly; or in cycles comprising a ned dosing period ed by a non-dosing period; or on an as-needed basis.

In certain instances, it may be appropriate to administer at least one of the compounds bed herein (or a pharmaceutically acceptable salt, ester, or g thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects enced by a subject upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial therapeutic agent. Or, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be ed by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the subject is enhanced). Or, by way of example only, the benefit experienced by a subject may be increased by administering one of the nds described herein with another therapeutic agent (which also includes a therapeutic n) that also has therapeutic benefit. By way of example only, in a ent for athy involving administration of one of the nds described herein, increased therapeutic benefit may result by also providing the subject with another therapeutic agent for neuropathy. In any case, regardless of the disease, disorder or condition being treated, the overall benefit experienced by the subject may simply be additive of the two therapeutic agents or the subject may experience a synergistic benefit.

In certain embodiments, the other therapeutic agent is an agent for the treatment of multiple sclerosis such as interferon a, interferon beta-lb, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, dimethyl fumarate (tecfidera) and unomide, as well as other interferons and immunomodulatory, immunosuppressant, or anti-in?ammatory drugs.

In other embodiments, the other therapeutic agent is a TNF inhibitor. The TNF inhibitor may be: a monoclonal antibody such as, for example, in?iximab (Remicade), adalimumab a), certolizumab pegol (Cimzia), or golimumab (Simponi); a ating receptor fusion protein such as etanercept l); or a small le, such as pentoxifylline or bupropion (Zyban, Wellbutrin).

In other embodiments, the other therapeutic agent is a disease-modifying anti- rheumatic drug (DMARD). Examples of DMARDs e azathioprine, ciclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, rexate (MTX), minocycline, sulfasalazine ($82), and cyclophosphamide.

In further embodiments, the other therapeutic agent is methotrexate.

Other agents for used in combination include interleukin 1 (IL-1) blockers such as ra (Kineret), T-cell costimulation rs such as abatacept (Orencia), interleukin 6 (IL-6) blockers such as tocilizumab (an anti-IL-6 receptor antibody; RoActemra, Actemra), monoclonal antibodies against B cells such as rituximab (Rituxan), and other biologics (eg.

Ocrelizumab, Ofatumumab, Golimumab, and Certolizumab .

In other embodiments, the other eutic agent is a glucocorticoid or a non- steroidal anti-in?ammatory drug (NSAID). NSAIDS include propionic acid derivatives such as ibuprofen, naproxen, ofen, ketoprofen, ?urbiprofen, and oxaprozin; acetic acid derivatives such as indomethacin, sulindac, etodolac, and diclofenac; enolic acid (oxicam) derivatives such as piroxicam and meloxicam; fenamic acid derivatives such as mefenamic acid and meclofenamic acid; selective COX-2 inhibitors (Coxibs) such as celecoxib (Celebrex), rofecoxib, valdecoxib, parecoxib, lumiracoxib, and etoricoxib.

In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills).

One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the doses of the multiple therapeutic agents may be any duration of time ranging from a few minutes to four weeks.

Thus, in another aspect, certain embodiments provide methods for treating disorders in a human or animal subject in need of such treatment comprising stering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, optionally in combination with at least one additional agent for the treatment of said disorder that is known in the art. Specific diseases to be treated by the compounds, compositions, and methods sed herein, singly or in combination, include, without limitation: pain; neuropathy; in?ammation and related disorders; arthritis; lic in?ammatory ers; atory disorders; autoimmune disorders; neurological disorders; and erative disorders, including cancer and non-cancerous diseases.

The compounds sed herein are useful to treat patients with pain, ing neuropathy and/or neuropathic pain, and in?ammatory pain. Pain indications include, but are not limited to, treatment or prophylaxis of surgical or post-surgical pain for s surgical procedures including amputation, post-cardiac surgery, dental pain/dental tion, pain resulting from cancer, muscular pain, mastalgia, pain resulting from dermal injuries, lower back pain, hes of various etiologies, including migraine, menstrual cramps, and the like. The compounds are also useful for the treatment of elated disorders such as tactile allodynia and hyperalgesia. The pain may be somatogenic (either nociceptive or neuropathic), acute and/or chronic.

Peripheral neuropathies which can be treated with the compounds disclosed herein include mono-neuropathies, mono-multiplex neuropathies, and poly-neuropathies, including axonal and demyelinating neuropathies. Both sensory and motor neuropathies are encompassed.

The neuropathy or neuropathic pain may be associated with a number of peripheral athies of g gies, including but not limited to: 0 -induced neuropathies, including those caused by physical injury (such as blunt trauma, abrasion, or burns) or disease state, physical damage to the brain, physical damage to the spinal cord, or stroke ated with brain damage; neurological disorders related to neurodegeneration; and post-surgical neuropathies and neuropathic pain (such as from tumor resection, mastectomy, and the like) 0 infectious and Viral neuropathies, including those caused by leprosy, Lyme disease, a herpes Virus (and more particularly by a herpes zoster Virus, which may lead to rpetic neuralgia), human immunodeficiency Virus (HIV, which may lead to HIV neuropathy), or a papilloma Virus, or any other pathogen-induced nerve ; 0 toxin-induced neuropathies (including but not limited to neuropathies induced by alcoholism, Vitamin B6 intoxication, rbon intoxication, amiodarone, chloramphenicol, disulfiram, zide, gold, lithium, metronidazole, misonidazole, nitrofurantoin) ; 0 drug-induced neuropathies, including therapeutic-drug-induced neuropathy, particularly a) herapy-induced neuropathies caused by anti-cancer agents such as taxol, taxotere, cisplatin, nocodazole, Vincristine, Vindesine and Vinblastine, and b) anti-Viral neuropathies caused by anti-Viral agents such as ddI, DDC, d4T, foscarnet, dapsone, metronidazole, and isoniazid); 0 Vitamin-deficiency-induced neuropathies ing those ing from Vitamin B 12 deficiency, Vitamin B6 deficiency, and Vitamin E deficiency); 0 hereditary athy (including but not limited to Friedreich ataxia, familial amyloid polyneuropathy, Tangier disease, Fabry disease; 0 diabetic neuropathy and neuropathy caused by lic disorders such as renal insufficiency and hypothyroidism; 0 neuropathy secondary to tumor infiltration, 0 auto-immune neuropathies, including those resulting from Guillain-B arre me, chronic in?ammatory de-myelinating uropathy, monoclonal gammopathy of undetermined significance and polyneuropathy, and multiple sclerosis; 0 other neuropathies and neuropathic pain syndromes including in?ammation-induced nerve damage, neurodegeneration, post-traumatic neuralgia, central neuropathic pain syndromes such as phantom limb pain, pain, complex regional pain syndromes (including but not limited to re?ex sympathetic dystrophy, causalgia), neoplasia- ated pain, vasculitic/angiopathic neuropathy, and sciatica; and 0 idiopathic neuropathies.

In certain embodiments, neuropathic pain may alternatively be manifested as allodynia, hyperalgesic pain, thermal hyperalgesia, or phantom pain. In another ment, neuropathy may instead lead to loss of pain sensitivity. Additional sub-categories of neuropathic pain are sed in Dworkin, Clin J Pain (2002) vol. 18(6) pp. 343-9. nds disclosed herein can also be used in the treatment or prevention of opiate tolerance in patients needing protracted opiate analgesics, and benzodiazepine tolerance in patients taking benzodiazepines, and other addictive behavior, for example, nicotine addiction, alcoholism, and eating disorders. Moreover, the compounds disclosed herein are useful in the treatment or prevention of drug withdrawal symptoms, for example treatment or prevention of symptoms of withdrawal from opiate, alcohol, or tobacco addiction.

Compounds disclosed herein can also be used in the treatment or prevention of respiratory disease or conditions, including: asthmatic conditions ing en-induced asthma, se-induced asthma, pollution-induced asthma, cold-induced asthma, and viral- d-asthma; chronic obstructive pulmonary diseases including chronic bronchitis with normal air?ow, chronic bronchitis with airway obstruction (chronic obstructive bronchitis), emphysema, asthmatic bronchitis, and bullous disease; and other pulmonary diseases involving in?ammation ing bronchioectasis cystic fibrosis, hypersensitivity pneumonitis, farmer's lung, acute respiratory distress syndrome, pneumonia, tion or inhalation injury, fat embolism in the lung, acidosis in?ammation of the lung, acute pulmonary edema, acute in sickness, acute pulmonary hypertension, persistent pulmonary hypertension of the n, perinatal aspiration me, hyaline membrane disease, acute pulmonary thromboembolism, heparin-protamine ons, sepsis, status asthamticus, hypoxia, xic lung injuries, and injury induced by inhalation of certain injurious agents including cigarette g, leading up to complications thereof such as lung carcinoma.

Compounds disclosed herein can also be used in the treatment or prevention of in?ammation and in?ammatory conditions. In?ammatory conditions include, without limitation: arthritis, including sub-types and related conditions such as rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, and pyogenic arthritis; osteoporosis, itis, bursitis, and other related bone and joint disorders; gastrointestinal ions such as re?ux esophagitis, diarrhea, in?ammatory bowel disease, Crohn's e, gastritis, irritable bowel syndrome, tive colitis, acute and chronic in?ammation of the pancreas; ary in?ammation, such as that associated with viral infections and cystic fibrosis; elated conditions such as psoriasis, eczema, burns, sunburn, dermatitis (such as contact dermatitis, atopic dermatitis, and allergic dermatitis), and hives; pancreatitis, hepatitis, pruritis and vitiligo. In addition, compounds of invention are also useful in organ transplant patients either alone or in combination with conventional immunomodulators.

Compounds disclosed herein can also be used in the treatment or prevention of autoimmune disorders. Autoimmune disorders include Crohns e, ulcerative colitis, dermatitis, dermatomyositis, diabetes us type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), autoimmune alomyelitis, Hashimoto's disease, idiopathic thrombocytopenic a, lupus erythematosus, mixed connective tissue disease, multiple sis (MS), myasthenia gravis, epsy, pemphigus vulgaris, pernicious anemia, psoriasis, psoriatic arthritis, ositis, primary biliary cirrhosis, rheumatoid arthritis, SjOgren's syndrome, scleroderma, al arteritis (also known as " giant cell arteritis"), vasculitis, and Wegener's granulomatosis. The compounds disclosed herein may regulate TH-17 (T-helper cells producing eukin 17) cells or IL-17 levels.

Autoimmune disorders may affect the nervous system. Examples of autoimmune disorders affecting the nervous system include polymyalgia, myasthenia gravis, Guillain- Barre Syndrome, chronic in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, acute disseminated encephalomyelitis (ADME), ophic lateral sclerosis (ALS), autoimmune peripheral neuropathy, lupus erythematosus, psoriatic arthritis, rheumatoid arthritis, osteoarthritis, and tic fever. nds disclosed herein can also be used in the ent or prevention of demyelinating diseases, ing multiple sclerosis (MS), optic neuritis, idiopathic in?ammatory demyelinating diseases, Guillain-Barre Syndrome (and sub-types), c in?ammatory demyelinating polyneuropathy, transverse myelitis, Balo concentric sclerosis, pernicious anemia, central pontine myelinolysis, Tabes dorsalis, neuromyelitis optica (NMO), ssive multifocal leukoencephalopathy (PML), anti-MAG (myelin-associated glycoprotein) neuropathy, hereditary motor and sensory neuropathy (Chacot-Marie-Tooth disease), cerebrotendinious xanthanomatosis, and leukodystrophies including adrenoleukodystrophy, adrenomyeloneuropathy, romatic leukodystrophy, globoid cell leukodystrophy (Krabbe disease), Canavan disease, vanishing white matter disease, Alexander disease, Refsum disease, and Pelizaeus-Merzbacher disease.

Compounds disclosed herein can also be used in the treatment or prevention of certain diseases and disorders of the nervous system. Central nervous system disorders in which nitric oxide inhibition is useful include cortical dementias including Alzheimer's disease, l s system damage resulting from stroke, ischemias including cerebral ischemia (both focal ia, thrombotic stroke and global ischemia (for e, ary to cardiac arrest), and trauma. Neurodegenerative disorders in which nitric oxide tion is useful include nerve degeneration or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in cases of central nervous system (CNS) trauma (such as spinal cord and head injury), hyperbaric oxygen-induced convulsions and ty, dementia e.g. pre-senile dementia, and elated dementia, cachexia, Sydenham's , Huntington's disease, son’s Disease, amyotrophic lateral sclerosis (ALS), Korsakoffs disease, cognitive disorders relating to a al vessel disorder, hypersensitivity, sleeping ers, schizophrenia, depression, depression or other symptoms ated with Premenstrual Syndrome (PMS), and anxiety.

Compounds disclosed herein can also be used in the treatment or prevention of metabolic disorders that are typically associated with an exaggerated in?ammatory signaling, such as insulin resistance, diabetes (type I or type II), metabolic syndrome, oholic steatohepatitis, atherosclerosis, cardiovascular disease, tive heart failure, myocarditis, atherosclerosis, and aortic aneurysm.

Compounds disclosed herein can also be used in the treatment or prevention of organ and tissue injury associated with severe burns, sepsis, , wounds, and hemorrhage- or resuscitation-induced hypotension, and also in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic , Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, tis, nephrotic syndrome, Behcet‘s syndrome, polymyositis, gingivitis, periodontis, swelling occurring after injury, ischemias including myocardial ischemia, cardiovascular ischemia, and ia ary to cardiac arrest, and the like.

Compounds disclosed herein can also be used in the treatment or prevention of (hyper) proliferative diseases, especially cancers, either alone or in combination of standards of care especially those agents that target tumor growth by re-instating the aberrant apoptotic machinery in the malignant cells. Hematological and non-hematological malignancies which may be treated or prevented include but are not limited to multiple myeloma, acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), and Chronic enous Leukemia(CLL), lymphomas, including Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (low, ediate, and high grade), as well as solid tumors and malignancies of the brain, head and neck, breast, lung, reproductive tract, upper digestive tract, as, liver, renal, r, prostate and colorectal. The present compounds and methods can also be used to treat the fibrosis, such as that which occurs with radiation therapy. The present compounds and methods can be used to treat subjects having atous , including those with familial adenomatous polyposis (FAP). Additionally, the present compounds and methods can be used to prevent polyps from forming in patients at risk of PAP. Non-cancerous proliferative disorders additionally include psoriasis, eczema, and dermatitis.

Compounds disclosed herein can also be used in the treatment or prevention of polycystic kidney e, as well as other diseases of renal dysfunction.

Compounds disclosed herein can also be used in the treatment or prevention of lmic diseases, such as glaucoma, retinal ganglion degeneration, ocular ischemia, corneal neovascularization, optic neuritis, retinitis, retinopathies such as glaucomatous retinopathy and/or diabetic retinopathy, uveitis, ocular photophobia, dry eye, Sjogren's syndrome, seasonal and chronic allergic ctivitis, and of in?ammation and pain associated with chronic ocular disorders and acute injury to the eye tissue. The compounds can also be used to treat post-operative in?ammation or pain as from ophthalmic surgery such as cataract surgery and refractive surgery.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-in?ammatory therapies, such as together with ds, NSAIDs, COX-2 selective inhibitors, 5-lipoxygenase inhibitors, LTB4 antagonists and LTA4 hydrolase inhibitors. The compounds of the subject invention may also be used to prevent tissue damage when therapeutically combined with antibacterial or antiviral agents. ary ments of the present methods are provided in the following examples. The ing examples are presented to rate the methods of the invention and to assist one of ordinary skill in using the same, and are not to be construed as limiting the scope of the invention.

MGBG Oral Activity Assays WO 10154 The following standard abbreviations are used to represent the associated cokinetic parameters.

AUC Area under the curve up to the last measurable tration plus the AUC extrapolated from the last measurable concentration (Clast at tlast) to infinity: AUCINFobS = AUleast + Clay/Lambda z (where kz is the first order rate constant associated with the terminal (log-linear) n of the curve) AUC0_12 Area under the curve between the time of dose and the 12 h time point AUC0_24 Area under the curve between the time of dose and the 24 h time point F Fraction available (bioavailability): F = [AUComl].doseiV / ].dose0ra1 ClobS Observed clearance VssobS Steady state volume of bution Vd Volume of distribution (often used with oral) Cl/FobS Apparent total body clearance as a function of bioavailability t1 /2 al half-life (HLM) Cmx The maximum observed concentration Tmax The time at which Cmax occurred Rhesus Macaque Single-Dose Two groups of three male rhesus monkeys were fasted overnight before being administered the test article, MGB G, as either a single bolus intravenous dose of 1 mg/kg (Group 1) or as a single oral gavage dose of 10 mg/kg (Group 2). Dose formulation analysis verified administered dose solutions as within 14% of ed concentrations of l and 10 mg/kg for Groups 1 and 2, respectively.

Blood samples were collected into tubes containing lithium heparin from the femoral vein/artery (approximately 1.0 mL) for plasma MGBG concentration measurement from all intravenously dosed animals prior to dosing and at approximately T=0.083 (5 min), 0.25 (15 min), 0.5 (30 min), 1, 2, 4, 8, and 24 hours after dosing. Blood samples for plasma MGBG concentration measurement were collected from all orally dosed animals prior to dosing at approximately T=l, 2, 4, 8, 12, 24, and 36 hours after dosing. Food was also withheld through the first four hours of blood sample collection.

The samples were centrifuged under refrigerated conditions following completion of sample collection at each interval. The resulting plasma was separated and stored frozen at approximately -700C until analysis.

WO 10154 PK analysis was performed on the individual plasma concentration-time profiles for MGBG using the WinNonlin non-compartmental approach (linear trapezoidal rule for AUC ations). Nominal dose values and sampling times were used for calculations. All MGBG plasma concentration measurements reported as BQL (< 2.51 ng/mL) were set equal to zero for the purpose of analysis. Following IV and PO administration of MGBG, plasma PK disposition parameters were calculated using the WinNonlin default selection criteria for the selection of the Lambda Z.

Evidence of systemic plasma MGBG exposure was ed at all ted plasma time points following IV and PO administration of MGBG. Hemolysis was noted in one animal in Group 1 at a single time point, which may have vely impacted the MGBG plasma concentration is for this animal. Consequently, a model-dependent two- compartmental analysis was used to calculate bioavailability.

Dog Single-Dose Two groups of three male beagle dogs weighing 9.0-10.7 kg and aged 8-30 months were fasted overnight before being administered the test e, MGBG, as either a single bolus intravenous dose of 1 mg/kg (Group 1) or as a single oral gavage dose of 10 mg/kg (Group 2). Dose formulation analysis verified administered dose solutions as within 17% of targeted concentrations of 1 and 10 mg/kg for Groups 1 and 2, respectively.

Blood samples (approximately 2.0 mL) were collected for plasma MGBG concentration measurement from all intravenously dosed animals prior to dosing and at approximately T=0.083 (5 min), 0.25 (15 min), 0.5 (30 min), 1, 2, 4, 8, and 24 hours after . A similar procedure was used with orally dosed animals was used, except that collection took place at T=1, 2, 4, 8, 12, 24, and 36 hours after . The samples were centrifuged under refrigerated conditions following completion of sample collection at each interval. The resulting plasma was separated and stored frozen at approximately -700C until analysis.

Analysis was performed by LC/MS/MS, and plasma PK disposition parameters were calculated using the last five plasma concentrations for IV (1—24 h) and PO (4—36 h) administration for the selection of the Lambda Z. Due to inter-animal variability and limited terminal phase data, these results should be interpreted with n. [05 34] No clinically abnormal findings followed IV or oral stration. Systemic exposure was observed at all time points.

Rat Single-Dose Eighteen male Sprague Dawley rats (Charles River) weighing 217-263 g and aged 8-9 weeks were administered the test article, MGBG as either a single bolus intravenous dose of 1 mg/kg (Group 1) or as a single oral gavage dose of 10 mg/kg. A cohort of three animals was iced via C02 inhalation anesthesia after final blood collection at each of T = 2, 4, 12, 24, 36, and 48 hours post-dose. Dose formulation analysis verified administered dose solutions as within 17% of ed tration of 10 mg/kg.

Analysis was performed by LC/MS/MS. Pharmacokinetic analyses were performed on the mean MGBG plasma concentration versus time data using the non- compartmental approach (linear trapezoidal rule for AUC calculations). The WinNonlin sparse sampling tool was used for PK calculations. All samples reported as BLQ (Below the Limit of tation, in plasma 2.50 ng/mL) were changed to 0.00 ng/mL for the purpose of analysis. Dose formulation analysis revealed that formulations were within 15% of the targeted dose concentration of 10 mg/kg.

Abnormal clinical findings were not noted following dosing. A single PO administration of 10 mg/kg of MGBG resulted in evidence of measurable MGBG levels in plasma through the 12 hour time point; beyond that point, certain samples began measure BLQ.

Additionally, in rats dosed as above with single oral administration of MGBG at mg/kg, immediately ing the plasma sample collection for each cohort (i.e., 2, 4, 12, 24, 36, and 48 hours after dosing), three rats were sacrificed, and spleen and liver tissues collected and ?ask frozen. As shown on , a single oral administration of MGBG at 10 mg/kg ed in greater overall exposure (as assessed by Cmax and AUCau) 0f MGBG to liver (120- and 160-fold, respectively) and spleen (4.0- and 9.3-fold, tively) tissue compared to plasma. This is tent with a selective uptake mechanism for MGBG. t wishing to be bound by theory, other SAMDC inhibitors which are selectively uptaken by cells may, like MGBG, be useful in the methods and compositions disclosed herein.

Mouse Single-Dose Twenty-four male DBA/1 mice weighing 19.5-24.7 g and aged 7-9 weeks administered the test article, MGB G, as either a single bolus intravenous dose via a lateral tail vein of 1 mg/kg (Group 1, n = 12) or as a single oral gavage dose of 10 mg/kg (Group 2, n = 12). Each dose group ted of 4 cohorts of 3 animals each. Group 1 was sampled at 5, , and 30 minutes after dosing; and 1, 2, 4, 8, and 24 hours after dosing. Group 2 was d at 1, 2, 4, 8, 12, 24, and 36 hours after dosing. Starting with the first time point, a new cohort was sampled at each successive time point up to the 1-hour (Group 1) or 12-hour (Group 2) time point. The order of sampling among the s was repeated for the subsequent time points (some s may have been bled only once). The second bleed for each cohort was terminal. Animals were iced via C02 inhalation anesthesia after final blood tion.

The samples were centrifuged under refrigerated conditions following completion of sample collection at each interval. The resulting plasma was separated and stored frozen at approximately -700C until analysis. Analysis was performed by LC/MS/MS.

Pharmacokinetic analyses were performed on the mean MGBG plasma concentration versus time data using the non-compartmental approach (linear trapezoidal rule for AUC calculations). The WinNonlin sparse sampling tool was used for PK calculations. Dose formulation analysis revealed that the IV and PO formulations were within 15% of their targeted concentrations.

Abnormal al findings were not noted following dosing. Evidence of systemic plasma MGBG exposure was observed at all ted plasma time points following IV and PO administration of MGBG.

Results of the foregoing assays are shown below in Tables 2 and 3. Values ed are mean across treatment groups without standard deviation.

Table 2 t1/2 Clobs AUC IV TmaX (h) (h) (ng/mL) (mL/min/kg) (h*ng/mL) .8 0.139 757 13.7 17.4 0.083 684 13.4 mouse 13 Table 3 Tmax Cmax AUC Clobs Vd ORAL 111/2 (h) F % (h) (ng/mL) (h*ng/mL) (mL/min/kg) (L/kg) rhesus 24.2 3.33 192 4240 6.63 13.2 35.0% rat 28.1 4.67 55.8 1280** 3.18 15.4 11.6% mouse 11.8 1 106 1420 6.68 38.3 44.3% dog 15.5 1 616 6290 8.29 14.6 49.0% In Table 2 above, the double asterisk indicates that the rat AUC reported is the AUCau, computed from time zero to the time of the last plasma concentration measurement.

Each of these values carries the caveat that terminal measurements are subject to different s of olation.

MULTI-DOSE RAT PHARMACOKINETIC AND TOLERABILITY STUDY The purpose of this study was to determine the pharmacokinetic (PK) properties and tolerability of MGBG in rats. Additionally, recovery from any toxic effects was assessed after a seven day non-dosing . Tolerability was demonstrated in test article-treated animals by body weight changes r to the control group and a lack of adverse clinical observations.

Three per group of male Sprague Dawley (CD® IGS, Charles River) aged 7—9 weeks and weighing 222.7—252.0 g were administered by oral (PO) gavage, twice daily, at , 20, or 30 mg/kg/dose (20, 40, or 60 mg/kg/day) for seven consecutive days. A washout period of seven days followed. Collection of approximately 200 ”L of whole blood was collected from the tail vein of all animals in Groups 5, 6, and 7 were bled at six (Day 1), seven (Day 7), or one (Days 9 through 15) time point(s), respectively. Whole blood samples were collected in a lithium heparin microtainer and sed to plasma by centrifugation.

Plasma was frozen at -700C. Pharmacokinetic analyses were performed on the individual animal plasma concentration versus time data for MGBG using WinNonlin (linear trapezoidal rule for AUC calculations). Nominal dose values and sampling times were used for calculations. For Study Day 7, the reported values for MGBG concentrations at time zero were used in the calculations of AUC. Study Day 1 disposition parameters were not reported due to insufficient terminal phase data to adequately characterize these ters. Following PO stration of MGBG on Study Day 7, plasma PK disposition parameters were calculated on plasma trations obtained following the second administered dose (T=12— 192 h) using the WinNonlin default selection criteria for the selection of the Lambda Z, the ation rate constant, upon which half-life, AUCINFobs, and s, were based; inter-animal variability was noted.

Plasma samples ted from test article-treated animals on Day 1 and Day 7 were subjected to lysis and confirmed systemic exposure to the test article at all time points. Over the dose range evaluated, Tmax values were dose-dependent and ranged from 3.33 to 14.0 h, and indicated absorption was ly d on Study Day 7 compared to Study Day 1. Systemic exposure (as assessed by Cmax and AUCau) increased with increasing dose, and the increase in both parameters was slightly less than dose-proportional at each evaluation interval. Repeat, twice-daily PO dosing of MGBG was associated with 3.77-, 4.03-, and old increases in mean AUCau values compared to Study Day 1 for the 20, 40, and 60 mg/kg/day dose groups, respectively. On Study Day 7, evidence of dose-dependent dispositions for Cl/FobS and elimination half-life were observed as mean parameter values for Cl/FobS and elimination half-life increased and decreased, respectively, with sing dose levels. ences between the control group and the 60 mg/kg/day dose group were noted for a few hematology parameters (lower reticulocyte count and percentage) and some serum chemistry parameters (e.g., osmolality and electrolyte changes consistent with slight dehydration). However, these changes were not thought to be adverse as they did not coincide with other signs of frank toxicity and the serum chemistry changes were demonstrated to be reversible. No gross or copic lesions were observed in test article- treated animals at terminal sacrifice, and no gross lesions were ed in test article-treated animals at recovery sacrifice.

Based on the findings of this exploratory study, the no observable adverse effect level (NOAEL) for MGBG administered by P0 gavage twice daily for seven consecutive days to male Sprague Dawley rats is 30 mg/kg/dose (60 mg/kg/day).

Table 4 PO Dose Day 1 2 AUC0-24 (mg/kg/day) (h*ng/mL) (h*ng/mL) (h*ng/mL) 773 1750 40 175 7.33 NC 1380 2980 NC 60 296 3.33 NC 2170 4380 NC Table 5 PO Dose Day 7 Cmax Tmax AUC AUC0.12 AUC0.24 (mg/kg/day) (ng/mL) (h) (h*ng/mL) (h*ng/mL) mL) Cl/Fobs 117 14 7930 1030 2190 24.3 40 194 9.33 13700 1800 3690 28.2 60 337 7.33 17100 3130 6040 35.8 ALLOMETRIC SCALING AND PREDICTED HUMAN EFFICACY Multi-species allometric scaling based on cokinetic parameters disclosed in Tables 2 and 3 was employed to calculate predicted pharmacokinetic parameters in humans according to methods known in the art. See, e. g., Ings RM, “Interspecies scaling and comparisons in drug development and toxicokinetics,” Xenobiotica, 1990 Nov;20(11):1201- 31 and Khor, SP et al., “Dihydropyrimidine dehydrogenase inactivation and 5-?uorouracil pharmacokinetics: tric scaling of animal data, pharmacokinetics and toxicodynamics of -?uorouracil in ,” Cancer Chemother Pharmacol (1997) 39(3): 833-38. Expected values are given below in Tables 6 and 7.

Table 6 CL Vss IV t1/2 (h) (mL/min/kg) (L/kg) Based 0“ 13.4 7.7 9.0 Mouse, Rat, Do , Rhesus Based 0“ 13.3 7.9 9.1 Mouse, Dog, Rhesus Table 7 CL Vss ORAL t1/2 (h) (mL/min/kg) (L/kg) Based 0“ 23.3 21.0 42.4 Mouse, Rat, Dog, Rhesus Based 0“ 23.0 20.9 41.6 Mouse, Do , Rhesus In both the murine carrageenan-induced paw edema and hyperalgesia models, the top efficacious dose of MGBG is 30 mg/kg PO BID (totaling 60 mg/kg/day). Based upon this dosing gm in mice, at least two methods to te the equivalent dosing in humans may be used.

The first method is based upon body surface area (BSA) ization (described in Reagen-Shaw et al. (2007) FASEB J. 22, 659-661), as the authors note that BSA correlates well across species for various biological parameters, ing basal metabolic rate, blood volume, caloric expenditure, plasma protein levels, and renal function. Using this method, a 60 mg/kg/day dose in mice would convert to about 4.9 mg/kg/day in humans.

The second method used to convert the cious 60 mg/kg/day dose in mice to an equivalent dose in humans was based more directly on allometric scaling. Data from an MGBG pharmacokinetic study consisting of a 10 mg/kg oral dose in mice was modeled in a simulation to determine the theoretical AUCINF value for a dosing regimen of 30 mg/kg PO BID, which was 9050 h*ng/mL. Next, predicted human clearance values as determined by single- and multi-species allometric scaling were used to estimate doses likely to produce an exposure in humans (AUCINF) similar to that of the 60 mg/kg/day in mice. Using single- species allometric scaling and a range of predicted human clearance values, a human equivalent dose would be in the range of 1.73 mg/kg/day to 451 mg/kg/day. Using multi- s allometric g, the predicted human equivalent dose is about 4.2 mg/kg/day.

In the murine carrageenan , we also observed efficacy of MGBG at lower doses, including 3 mg/kg PO BID and 10 mg/kg PO BID, which would proportionally convert to human doses of ~0.49 mg/kg/day and ~l.6 mg/kg/day.

The average body weight of a normal male human is often presumed to be 70 kg.

Thus, daily doses based on the predictions above could be estimated to range from about 25mg/day to about 350 mg/day.

The proper dose depends, of course, on a number of factors. The patient may weigh much more or much less, or be female, elderly, or juvenile, ing a lower or higher dose. The patient may exhibit a drug metabolic profile which might counsel for a lower or higher dose, such as a low expression level or activity of metabolizing enzymes such as cytochromes P450 (CYPs). This low expression or activity level may be due to a number of factors. Polymorphic expression of one or more CYPs (for example CYP2C19 and , though polymorphisms have been described for nearly all the CYPs) is known to be responsible for some populations to be “deficient” as compared to the population at large, leading to a “poor metabolizer” phenotype, requiring a lower dose. Additionally, exposure to an infectious agent or xenobiotic may cause repression of CYP sion or inhibition of existing CYPs. Alternatively, the patient may be physically weak, injured, or immunocompromised, all of which might counsel a lower dose. The t may be taking a number of other drugs which compete with metabolic systems (including CYPs as sed above) for disposal; this now polypharmaceutical effect may call for a lower dose. The dose also depends, as discussed above, on the condition and its severity. The efficacious dose for one disease or clinical endpoint will not necessarily be the same as the dose for another, and a severe, c, or otherwise serious case may call for a higher dose. However, a chronic case may also call for a lower dose administered over a longer or even indefinite period of time. All of these are discussed by way of example to illustrate the variability of ideal dosing; it is within the capacity of the skilled artisan to select an appropriate dosing range for a disease, population, or individual.

With these factors in mind, it should be clear that it is possible that the daily human dose may be as low as 1 mg/day, and as high as a 1g/day. In certain embodiments, the human dose may range: from 10 mg/day to 500 mg/day, from 20 mg/day to 400 mg/day, or from 25 mg/day to 350 mg/day. In further ments, the human dose may range: from120 mg/day to 350 mg/day, from 150 mg/day to 350 mg/day, from 200 mg/day to 350 mg/day, or from 250 mg/day to 350 mg/day. In certain embodiments, the human dose may be any one of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 75, 80, 85, 90, 95, 100, 110,120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 210, 220, 225, 230, 240, 250, 260, 270, 275, 280, 290, 300, 310, 320, 325, 330, 240 or 350 mg/day.

In certain embodiments, the human dose may be any one of 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 350, 355, 360, 365, 370, or 375 mg/day. In one embodiment, the dose may be 275 mg/day. In another embodiment, the dose may be 300 mg/day. In another embodiment, the dose may be 305 mg/day. In another embodiment, the dose may be 310 mg/day. In another embodiment, the dose may be 315 mg/day. In another embodiment, the dose may be 320 . In another embodiment, the dose may be 325 . In another embodiment, the dose may be 330 mg/day. In another embodiment, the dose may be 335 . In another embodiment, the dose may be 340 mg/day. In another embodiment, the dose may be 345 mg/day. In another embodiment, the dose may be 350 mg/day.

In certain embodiments, the human dose may be any one of 350, 375, 400, 425, 450, 475, 500, 525, 550 or 600 . In one embodiment, the dose may be 375 mg/day.

In r embodiment, the dose may be 400 mg/day. In another embodiment, the dose may be 450 mg/day. In another embodiment, the dose may be 500 mg/day.

In certain embodiments, the human dose may be any one of 25, 50, 75, 100, or 125 mg/day. In one embodiment, the dose may be 375 mg/day. In another embodiment, the dose may be 25 mg/day. In another embodiment, the dose may be 50 mg/day. In another embodiment, the dose may be 75 mg/day. In another embodiment, the dose may be 100 mg/day. In another embodiment, the dose may be 125 mg/day.

IN VIV0 CARRAGEENAN TESTS Carrageenan Paw Test for Edema and Hyperalgesia [05 60] Injection of carrageenan subcutaneously into the hind foot (paw) of a rat or mouse induces robust in?ammation and pain. The in?ammatory response begins 1-2 hrs post- carrageenan ion and persists for at least five hours following inoculation. In addition, the animal’s in?amed hind paw is sensitive to noxious (hyperalgesia) or innocuous (allodynia) stimuli, compared to the lateral hind paw. nds can be evaluated in this model for anti-hyperalgesia and anti-in?ammatory activity. A general increase in threshold or time to respond following drug administration suggests analgesic efficacy. A general decrease in paw swelling following drug administration suggests anti-in?ammatory efficacy. It is possible that some compounds will affect the in?amed paw and not affect the responses of the contralateral paw.

Embodiments of the eenan foot edema test are performed with als, reagents and procedures essentially as described by Winter, et al., (Proc. Soc. Exp. Biol.

Med., 111, 544 (1962)). Prophylactic and therapeutic embodiments have been developed, and are known in the art. The animals are evaluated for their siveness to noxious (paw pinch, plantar test) or innocuous (cold plate, von Frey filaments) i. In the ing protocol, mice were used.

Animals, nds, and dosing. y young male Swiss Webster mice in which weight variation of the mice will not exceed i 20% of the mean were used for the study. Animals were d into four groups of forty, and each group was dosed by oral gavage with either MGBG (BID, 12 hours apart at 30 mg/kg in 5 mL/kg normal saline), dexamethasone as positive control (QD, 1 mg/kg in 5mL/kg 0.5% methylcellulose), or saline vehicle (BID, 5 mL/kg). A fourth group served as naive l (no carrageenan, no treatment). Treatment with MGBG took place on each of three days prior to carrageenan, one hour prior to carrageenan, and 11 hours post-carrageenan. Paw edema is developed by injecting carrageenan (Sigma: k-carrageenan) subcutaneously in the subplantar region of the right paw of the mouse at a volume of 50 uL of 1% carrageenan (w/v) in . The contra- l paw (left paw) received the same volume (50 uL) of saline and serve as control. Mice will be anesthetized using light dose of ketamine before carrageenan injection.

Paw Edema. Immediately before sub-plantar administration of carrageenan and after 2, 3, 5 and 24 hours post carrageenan, mouse paw volume was measured using the plethysmometer (Ugo Basile). The assessment of edema was expressed as the mean increase in paw volume ve to control. ment ofPaw Withdrawal Latency. Prior to sub-plantar administration of carrageenan and after 0.5, 2, 3, 5, and 24 hours post- carrageenan, the latency of withdrawal response was determined by placing mice on a hot plate analgesia meter with surface temperature maintained at 510C. A cut-off period of 30s was maintained to avoid any thermal injury to paw. ately after testing, all paws were immersed in ice-cold water before returning to the cage. Paw withdrawal latency is calculated as At = right paw withdrawal - left paw withdrawal.

Serum, Plasma, and Histological Collection. Prior to first drug dose on day 0 and at peak disease times (5 and 24 hours post-carrageenan challenge for serum, prior to first drug dose on day 0 and at conclusion of , serum or plasma was collected from eight mice per group (each) and stored at -700C until cytokine level determination or MGBG drug level determination. For serum collection, whole blood samples are collected in a serum separator tube, processed by centrifugation and frozen at -700C. For drug level determination, whole blood samples are ted in a lithium heparin microtainer, processed to plasma by fugation and plasma frozen at -700C. Additionally, paws are ted and preserved in % in for histology.

Alternative Protocol. In an alternative embodiment of this assay, MGBG was dosed PO, BID at 3, 10, and 30 mg/kg (with dexamethasone as positive control, saline as negative, and a treatment/carrageenan-naive group, n = 16 each).

Results. MGBG was efficacious in reducing edema and hyperalgesia in the above assay.

Carrageenan Air Pouch Model [05 68] Injection of air subcutaneously will induce the formation of a connective tissue cavity lined with cells that le and function like a synovial lining. This method is commonly known as the Air Pouch Model and is a useful animal model of in?ammation that can be generated in a relatively short period of time. The air pouch may be created by aneous (SQ) injection of a volume of sterile air in the dorsal neck region. The model may be used to test the efficacy and potency of compounds such as polyamine analogues and polyamine biosynthesis inhibitors such as MGBG in ng various cellular and biochemical indicators of ation when administered as an oral (PO) gavage administration.

Animals, compounds, and dosing. Healthy Male Lewis rats (Charles River Laboratories, Wilmington, MA) weighing between 175-200 g were used. MGBG at doses n 1 and 60 mg/kg or vehicle (0.5% cellulose, 0.025% Tween-80) were administered by oral gavage (once daily at a volume of 10 mL/kg) for 6 days. A correction factor of 1.49 was used to account for the dihydrochloride salt/monohydrate form of MGB G.

Naproxen and dexamethasone at doses of 10 and 1 mg/kg, respectively, were dosed 1 day prior to, as well as the morning of, carrageenan injection.

Air pouches were formed on the dorsum of the rats during the last 4 days of MGBG or vehicle administration prior to carrageenan injection. Brie?y, rats were anesthetized with iso?urane, during which dorsal hair was removed and 20 mL of e air was injected subcutaneously into the intrascapular region. Pouches were d to develop for the next 4 days, with re-in?ation (to maintain pouch volume) of s 1 day prior to carrageenan injection.

One hour prior to carrageenan injection, animals were given their last dose of drug (MGBG, vehicle, naproxen, or dexamethasone). A 1% suspension of carrageenan (2 mL; FMC BioPolyer, Philadelphia, PA) suspended in saline was injected into the pouch cavity. At either 3 hours or 24 hours post-carrageenan injection, rats were euthanized by C02 asphyxiation and 2.5 mL of PBS (Sigma Chemical, St. Louis, MO) was injected directly into the pouch. The pouch was opened with surgical scissors and the pouch ?uid was collected using a transfer pipette. One aliquot was collected for measurement of total cell count with ential, and the other t for PGEz determination. In the latter case, the aliquot was centrifuged at 1200g for 10 minutes at 40C and the atant was collected for analysis of PGE2 via ELISA (Cayman Chemical Company, Ann Arbor, MI).

Samples for the 3- and 24-hour groups were collected as previously described at either 3 or 24 hours post carrageenan injection.

The protocol may be varied according to s known in the art. Additional tissue may be collected and/or weighed, and onal sectioning, staining, and microscopic examination may be ted.

Results. MGBG was efficacious in this model, as shown by changes relative to control indicative of reduced in?ammation. Fundamentally, MGBG selectively inhibited WO 10154 peak in?ammatory production of PGE2, without affecting basal levels of this mediator. By contrast, both naproxen and dexamethasone inhibited production of both in?ammatory and basal levels of this mediator.

IN VIV0 MURINE EN-INDUCED ARTHRITIS Collagen-Induced Arthritis Models of Arthritis and Rheumatoid Arthritis The collagen-induced arthritis (CIA) model is considered a suitable model for studying potential drugs active in human arthritis because of the many immunological and pathological similarities to human rheumatoid arthritis (RA), the involvement of localized major histocompatibility, complete II-restricted T helper lymphocyte activation, and the similarity of histological lesions. See, e. g., iec EF et al., gen-Induced Arthritis,” Current Protocols in Immunology, Unit 15.5 (1993). See also the model using a monoclonal antibody to CD18 and VLA-4 integrins bed in Issekutz, A.C. et al., logy (1996) 88:569. Features of this CIA model that are similar to that found in RA patients include, without limitation: erosion of cartilage and bone at joint margins (as can be seen in radiographs), proliferative synovitis, symmetrical involvement of small and medium-sized peripheral joints in the appendicular, but not the axial, skeleton. The following procedure was followed to assess the efficacy of MGBG in the treatment of arthritic diseases.

Animals and dosing. Inbred male DBA/1 mice (DBA/lOlaHsd, Harlan Laboratories), at least 7 weeks old, may be used in the following en-induced arthritis model. Twenty s per compound or vehicle are assigned to the arthritis and saline groups, 4 to the control group. To induce an arthritic state, mice are anesthetized with iso?urane and given 1501 uL of bovine type II collagen in Freund's complete adjuvant injections (day 0 and day 21). Mice are randomized by body weight into treatment groups on study day 7. Treatment consists of 25 mg/kg MGBG, 0.2 mg/kg thasone as ve control, or saline as vehicle control, all given as oral gavage beginning on study day 0 and continuing daily (PO, BID twice daily/12 hours apart). Twenty mice per group may be used, in which serum is collected from 15 animals, and plasma from five. Four additional animals serve as normal (untreated, non-arthritic) control group. The in-life portion of the study may proceed for 35 days.

Compounds. MGBG solution may be made from the ed dihydrochloride salt; other salts could be used, and in any case a salt/hydrate correction factor should be implemented. Solid MGBG can be stored at room temperature, but dose formulations should be made fresh for each administration. Dexamethasone is commercially available.

Data. On days 21-35, onset of tis typically occurs. During this time clinical scores for paw edema and swelling were given for each of the paws (right front, left front, right rear, left rear). Plasma draws are taken on days 0, l4, and 25 to assess pharmacokinetics, and blood draws taken on days 0 and 28 for disease analysis. Edema is measured on days 18-20, 22-27, and 29-34. In?ammation is assessed by infiltration of in?ammatory cells and edema. Post-euthanasia, terminal blood draws are collected, heparinized, and frozen at -700C until analyzed for cytokines such as osteopontin, TNFalpha, IL-l, CRP, MCPl, eta, RANTES, IFNgamma, a, IP-10, IL-l7, and MMP9.

Fore and hind paws and knees are collected, and following 1-2 days in fixative and then 4-5 days in decalcifier, processed, embedded, sectioned and stained with ine blue for ogical analysis. Bone resorption is quantified by presence of lasts, defects in or loss of medullary trabecular or cortical bone. age damage is assessed by examining the severity and spread of chondrocyte loss and collagen disruption. Pannus tissue formation and the severity and spread of other evidence of destruction of joint architecture are followed.

Statistical Analysis. Clinical data for paw scores (means for ) are analyzed by determining the area under the dosing curve (AUC) for days 1-15. For calculation of AUC, the daily mean scores for each mouse are entered into Microsoft Excel and the area between the treatment days after the onset of disease to the termination day is computed.

Means for each group are determined and % inhibition from arthritis controls calculated by ing values for treated and normal animals. Paw scores and histologic parameters (meaniSE) for each group are analyzed for differences using a Student's t-test with significance set at p 0.05. Percent inhibition of histologic parameters and AUC is calculated as [(mean disease control- mean normal)-(mean treated - mean normal)]/[ [(mean disease control- mean normal) ' (mean treated - mean normal)] ‘100. [05 80] MGBG was not efficacious in this model as a disease-modifying anti-rheumatic drug (DMARD), but did affect the early phase of paw swelling/in?ammation. The ols above may be varied according to methods known in the art.

IN VIV0 MURINE MOG-EAE MULTIPLE SCLEROSIS MODEL An experimental murine model of multiple sclerosis employing a myelin oligodendrocyte glycoprotein (MOG) peptide to induce experimental autoimmune encephalomyelitis (EAE) was employed to determine the efficacy of MGBG in preventing and treating that e. Because of its many similarities to MS, EAE is commonly used to study enesis of autoimmunity, CNS in?ammation, demyelination, cell trafficking, and tolerance induction. EAE is characterized by paralysis (in some models the paralysis is remitting-relapsing), CNS in?ammation and demyelination. EAE is ed primarily by tic cells, myelin-specific T cells (e. g. Th1 and Thl7), and M1 macrophages. B cells may also play a role in some models of EAE. Body weight also tracks disease progression.

EAE is induced in C57BL/6 mice by immunization with MOG35_55 or MOGst in CFA emulsion followed by administration of pertussis toxin (PTX) in PBS. The emulsion es antigen which initiates expansion and differentiation of MOG-specific autoimmune T cells.

PTX enhances EAE development by providing additional nt and facilitating entrance of autoimmune T cells into the CNS.

EAE induction. Chronic EAE develops in C57BL/6 mice after immunization with an emulsion of MOG35_55/CFA or MOGst/CFA followed by injection of pertussis toxin.

This model is used to test the potential of compounds to prevent or mitigate EAE disease. It can be run with the compound dosed from the time of immunization (prophylactic treatment), or with the aim of reversing the course of disease and facilitating recovery by dosing the compound from the time of EAE onset (therapeutic treatment). The model uses female C57BL/6 mice of age 10 to 14 weeks at the start of the study. Typically, EAE develops 8-18 days after immunization. EAE development is usually followed for 4 weeks (28 days) after immunization.

Stress reduces mouse susceptibility to EAE. Aside from any compound s, the administration of treatment during the disease ion period (~0-10 days after immunization) postpones disease onset and s disease severity. This is due to the stress of compound administration and the s of the vehicle on the mice. The more frequent the administration and the less tolerated the vehicle, the greater the impact on e pment. The stress of treatment and administration of vehicle has much less effect on disease development after clinical signs of EAE have ed.

Prophylactic treatment. In prophylactic studies, treatment begins before disease onset, at the time of immunization and group assignment. Mice are assigned to treatment groups in a balanced manner to achieve groups with similar distributions of body weights.

Prophylactic studies assess if treatment will affect the course of disease both before and after the first clinical signs of EAE. To compensate for the stress of treatment in prophylactic treatment studies and achieve the target disease severity, EAE may be induced with a higher dose of pertussis toxin than used in eutic studies. The dose of sis toxin is based on expected stress due to dosing (route, frequency, and formulation of vehicle). 2014/010714 In prophylactic studies, median time to disease onset is a sensitive measure of compound efficacy. Small changes in the immune response can result in postponed e onset - suppression of T cell activation and eration, antigen presentation, differentiation into Thl and/or Thl7 cells will all result in postponed onset of EAE. Delayed onset of EAE accompanied with lower maximum severity indicates overall efficacy of treatment compared to the negative control group.

Some studies will show ned EAE onset without other icant compound effects. In these cases the nd may affect an early pathway in immune response development, but eventually redundant processes compensate for the loss of the blocked pathway. Another possible explanation is that the drug was not able to maintain the blockade of the pathway for the duration of the study. [05 87] In other studies EAE is postponed but mice have higher end EAE scores than the vehicle-treated mice. Usually this is not caused by the compound making EAE worse but by the peak of disease in the nd-treated mice being postponed and coinciding with the period of recovery for the vehicle-treated mice.

When a compound is dosed prophylactically, one important readout of efficacy is reduction in maximum disease severity (mean maximum score, MMS). Reduced MMS indicates an overall reduction in EAE severity.

Scoring. Clinically, EAE progression is scored on a scale of 0 to 5, wherein each score represents the following clinical observations: 0 0: no change in function; 0 l: limp tail; 0 2: limp tail and weakness of hind legs; 0 3: one of the following: - limp tail and complete sis of hind legs; or - limp tail and complete paralysis of one front and one hind leg; or - severe head tilting, walking along edges of cage, pushing against cage wall, and spinning when picked up by tail; 0 4: limp tail and complete hind leg and partial front leg paralysis; 0 5: one of the following: - complete front/hind leg paralysis; or - neous rolling in cage; or - death ary to paralysis.

Course ofEAE development in untreated mice. Individual mice will have somewhat differing courses of disease. Most mice show initial signs of EAE between 9 and 14 days after immunization. Once EAE starts, the peak of disease almost always occurs 3-4 days later. The maximum score continues for several days and then mice partially recover. In some mice, disease will stay at maximum ty until the end of the study. Less often, a mouse will stay at the peak severity for only one day and then start recovering. The extent of recovery largely depends on the maximum ty reached by the mouse. Most untreated or vehicle-treated mice will not fully recover, but their end score will usually be 0.5 to 1.5 points lower than their maximum score. About 25% of untreated or vehicle-treated mice show ing EAE between 24 and 28 days after immunization, resembling a relapse.

Spinal cords of these mice at the time of EAE worsening have a large number of in?ammatory foci (2 7 foci per section), similar to histological findings at the time of EAE onset and peak, suggesting that these are true relapses with a new wave of in?ammation in the spinal cords. When mice are ed for a longer period of time, e slowly increases in severity, resembling the chronic progressive course of disease observed in human MS patients.

During the course of EAE, changes in body weight re?ect disease severity. Mice often lose a small amount of weight on the day ing immunization. This appears to be due to effects of the administered adjuvant and sis toxin. Mice then steadily increase their body weight until disease onset. On the day of EAE onset, mice consistently lose 1-2 g of their body weight (5-10% of body weight). The weight loss continues with the ssion of EAE ty, with the loss reaching around 20% of their set body weight at the peak of disease. The weight loss is most likely due to both paralysis and reduced food intake as well as high production of pro-in?ammatory cytokines such as TNF during the acute phase of in?ammation. After the peak of disease is reached, mice slowly gain weight, even if their al score does not improve. This increase in weight may be due to down regulation of in?ammation which results in lower levels of pro-in?ammatory cytokines in blood.

Untreated or vehicle-treated mice usually have around 90% of their pre-immunization body weight 28 days after immunization.

Histology. Typically, histological analysis is performed either at the end of the study (usually around 28 days after immunization) or at the time when the vehicle group reaches peak of disease (usually 14-18 days after immunization), and s on in?ammatory foci, apoptosis, and demyelination, each of which is addressed below.

In?ammation in EAE normally starts in the lumbar region of the spinal cord, spreading to the entire spinal cord by the peak of disease. [05 93] Apoptosis. Apoptotic cells are identified in H&E sections, and are usually not found during the first two days of disease development. They are found at the peak and during the chronic stage of EAE. The average number of tic cells is usually between 2 and 4 per section. The tic cells are neurons and their number correlates with disease stages. Apoptotic cells appear soon after disease onset, so at EAE onset there will be many in?ammatory foci, but few apoptotic cells. Then, the number of apoptotic cells increases until the peak of disease, then remains elevated. ation. At onset of disease the number of in?ammatory foci correlates ly with disease severity. The number of foci increases somewhat until the peak of e, when 6-15 in?ammatory foci /section are typically found throughout the spinal cord.

In the chronic stage of EAE (starting several days after the peak of disease), many in?ammatory foci resolve, typically resulting in 3-4 in?ammatory foci in each spinal cord section by approximately 28 days after immunization. [05 95] Because the t numbers of in?ammatory foci are t early in the course of disease, if histological analysis is performed at the end of the study, mice which have late EAE onset often have more in?ammatory foci in their spinal cords than might be expected from their clinical score. For example, in a 28 day study a mouse with EAE onset on 27 days after immunization and an end clinical score of 2 will likely have more atory foci than a mouse with EAE onset 9 days after immunization and an end score of 3.5. Similarly, a mouse which relapses shortly before the end of the study se is defined as l or more points of increase in clinical score) will usually have more in?ammatory foci at the end of the study than a mouse with stable chronic disease, even if the two have the same clinical score at the end of the study. [05 96] In?ammatory foci of approximately 20 cells were counted in each H&E stained section. When in?ammatory infiltrates ted of more than 20 cells, an estimate was made of how many foci of 20 cells were present. ination. Demyelination is usually not found during the first two days after disease onset, but is found at the peak of disease (4-5 days after EAE onset) and continues during the chronic phase of EAE. Demyelination scores do not change much between the peak and 28 days after immunization and usually average between 1.2 and 2.5.

Demyelination is scored in both Luxol fast blue stained sections (LFB) and in H&E sections.

In LFB sections, spinal cord white matter stains dark blue and demyelinated areas are a lighter blue color, and are associated with large vacuoles. In H&E stained sections disruption of normal structure with large vacuoles is indicative of demyelination.

The ination score represents an estimate of demyelinated area for each section as follows: 0 — no demyelination (less than 5% demyelinated area) 1 — 5 to 20% demyelinated area 2 — 20 to 40% demyelinated area 3 — 40 to 60% demyelinated area 4 — 60 to 80% inated area — 80 to 100% demyelinated area [05 99] For Luxol fast blue stained slides, the size of the demyelinated area was estimated based on less e blue staining of myelin. For H&E stained sections, the demyelinated area was estimated by g for interruption of normal structure — pallor and vacuolation consistent with edema and demyelination, and dilated axons.

Statistical is. Unless otherwise noted, statistical analysis was performed as follows: disease incidence compared using chi-square test; mean day of EAE onset, change in body , and number of apoptotic cells compared using 2-tailed Student’s t-test; median day of EAE onset compared using Wilcoxon’s survival test; mean maximum score (MMS), end score, and demyelination scores (LFB and H&E) compared using Wilcoxon’s non-parametric test.

First MOG EAE Protocol.

Materials and Methods. Ten week old female C57BL/6 mice weighing 18-23 g (Taconic Farms) were divided into four groups: mock immunized (n = 3) and three MOG- immunized groups receiving MGBG at 30 mpk BID (as the di-HCl monohydrate with a correction factor of 1.49), imod (FTY720) at 3 mpk QD with a second mock vehicle dose, or 0.9% saline vehicle BID (n = 12 each). MOG35.55 peptide was administered by subcutaneous ion at two sites in the back with the on component (containing MOG35_55 for test article or positive control, or PBS for negative control) of Hooke KitTM MOG35_55/CFA Emulsion PTX, g number EK-2110 (Hooke Laboratories, Lawrence MA). One site of injection was in the area of upper back, imately 1 cm caudal of the neck line. The second site was in the area of lower back, approximately 2 cm cranial of the base of the tail. The injection volume was 0.1 mL at each site. Within 2 hours of the injection of emulsion, and then again 24 hours after the injection of emulsion, the pertussis toxin component of the kit (diluted with PBS to achieve 176 ng/dose for the first injection and 165 ng/dose for the second ion) was stered intraperitoneally. The volume of each injection was 0.1 mL.

Inoculated, untreated mice develop EAE 8-14 days after immunization with MOG35_55/CFA and stay chronically paralyzed for the 28-day duration of the experiment.

Clinical scores, body weights, and histopathology of spinal cord (e. g., demyelination, in?ammatory infiltrates, and/or apoptosis) may be measured and ed as set forth above. s . Clinical scores, given as mean score +/- the standard error of the mean (SEM), are shown in As can be seen in vehicle-treated animals developed EAE clinical signs beginning on day 10 as expected, with mean clinical signs increasing until day 16, when scores surpassed 2 and thereafter remained between 2 and 3. Fingolimod was the most efficacious at the high dose tested, yielding mean clinical scores of 0 throughout the experiment, a level almost indistinguishable from the mock-immunized group. MGBG also prevented onset and progression of EAE, with the first clinical signs becoming evident on day 15 and slowly increasing fter to a level still below 1 on day 21, and remaining below 1 for the on of the ment. Results demonstrate that MGBG, like fingolimod, is efficacious in ting and ng neurological symptoms of MS in an accepted model of the disease.

Additionally, as shown in treatment with either fingolimod or MGBG prevented loss of body weight in the EAE model. Results in given as the mean percent change from baseline (study start) +/- SEM, show that all groups continued to gain weight until approximately day 8 when body weights of approximately 107-113% were seen.

Thereafter, the vehicle-treated group began to lose weight, with rapid loss to 95% on day 15, and reaching a low of about 93% on day 20 before recovering slightly by the end of the study to about 95 %. The sham-immunized and MGBG- and imod- treated groups, generally speaking, each retained weight gained throughout the study, hovering between about 108% and about 114%. Fingolimod and vehicle groups demonstrated a slight trend of gradual and continued weight gain over the course of the study. MGB G-treated subjects showed the most substantial gains initially, nearing 115% on day 11, but showed gradual loss to about 108% on day 24, before rising slightly again. These results further demonstrate that MGBG, like fingolimod, is efficacious in preventing and treating symptoms of MS. athology. On day 28 (end of the study) all mice were sacrificed for histological analysis and ed with PBS, and spines were collected in 10% buffered formalin. For each mouse, 3 Luxol fast blue stained sections and 3 H&E sections, from WO 10154 lumbar, thoracic, and cervical spinal cord, were prepared and analyzed by a pathologist blinded to the experimental groups and all clinical readouts. The number of in?ammatory foci, tic cells, and demyelinated regions in each of the three H&E sections was determined.

Histopathological results are shown in FIG.s 3-5, which confirm that MGBG, like fingolimod, reduces histopathological signs of MS such as nflammation, demyelination (via both stains), and apoptosis. onally, the negative control group (data not shown) demonstrated scores of zero.

Second MOG EAE Protocol.

A second EAE experiment was run substantially as disclosed above, except that fingolimod was dosed at 1 mpk QD, and the pertussis toxin was administered at 165 ng/dose for both injections.

Results. EAE was more severe in this study than in the typical study conducted according to this protocol, and more severe than in the previous study. All mice in the vehicle group developed severe EAE. Disease development in the fingolimod-treated group was not as strongly suppressed as in the previous study or as in the typical study. This is not surprising, given that more severe disease is generally more difficult to ss. Mice in the MGBG-treated group developed ntially reduced disease compared to that of the vehicle group, displaying comparable efficacy to that of fingolimod.

Results are given in Figs 6-10. Consistent with the previous study, MGBG was efficacious at postponing disease onset and reducing EAE severity.

Fluorescence-Activated Cell Sorting. In addition to clinical scoring, flow tric analysis was med on CNS-infiltrating cells from 6 mice in each of the vehicle-, imod- and MGBG-treated groups, as well as in all three mice from the mock- immunized (disease-free) group.

On Day 28, the brain and spinal cord tissue (from 6 of 12 mice from each of the MOG-immunized groups; and from all 3 mice from the mock-immunized group) in the second MOG EAE study were pooled and infiltrating cells were isolated by Percoll gradient.

After isolating infiltrating cells from each mouse separately, cells were placed in culture with phorbol myristate acetate (PMA, 50 ng/mL), ionomycin (0.5 ug/mL) and brefeldin (1 ug/mL) and incubated for 4-5 hours. The cells were then washed and stained for ?ow tric is, as specified below. The following analyses were performed (Becton Dickinson FACScan): Anti-CD4-Cy-5/anti-IL-l7A-PE/anti-IFNy-FITC (Thl/Thl7 cells) Anti-CD4-Cy-5/anti-CD1 lc-PE/anti-CD45.2-FITC (infiltrating tic cells) Anti-CD1lb-Cy-5/anti-IL-lZ-PE/anti-CD45.2-FITC (Ml macrophages) Anti-CD1lb-Cy-5/anti-CD206-PE/anti- IL-lO-FITC (M2 macrophages) The number of cells positive for relevant stains and stain combinations was computed both as a percentage of the analyzed cells and as the average number of cells per mouse for each group.

Table 8 — Roles of CNS-infiltrating cells and nes These cells trigger EAE. Mice with EAE are known to have more CNS-infiltrating CD4+ cells than disease-free mice, and the number of rating CD4+ cells in the CNS often correlates with disease severity A pro-in?ammatory cytokine produced by Th-l7 cells. Th-l7 cells are believed to play a major pathogenic role in EAE development.

IFNy is the main cytokine produced by Th-l cells. While the role CD4+IL— of IFNy in EAE is not clear, it is believed to be highly pathogenic in EAE.

IFNy is the main cytokine produced by Th-l cells. While the role of IFNy in EAE is not clear, it is believed that Th-l cells, which produce IFNy play a pathogenic role in EAE, especially during the chronic phase of disease.

Dendritic cells Play a critical role in presenting antigen to T cells and their (DC) activation. Therefore they play a critical role in controlling CD4-CDl lc+ immune pI'OCCSSCS.

CD452 high Part of integrin heterodimer (Mac-l) and is expressed ily on macrophages (and microglia cells in the CNS) and other cells CDllb of the innate immune system (NK cells, granulocytes, some (integrin alpha M) dendritic cells). Most of these cells are ed to play a pathogenic role in EAE development. 2014/010714 A mannose receptor, which is up-regulated in M2 macrophages (which are believed to suppress Th-1 and Th-17 type T cell responses). This is usually ed on macrophages (CD11b+).

The final enzyme in the urea cycle. It converts L-arginine into L- omithine and urea. It is expressed in cytoplasm and it competes with nitric oxide synthase for L-arginine. Arginase-l is expressed Arginase-l in tively-activated macrophages (M2 type hages), and plays an important role in suppressing T cell functions. This is usually measured on macrophages (CD11b+).

The main marker of dendritic cells. F4/80 is one of the markers of mature macrophages. Therefore CD11c+F4/80- cells are mostly dendritic cells.

An anti-in?ammatory ne produced primarily by monocytes, macrophages (M2-type), Treg and Th-2 cells.

A ne produced by dendritic cells and macrophages. It is essential for Th-l cell differentiation and is believed to play an important role in development of autoimmune diseases.

Mice treated with MGBG had a significantly reduced relative and absolute number of CNS infiltrating dendritic cells (DCs, high, CD11c+) and a significantly reduced number of ILproducing cells among CNS-infiltrating CD11b-cells. Results are given in the tables below, where * indicates p<0.05 and ** indicates p<0. 1. Tables 9 and 11 show results in terms of percentages of total cells, and Tables 10 and 12 shows results in terms of raw numbers of cells (103).

Table 9 % IL- % Total # of 17A+ CD11c+ CNS- % of cells of % CD4+ of CD45.2 infiltrating CD4+ CD4+ IFNy+ high CD4- Treatment cells (103) cells cells cells cells vehicle 723.33 +/- 34.32 +/- 14.77 +/- 15.75 +/- 12.05 +/- (0.9% saline) 258.43 5.36 2.14 6.98 4.75 % IL- % Total # of 17A+ CD11c+ CNS- % of cells of % CD4+ of CD45.2 infiltrating CD4+ CD4+ IFNy+ high CD4- Treatment cells (103) cells cells cells cells fingolimod, 620.00 +/- 15.22 +/- 30.89 +/- 11.39 +/- 190.16 2.06 5.36 MGBG, 30 500.00 +/- 15.24 +/- 15.85 +/- 7.21 +/- mg/kg BID 142.55 ** 6.02 6.48 1.89 * Negative 286.67 +/- 7.65 +/- 25.82 +/- 11.87 +/- EAE control 41.63 * 1.31 * 9.71 5.26 Table 10 Total # of CD45.2 CD4+ IL- CNS- high CD4- Treatment CD4+ cells 17A+ infiltrating CD11c+ cells cells (10 ) cells vehicle 723.33 +/- 245.68 +/- 35.71 +/- 24.70 +/- (0.9 % ) 258.43 88.17 11 .94 4.88 fingolimod, 620.00 +/- 117.89 +/- 17.67 +/- 18.10 +/- 1mg/kg QD 190.16 76.59 * 12.15 * 4.64 * MGBG, 30 500.00 +/- 152.11 +/- 23.55 +/- 11.90 +/- mg/kg BID 142.55 ** 82.13 ** 17.12 4.14 * Negative EAE 286.67 +/- 30.26 +/- 2.28 +/- 8.87 +/- 1. control 41.63 * 4.25 * 0.21 * 79 * Table 11 Total # of % % IL12+ of CNS- CD206+ IL10+ # of CD45.2 infiltrating % of of of IL12+ high cells CD11b+ CD11b+ CD11b+ cells CD11b- Treatment (10"3) cells cells cells (10"3) cells Total # of % % IL12+ of CNS- CD206+ IL10+ # of CD45.2 infiltrating % of of of IL12+ high cells CD11b+ CD11b+ CD11b+ cells CD11b- Treatment (10"3) cells cells cells (10"3) cells vehicle 723.33 +/- 21.04 +/- 1.48 +/- 3.31 +/- 1.89 +/- 0.14 +/- (0.9% saline) 258.43 3.83 0.21 1.42 1.15 0.08 fingolimod, 620.00 +/- 1.81 +/- 1.65 +/- 1.86 +/— 0.16 +/— 190.16 0.65 1.04 0.12 MGBG, 30 500.00 +/— 1.39 +/— 2.37+/— 0.89 +/— 0.06 +/— 142.55 ** 0.65 0.41 ** 0.06 ** Negative 286.67 +/- 29.94 +/- 2.07 +/- 1.36 +/- 0.20 +/- 0.00 +/- EAE l 41.63 * 2.34 * 1.27 0.82 ** 0.19 * 0.00 * Table 12 Total # of CD45.2 CNS- CD11b+ CD11b+ high CD11b+ IL12+ Treatment infiltrating CD206+ IL10+ CD11b- cells cells cells cells cells IL12+ (10"3) cells vehicle 723.33 +/- 145.80 +/- 2.11 +/- 4.46 +/- 1.89 +/- 0.63 +/- (0 9. (70 258.43 37.87 0.43 1.01 1.15 0.40 saline) fingolimod, 620.00 +/- 244.75 +/- 4.07 +/- 4.22 +/- 1.86 +/- 0.41 +/- 1 mg/kg 190.16 95.47 * 1.54 * 2.64 1.04 0.33 MGBG, 30 500.00 +/- 137.88 +/- 1.92 +/- 3.37 +/- 0.89 +/- 0.21 +/- mg/kg BID 142.55 ** 38.51 1.03 2.14 0.41 ** 0.20 * Negative 286.67 +/- 85.54 +/- 1.68 +/- 1.22 +/- 0.20 +/- 0.00 +/- 41.63 * 11 .29 * 0.89 0.87 0.19 * 0.00 * control Third MOG EAE Protocol.

A third EAE experiment was run substantially as disclosed above, except that imod was dosed at 0.1 mpk QD (which corresponds well with the typical human dose or 0.5 mg/day, scaling for body e area), and an additional group combining MGBG 30 mpk and fingolimod 0.1 mpk was added. Here as well, the pertussis toxin was administered at 165 ng/dose for both injections.

Results. Both fingolimod and MGBG separately showed comparable efficacy in ng disease severity and postponing disease onset at the doses tested. There were also icantly fewer in?ammatory foci and icantly less demyelination in treated mice ed to the vehicle-treated mice. Importantly, no mice in the fingolimod/MGBG combination group developed EAE, and all other clinical readouts (e.g. body weights) were significantly improved (no signs of EAE) compared to the vehicle group — no disease was detectable in these mice.

Collectively, these results indicate that the combination of fingolimod and MGBG was highly efficacious at preventing development of EAE. In addition, mice which received the combination treatment had significantly improved clinical and histological readouts compared to the mice receiving either imod or MGBG alone. The combination appeared to prevent disease from developing.

Other combinations of agents could be readily tested in a protocol r to the above. For example, interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, zumab, laquinimod, dimethyl fumarate (tecfidera), and teri?unomide could each be tested in combination with MGBG. Other SAMDC inhibitors could be tested as well. It is expected that these combinations would be similarly efficacious. Without wishing to be bound by theory, the combination of MGB G, which appears to affect early events in the pment of MS such as antigen presentation and the infiltration of dendritic cells into the CNS, should be efficacious in ation with other drugs, for example, those like fingolimod which act at a different (in certain embodiments, later) stage in the pment of an episode or ?are-up of multiple sclerosis, or another demyelinating disease.

Fourth MOG EAE Protocol.

A fourth EAE experiment was run similarly to the above, but was designed to examine the effect of MGBG on cell populations during onset and peak disease. In this ol, there were 3 experimental groups with 20 mice/group and 1 mock-immunized group with 8 mice. Fingolimod was dosed at 1 mpk QD, MGBG at 30 mpk BID, and the pertussis toxin was administered at 165 ng/dose for both injections. Flow cytometric analysis was performed on CNS-infiltrating cells from 16 mice from each of the e-, fingolimod- and MGBG-treated groups, as well as from all mice in the mock-immunized group. Half of the analyzed mice from each group were collected at the time of EAE onset in the e group and half were collected at the time of EAE peak in the vehicle group. Mouse termination was over eight separate days, because individual mouse in the e group d EAE onset and EAE peak on different days. Eight (8) of the mice in the vehicle group were sacrificed at each time-point. For each of these mice, a matching mouse from each of Groups 2 and 3 was sacrificed on the same day. For each two (2) of these vehicle group mice, a matching mouse from Group 4 was sacrificed. When selecting matching mice from other groups for termination, the mouse with the highest EAE score was chosen. If no mouse in the group had signs of EAE, a mouse was chosen at random.

Results. CNS infiltration by proin?ammatory cells was reduced in MGBG-treated mice, consistent with the clinical finding that MGBG reduces EAE pment. Multiple proin?ammatory cell populations were d in the CNS of MGBG-treated mice.

Interestingly, the proportion and number of rating dendritic cells was reduced in MGBG- treated mice more than in fingolimod-treated mice, and some of the differences were statistically significant. These results are consistent with previous studies, and suggest that MGBG selectively targets dendritic cells. In addition, the reduction in the number of IL-12 producing cells supports the notion that MGBG affects development of Th-l type responses. s are given in the tables below, where * indicates p<0.05 and ** indicates p<0.1. Table 13 shows results in terms of percentages of total cells, and Table 14 shows results in terms of raw numbers of cells (103).

Table 13 Onset Peak % cells unless ise indicated % cells unless otherwise indicated . fingoli- MGB (-) fingoli- (-) vehicle vehicle. MGBG mod G l mod control 31625 655.00 383.75 373.33 1032.50 343.75 346.25 387.50 Total # +/- +/- +/- +/- +/- +/- +/- +/- 2’10?)f 115 107 70 321.11 144.12 * *‘ 60.28 320.35 75.77 * 82.10 * 97.43 * 27.27 5.35 +/- 10.42 8.77 29.42 5.82 +/- 13.40 7.40 +/- CD4+ +/- 4.42 1.21 * +/- +/- +/- 4.50 1.29 * +/- 5.16 2.79 * WO 10154 3.09 * 2.79 * * 12.22 18.39 17.25 CD4+ +/- 5.56 +/- 521538 +/- 5.27 5518133 IL-17A+ * 7.30 * ‘ * ‘ ICLDll7A+ 2.60 +/- 434 14.37 4.82 +/- 5.45 +/- _ - 1.90 * +/_ 2.69 2.54 >l< 3.45 >l< IFNy+ 2.75 * 9.57 .16 20.01 17.15 9.37 +/- CD4+ +/' +/ >l< _ 3.37 +/_ 6.51 +/_ 3.77 1.87 IFNy+ 3.73 CD4- CD11c+ CD45.2 high CD11b+ CD11b+ CD206+ CD11b+ Arginase CD206+ Arginase CD11c+ 3.711;/- F4/80- ‘ 4.222:/-‘ 4.365:-‘ 0.59 +/- 0.43 * IL-12+ Table 14 Onset Peak # cells (103) # cells (103) fingoli- MGB (-) fingoli- (-) vehlcle. vehlcle. MGBG mod G control mod control 316.25 Total # 655.00 383.75 +/- 373.33 1032.50 343.75 346.25 387.50 of cells +/- +/- 107.70 +/- +/- +/- +/- +/- (103) 321.11 144.12 * * 60.28 320.35 75.77 * 82.10 * 97.43 * 187.68 20.14 32.66 33.38 310.86 20.58 47.51 28.47 +/- +/- 6.78 +/- +/- +/- +/- 8.42 +/- +/- CD4+ 109.88 * 13.83 15.06 119.64 * * 21.25 * 12.01 * 102.99 6.52 76.35 12.44 CD4+ +/- 2.19 +/— +/- +/- 3.82 +/- +/- 7.83 IL-17A+ 12.16 0.46 * 4.74 * 39.56 2.54 * >l< CD4+ 15.70 1.56 45.90 IL-17A+ +/- 0.50 +/— +/- +/- 1.05 +/- 3.01 +/- IFN + 11.50 0.38 * 1.52 * 21.79 0.88 * 2.54 * 23.71 3.19 59.72 CD4+ +/- 3.09 +/— +/- +/- 3.64 +/- 4.57 +/- IFN + 15.97 1.35 * 1.73 * 24.57 2.06 * 2.52 * CD11b+ CD11b+ CD206+ CD11b+ Arginase CD206+ Arginase .93 14.03 8.93 39.18 CD11c+ +/- +/- +/- +/- 14.93 1621 8.95 +/— F4/80- 16.78 12.69 * 5.06 * 19.87 +/- 7.32 +/— 9.38 1.02 2.33 .09 +/— 2.93 +/- +/- 10.78 1.93 +/- 2.21 +/— 1.36 +/- IL-12+ 2.88 2.06 1.82 * +/— 5.36 1.32 1.52 1.00 Table 15 below rates the effects seen in a subset of animals which did not p disease at the time when vehicle-treated animals were at the peak of disease.

MGBG, but not fingolimod, reduced the number of dendritic cells. This suggests that MGBG (and more broadly, a SAMDC inhibitor having an effect on dendritic cell antigen presentation and CNS infiltration) may be ant component in preventing or reducing the severity of EAE and MS, and/or their progression and associated symptoms, such as demyelination.

Table 15 Group CD11c+ of CD4- CD45.2+ high cells In Peak of Disease in Animals Without EAE Disease Fingolimod 5.41 +/- 0.62 MGBG 2.93 +/- 0.37 (-) Control 4.64 +/- 0.5 ADDITIONAL IN VIV0 MODELS OF THERAPEUTIC CY The following models, presented by way of e, may be used to te compounds disclosed herein for efficacy in the treatment of a number of diseases and tions. It is within the capacity of one skilled in the art to modify these models to suit the needs of the study. Additionally, those skilled in the art will be familiar with additional models of disease which may be employed. It is ed that MGB G, as well as other polyamine s and polyamine biosynthesis inhibitors and nds disclosed herein, will be efficacious in these models.

Neuropathy and Neuropathic Pain Models Bennett Model of Neuropathic Pain: A peripheral mononeuropathy is produced in adult rats by placing loosely ictive ligatures around the common sciatic nerve. The postoperative behavior of these rats indicates that hyperalgesia, allodynia and, possibly, spontaneous pain (or hesia) were produced. Hyperalgesic responses to noxious radiant heat are typically evident on the second postoperative day and lasted for over 2 months. Hyperalgesic responses to chemogenic pain were also present. The presence of allodynia may be ed from nocifensive responses evoked by standing on an innocuous, chilled metal ?oor or by innocuous mechanical stimulation (e. g., with von Frey filaments), and by the rats' persistence in holding the hind paw in a guarded position. The presence of spontaneous pain is suggested by a suppression of appetite and by the frequent occurrence of apparently spontaneous nocifensive responses. The affected hind paw is typically abnormally warm or cool in about one-third of the rats. About one-half of the rats develop grossly overgrown claws on the affected side. In compound efficacy models, test compound is typically delivered prior to stimulation and vehicle serves as control. Experiments with this animal model may e understanding of the neural mechanisms of neuropathic pain disorders in humans. Bennett GJ, Xie YK, 1988 “A peripheral mononeuropathy in rat that produces ers of pain sensation like those seen in man.,” Pain, (1):87-107 (PMID: 2837713).

Chung Model of Neuropathic Pain Since its introduction in 1992, the spinal nerve ligation (SNL) model of neuropathic pain has been widely used for various investigative works on neuropathic pain mechanisms as well as in screening tests for the development of new analgesic drugs. This model was developed by tightly ligating one (L5) or two (L5 and L6) segmental spinal nerves in the rat. The operation results in long-lasting behavioral signs of ical allodynia, heat hyperalgesia, cold allodynia, and ongoing pain. In the process of widespread usage, many different variations of the SNL model have been produced, either ionally or unintentionally, by different investigators. Although the factors that cause these variations themselves are interesting and important topics to be studied, the pain mechanisms involved in these variations are likely different from the original model. The method for producing the spinal nerve ligation model that will minimally induce potential factors that may contribute to these variations is described in detail in Chung JM, Kim HK, and Chung K, “Segmental spinal nerve ligation model of neuropathic pain,” Methods M01Med.; 2004 99:35-45 (PMID: 1 5 13 1327).

Chung Model in NHP In a model of painful neuropathy in the primate (Macaca fascicularis), a neuropathic state is induced by tight ligation of the L7 spinal nerve, just distal to the L7 dorsal root ganglion. y g may be done on the ventral surface of the foot, a region that includes the L7 dermatome. Within 1 week following surgery, primates lly develop a marked sensitivity to mechanical stimulation (e. g., with von Frey hairs), indicating the presence of mechanical allodynia. Increased ivity to mechanical stimulation is mes also observed on the contralateral side. The threshold for withdrawal to a heat stimulus decreases, indicating the presence of heat hyperalgesia. Presentation of various cooling stimuli, such as acetone and cold water baths, indicates that cold allodynia also ps. Observed behavioral phenomena are similar to those seen in humans diagnosed with peripheral athic pain. Thus, the model is useful for assessing a number of parameters relevant to human neuropathy and neuropathic pain ers, and for evaluating the efficacy of drug candidates as treatments for related ers. See, e.g., Carlton SM et WO 10154 al., “Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate,” Pain 1994 Feb;56(2):155-66 (PMID: 8008406).

Tactile Allodynia ment with Von Frey Filaments The following quantitative allodynia assessment technique may be modified to e tactile allodynia in any of the various animal models of neuropathic pain. The following summary is given by way of example and refers to a rat surgical neuropathy model wherein nocifensive behaviors are evoked by light touch to the paw. Employing von Frey hairs from 0.41 to 15.1 g, the percent response at each us intensity may first be characterized. A smooth log-linear relationship is typically observed. Additionally or alternatively, a paradigm using stimulus oscillation around the response threshold may be employed, which allows more rapid, efficient ements. Correlation coefficient between the two methods is typically high. In neuropathic rats, good intra- and observer reproducibility is found for the up-down paradigm; some variability may be seen in normal rats, attributable to extensive testing. The fact that thresholds in a sizable group of neuropathic rats show ificant variability over 20 days, and after 50 days, 61% still met strict neuropathy criteria (using survival analysis), tes that threshold measurement using the up-down paradigm, in combination with the neuropathic pain model, represents a powerful tool for analyzing the effects of manipulations of the neuropathic pain state. See, e. g., Chaplan SR et al., “Quantitative assessment of tactile allodynia in the rat paw.,” J ci Methods, 1994 (1):55-63 (PMID: 7990513). aves Method of Assessing Thermal Nociception Alternatively, a method to measure cutaneous hyperalgesia to thermal stimulation in unrestrained s has been described. The testing paradigm uses an automated detection of the behavioral end-point; repeated testing does not contribute to the development of the observed hyperalgesia. Carrageenan-induced in?ammation results in significantly shorter paw awal latencies as ed to -treated paws and these latency changes corresponded to a decreased thermal nociceptive threshold. This sensitive thermal method detects dose-related hyperalgesia and its blockade by test compounds and allows for the measurement of other behavioral parameters in addition to the nociceptive threshold.

See, e. g., Hargreaves K, et al., “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” Pain, 1988 Jan;32(1):77-88 (PMID: 3340425).

Inflammatory and Autoimmune Models Contact Dermatitis and Related Disorders Contact hypersensitivity is a simple delayed type hypersensitivity in vivo assay of cell-mediated immune on, which can be used to assess potential eutic efficacy in a number of ers having an in?ammatory and/or autoimmune component. Such diseases include contact dermatitis, atopic itis, psoriasis, allergic dermatitis, and dermal irritation. nds may be topically applied, optionally in a topical formulation, or may be delivered by a non-topical (e. g., oral, IV, etc) route.

Murine Model In one procedure, cutaneous exposure to exogenous haptens gives rise to a delayed type hypersensitivity reaction which is measured and quantitated. Contact sensitivity involves an initial sensitizing phase followed by an elicitation phase. The elicitation phase occurs when the T lymphocytes encounter an antigen to which they have had previous contact. Swelling and in?ammation occur, making this an excellent model of human allergic contact dermatitis. Murine models also typically have the additional benefit of being economical to run. A suitable procedure is described in detail in Gaspari AA and Katz SI, “Contact Hypersensitivity,” t Protocols in Immunology, Unit 4.2, John Wiley & Sons, Inc. (1994). See also Grabbe S and Schwarz T, “Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity,” Immun. Today 19 (1): 37-44 (1998).

Porcine Model The choice of animal can be important in dematological studies intended to predict human response. For this , pigs and in particular minipigs are favored due to the similarities between human and pig skin (particularly ular density). See, for example, an exemplary model in Bilski AJ and Thomson DS, “Allergic contact dermatitis in the domestic pig. A new model for evaluating the l anti-in?ammatory ty of drugs and their formulations,” Br J ol, 1984 1 Suppl 27:143 (PMID: 6743545).

Hairless Guinea Pig Model Allergic and irritant contact reactions have also been evaluated in the recently identified hairless guinea pig, Crl:IAF(HA)BR, a mutant from the Hartley strain. The irritant contact dermatitis may be induced by croton oil, 2,4-dinitrochlorobenzene (DNCB), or anthralin. Both ss and hairy guinea pigs develop similar reactions to these chemicals. llergic contact sensitization may be also induced with tetrachlorosalicylanilide , or with cyclophosphamide before sensitization with tribromosalicylanilide (TBS).

Cutaneous changes are observed macro- and microscopically according to s known in the art. Thus, ss guinea pigs can be used as animal models for assessment of test compounds in the treatment of immunologic and nonimmunologic contact reactions and related disorders. See, e. g., hi H and Horio T, “A new animal model for contact dermatitis: the hairless guinea pig ,” J Dermatol. 1992 Mar;19(3):140-5(PMID: 1640019).

Simple dermal irritation may also be studied in hairless guinea-pigs. In an exemplary model, test compounds are red in one or more topical ations for 30 min daily exposure for 4 days. Scoring is performed daily; evaporimetry (total epidermal water loss (TEWL)), hydration and colorimetry are measured at baseline (day 0) in the middle and at the end of treatment. Test compounds are d twice daily. See, e.g., Andersen F et al., “The hairless guinea-pig as a model for treatment of cumulative irritation in humans,” Skin Res Technol. 2006 (1):60-7 (PMID: 40).

Psoriasis Murine Chimera Model Additionally, the compounds sed herein can be tested in animal models for psoriasis-like diseases. Research into the cause and pathophysiological isms underlying expression of psoriatric skin lesions has been hampered by lack of an appropriate animal model for this common and tic cutaneous e. One suitable model is the human skin/scid mouse chimera prepared as described by Nickoloff BJ et al., “Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model,” Am J Pathol., 1995 Mar;146(3): 580-8 (PMID: 7887440) . The methods described therein characterize normal skin, pre-psoriatic skin, and psoriatic plaque skin samples transplanted onto severe combined immunodeficiency mice. Either normal, prepsoriatic, or psoriatic plaque keratome skin samples are transplanted onto severe combined immunodeficiency mice reliably with high rates of graft survival (> 85%) and with ucible changes consistently observed over prolonged periods of engraftment. After transplantation, by clinical assessment and routine light microscopy, normal skin remains essentially normal whereas pre-psoriatic skin became thicker, and psoriatic plaque skin retains its characteristic plaque-type elevation and scale. By using a panel of antibodies and immunohistochemical analysis, the overall phenotype of human cell types (including immunocytes) that persisted in the transplanted skin was remarkably similar to the 2014/010714 immunophenotype of pretransplanted skin samples. Additionally, clearly recognized interface zones between human and murine skin within the epidermal and dermal compartments can be identified by routine microscopy and immunostaining, with focal areas of chimerism. The many similarities between pre- and post-transplanted human samples of normal and psoriatic skin that are grafted onto severe ed immunodeficiency mice make this animal model appropriate for use in evaluating test compounds for efficacy in treating psoriasis and d ers.

Psoriasis Murine scid/scid Model Alternatively, the nds disclosed herein can be tested in the scid/scid mouse model described by SchOn MP et al., “Murine sis-like disorder induced by naive CD4+ T cells,” Nat Med, 1997 Feb;3(2):183-8 (PMID: 9018237). In this model, reconstitution of scid/scid mice with minor histocompatibility mismatched naive CD4+ T lymphocytes results in skin alterations that strikingly resemble human psoriasis ally, histopathologically and in cytokine expression.

Asthma Compounds may additionally be ted for cy in the treatment of asthma and related pulmonary disorders. In one murine model of asthma, wild-type control [C57BL/6J, (+/+)] and ICAM-1 (intercellular adhesion molecule-1) knockout [C57BL/6J- ICAM-l, (-/-)] mice are sensitized to ovalbumin (OVA), and challenged with OVA delivered by aerosol (OVA-OVA) to induce a phenotype consistent with an asthmatic response.

Bronchial responsiveness to methacholine and counts of cell s and measurements of eosinophil content and cytokine levels in bronchoalveolar lavage ?uid (BALF) may be ed. Additionally, lymphocyte proliferation in response to antigen, eosinophil migration into the airways, and the pment of airway hyperreactivity (AHR) in allergen- sensitized and -challenged mice may all be measures in vivo or ex vivio according to methods known in the art. See Wolyniec WW et al., “Reduction of antigen-induced airway hyperreactivity and eosinophilia in ICAM-l-deficient mice,” Am J Respir Cell M01 Biol., 1998 (6):777-85 (PMID: 9618382).

In?ammatog Bowel Disease, Crohn’s e, and Ulcerative Colitis The compounds disclosed herein can also be evaluated for activity in animal models of in?ammatory bowel disease, Crohn’s disease, and ulcerative colitis. The protocol described by Scheiffele F, Fuss IJ, “Induction of TNBS colitis in mice,” Curr Protoc Immunol, 2002 Aug; Chapter 15:Unit 15.19 (PMID: 18432874), is one of several that have been used to study the immunopathogenesis of these diseases. The model employs the use of 2,4,6-trinitrobenzenesulfonic acid , which induces severe colonic in?ammation when administered intrarectally in SJL/J mice. The colitis which results from this procedure presents clinical and histopathological findings that resemble those seen in Crohn's disease.

Scheif?ele and Fuss discuss the critical ters needed for successful induction of TNBS- colitis as well methods for monitoring and grading disease levels, and give a support protocol for isolating lamina propria mononuclear cells from mouse colons. See also Morris GP et al..

“Hapten-induced model of chronic in?ammation and ulceration in the rat colon,” Gastroenterology, 1989 Mar;96(3):795-803 (PMID: 2914642), bing the original rat model of chronic colonic in?ammation by the intraluminal instillation of a solution containing a "barrier breaker" (e. g., 0.25 ml of 50% ethanol) and a hapten (e. g., TNBS, 5-30 mg) At a dose of 30 mg, trinitrobenzenesulfonic acid/ethanol-induced ulceration and marked thickening of the bowel wall ted for at least 8 weeks. Histologically, the in?ammatory se included mucosal and submucosal infiltration by polymorphonuclear leukocytes, hages, lymphocytes, connective tissue mast cells, and fibroblasts. Granulomas (3 wk after induction of in?ammation), Langhan's-type giant cells, tal ulceration and in?ammation. The characteristics and relatively long on of in?ammation and ulceration induced in these models afford an opportunity to study the pathophysiology of colonic in?ammatory e in a ically controlled fashion, and to evaluate new treatments potentially applicable to in?ammatory bowel disease in humans.

EXEMPLARY ORAL PHARMACEUTICAL FORMULATIONS The following are examples of compositions which may be used to orally r compounds disclosed herein as a capsule.

A solid form of a compound of Formula VI may be passed through one or more sieve screens to produce a consistent le size. Excipients, too, may be passed through a sieve. riate weights of compounds, sufficient to achieve the target dosage per capsule, may be measured and added to a mixing container or apparatus, and the blend is then mixed until uniform. Blend uniformity may be done by, for e, sampling 3 points within the container (top, middle, and bottom) and testing each sample for potency. A test result of 95— 105% of target, with an RSD of 5%, would be considered ideal; optionally, additional blend time may be d to achieve a uniform blend. Upon acceptable blend uniformity results, a measured aliquot of this stock formulation may be separated to manufacture the lower ths. Magnesium stearate may be passed through a sieve, collected, weighed, added to the blender as a lubricant, and mixed until dispersed. The final blend is weighed and reconciled. es may then be opened and blended materials ?ood fed into the body of the capsules using a spatula. es in trays may be tamped to settle the blend in each capsule to assure uniform target fill weight, then sealed by combining the filled bodies with the caps.

COMPOSITION EXAMPLES In the composition examples below, target dosages may be adjusted to account for the weight of rions and/or solvates if given as a salt or solvated polymorph thereof. In such a case the weight of the other excipients, typically the filler, is reduced. For example, with the dihydrochloride monohydrate MGBG salt, a correction factor of 1.49 is used (e. g., 360 mg of the salt to give 240.8 mg of the free base).

Example 1A: 300 mg Capsule: Total fill weight of capsule is 500 mg, not including capsule weight. Target compound dosage is 300 mg per capsule Ingredient ty per Capsule, mg MGBG 300.00 e monohydrate 179.00 Silicon dioxide 3.00 Crospovidone 15 .00 Magnesium stearate (vegetable grade) 3.00 Example 1B: 150 mg e: Total fill weight of capsule is 300 mg, not including e weight. Target compound dosage is 150 mg per capsule Ingredient Quantity per Capsule, mg rystalline cellulose (MCC) Magnesium stearate (vegetable grade) MGBG-Fingolimod Combination Examples: Total fill weight of capsule is given below in mg, not including capsule weight.

Ingredient MGBG Fingolimod Mannitol, lactose, and/or microcrystalline cellulose (MCC) stearate (vegetable grade) TOTAL FILL WEIGHT All references cited herein are incorporated by reference as if written herein in their entireties. From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without ing from the spirit and scope f, can make various changes and modifications of the invention to adapt it to various usages and conditions. The invention disclosed herein provides for embodiments in which each of the embodiments above is combined with one or more of the other non-contradictory embodiments, such that the resulting embodiment includes the two or more recited ts and/or limitations.

Claims (12)

WHAT IS CLAIMED IS:

1. An oral pharmaceutical composition comprising MGBG and fingolimod together with a pharmaceutically acceptable carrier.

2. The oral pharmaceutical composition as recited in claim 1, wherein MGBG is dosed at 20 mg/day to 400 mg/day.

3. The oral pharmaceutical composition as recited in claim 1, which yields a therapeutically effective systemic plasma MGBG level when orally administered to a subject.

4. The oral pharmaceutical composition as d in claim 2, formulated for aily dosing.

5. The oral pharmaceutical composition as recited in claim 4, comprising 0.5 mg fingolimod per dosage unit.

6. The oral pharmaceutical composition as recited in claim 4, sing less than 0.5 mg fingolimod per dosage unit.

7. The oral pharmaceutical composition as recited in claim 4, comprising 0.25 mg fingolimod per dosage unit.

8. The oral pharmaceutical composition as recited in claim 2, formulated for twice-daily dosing.

9. The oral pharmaceutical ition as recited in claim 8, comprising 0.25 mg fingolimod per dosage unit.

10. The oral pharmaceutical composition as recited in claim 8, comprising less than 0.25 mg fingolimod per dosage unit.

11. The oral pharmaceutical composition as recited in claim 8, comprising about 0.125 mg fingolimod per dosage unit.

12. The oral ceutical composition of claim 1, substantially as herein described with nce to any one of the Examples and/or